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Abstract 
 
The use of chemical reagents for the modification of peptides has broad applications 
and, as a result, is a rapidly expanding area of research. Such methods serve to improve 
the pharmacokinetic properties of the peptide or add functionality for a desired 
application. Chemical modification of peptides has facilitated the development of a 
variety of bioconjugates for use as analytical probes, diagnostic agents and therapeutics. 
 
This project focuses on the modification of peptides by targeting disulfide bonds. 
Many peptides contain disulfide bonds which serve a crucial role in retaining their 
structure, function and stability. Reduction of these disulfides affords two reactive 
cysteine thiolates whose nucleophilicity can be exploited in peptide modification. To 
this end, a family of 3,4-disubstituted maleimide reagents were synthesised, designed to 
efficiently re-bridge a reduced, accessible disulfide bond. The bridging reagents vary in 
reactivity, properties and functionality but all serve to maintain the structural integrity 
conferred by a disulfide bond.  
 
With these reagents in hand, the scope of their utility was tested on peptides of 
biological and medicinal interest. One such peptide was tertiapin Q, a neurotoxin 
derived from the venom of the honey bee and consisting of two disulfide bonds in close 
proximity. Both singly and doubly bridged variants of the peptide were synthesised and 
isolated. Biological activity of the modified peptide was analysed by whole-cell patch 
clamp experiments on cells expressing the target of the peptide toxin, the G-coupled 
inwardly rectifying K+ (GIRK) channel, which tertiapin Q is known to inhibit. Loss of 
biological activity was observed upon modification, which led into a full structural 
characterisation study to determine the explanation for this intriguing result. 
 
A second peptide target, octreotide, a stabilised analogue of the hormone somatostatin 
with a single disulfide bond, was modified with relative ease. Biological activity was 
examined by whole-cell patch clamp on cells expressing the target of octreotide, the 
somatostatin receptor (SSTR) subtype 2. Pleasingly, nanomolar activity of the modified 
peptide was observed. A novel candidate for the next generation of diagnostics for 
SSTR positive tumours was subsequently developed, characterised and tested by 
confocal microscopy.  
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 Chapter 1: Introduction 
 
The introduction to this thesis will serve to place the project within its field; the 
continually expanding area of the chemical modification of proteins. The first section 
will cover the currently available strategies within this field and introduce the 
methodology employed within this project. The following sections will introduce the 
two peptides studied, tertiapin Q and the somatostatin analogue octreotide. Their 
biochemistry will be discussed before a review of the currently developed bioconjugates 
derived from these peptides. Finally, the electrophysiological technique of patch clamp 
will be described. This technique proved invaluable in the physiological analysis of the 
bioconjugates synthesised in this project and therefore its methodology and applications 
are discussed.  
 
1.1 Chemical Modification of Proteins 
 
1.1.1 Background 
Proteins play a vast number of fundamental roles in living organisms. They function in 
structure and stability, cellular signalling and the catalysis of a whole host of chemical 
reactions. They are synthesised on the ribosome through the polymerisation of 
individual amino acids; the sequence and properties of which determine the subsequent 
structure, function and reactivity of the final folded protein.1 
 
A large number of proteins undergo some form of modification following ribosomal 
synthesis. Some common examples of such post-translational modifications include 
amino acid phosphorylation, acetylation, methylation and ubiquitinylation,2,3 shown in 
Figure 1.1 on a lysine residue as an example. These modifications serve to extend the 
diversity of a protein’s amino acid functional groups beyond the 20 that naturally occur. 
As a result of such structural modifications, the function, location and lifetime of the 
protein can be altered.2 With greater understanding of these in vivo modification 
processes and the effects that result, the possibility of imitating and extending such 
processes in vitro has become an area of ongoing research.  
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Figure 1.1 Examples of post-translational modifications of lysine. 
 
Of key interest and importance is the idea of exploiting these processes to afford novel 
or improved therapeutics. Due to the poor solubility, short serum half-life, 
immunogenicity and protease degradation associated with protein and peptide-based 
therapeutics, small molecule drugs have prevailed thus far.4,5 Tailored modifications 
could help to overcome such problems by improving their pharmacokinetic and 
pharmacodynamic properties.6-8 In addition to therapeutics, advances in polypeptide 
synthesis and purification techniques have meant that these are increasingly being 
employed as diagnostic tools9,10 and imaging agents11,12. Controlled modifications could 
help improve characteristics such as solubility and stability and facilitate visualisation 
and tracking, further extending the potential uses of peptides and proteins in these 
areas.8,13,14 Much research has gone into the development of efficient strategies to 
 14 
achieve this, and promising developments within this field have lead to a wide variety 
of novel products. 
 
1.1.2 Site-Selective Modification 
For controlled, selective modification of a peptide or protein, a specific and accessible 
reactive centre is needed. In other words, one particular amino acid side chain needs to 
be targeted in preference to those around it, of which there are often hundreds. 
Selectively targeting a single amino acid functional group is a significant challenge. 
Usually the reactivity of a nucleophilic site on a protein is exploited by functionalisation 
using an electrophilic modification reagent. Lysine residues are commonly targeted as 
their side chains bear a nucleophilic amine group.15,16 Although lysine modifications 
have proved successful, they carry a distinct disadvantage; there are often multiple 
accessible lysine residues on the protein surface and targeting one selectively is 
difficult.17 Modification reactions often result, therefore, in a mixture of products, which 
can make purification to obtain the desired product challenging.  
 
Cysteine residues, with their unique sulfhydryl group, are the most nucleophilic residues 
in a protein, making them considerably reactive.2,17-19  This significant nucleophilicity is 
a result of the relatively low electronegativity of sulfur and the fact that its electrons 
reside in large, diffuse orbitals that are easily polarisable, increasing electron 
availability. In addition to their reactivity, cysteines also have the advantage of low 
natural abundance, helping to reduce the amount of unwanted side reactions in cases 
where a single modification is desired. Miseta et al. quantified the relative abundance of 
cysteine residues in human proteins to be just 2.26%.20 Procedures such as site-directed 
mutagenesis and recombinant engineering have made artificial insertion of cysteine 
residues at a desired location possible.21,22 Such methods are not always ideal however, 
as they can be expensive and technically demanding. Additionally, incorporating a 
single cysteine increases the chances of protein misfolding, aggregation or disulfide 
scrambling.23,24 Alternatively, native disulfide bonds can be reduced to form two free 
cysteines available for subsequent modification.25,26 Exploitation of disulfides in this 
way will be discussed later. 
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As cysteines are the target of the methodology employed in this thesis, offering the most 
convenient attachment points for site-selective modification, reagents that target these 
residues will be considered next. 
 
1.1.3 Modification Reagents Targeting Cysteine 
A variety of reagents have been developed to functionalise cysteine residues. These 
continue to advance in efficiency and commercial availability. Some of the more widely 
used methods are briefly outlined. 
 
1.1.3.1 Oxidation of Cysteine  
Cysteine is renowned for rapid oxidation to form disulfide bonds. Exploitation of this 
reactivity has lead to a number of disulfide-containing modification reagents. Here, a 
reactive cysteine thiol 1 can attack one sulfur of the disulfide bond in the reagent, 
resulting in disulfide bond cleavage and the formation of a new mixed disulfide product 
2, as shown in Scheme 1.1.27 
 
 
 
 
 
Scheme 1.1 Oxidation of cysteine (1) to form a new S-S bond. 
 
These reactions carry the advantage that they proceed over a broad pH range, working 
well in physiological conditions, and that they are reversible through the addition of 
reducing agents such as β-mercaptoethanol (BME) and dithiothrietol (DTT). Reversibility 
of a protein modification is often highly desirable as it allows for functionalisation to be 
controlled and removable. 
 
A classic example of a commonly used reagent of this family is Ellman’s reagent (5,5’-
dithiobis(2-nitrobenzoicacid)) shown in Figure 1.2. Since its introduction in 1959, Ellman’s 
reagent has been used most recognisably for cysteine quantification28, but more recently for 
modification of cysteine-containing proteins such as glutathione and haemoglobin.29 
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Figure 1.2: Ellman’s reagent (5,5’-dithiobis(2-nitrobenzoicacid)). 
 
1.1.3.2 Oxidative Elimination of Cysteine 
Another method of cysteine modification is via its prior conversion to dehydroalanine 
(Dha). Desulfurisation of cysteine through oxidative elimination has proven an efficient 
strategy for the formation of Dha 3. The resultant double bond within the residue 
provides a reactive site suitable for further functionalisation.30 
 
Research into the best oxidative elimination strategy has been pursued most recently by 
Davis and co-workers. Their aim was to establish a direct route from cysteine to Dha 
while overcoming drawbacks of previous methods, such as lengthy reaction times and 
lack of substrate selectivity31. They explored the use of O-
mesitylenesulfonylhydroxylamine 4 (MSH) as a potential reagent facilitating oxidative 
elimination (Scheme 1.2).30 Preliminary tests on a single amino acid model gave 
promising results and success continued when extended to a protein model; complete 
conversion of a single surface-exposed cysteine to Dha 3 took place in 20 minutes.30 
 
 
 
 
 
Scheme 1.2: Oxidative elimination of cysteine (1) using MSH (4). 
 
MSH presented itself as a rapid and selective reagent for oxidative elimination. The 
group went on to demonstrate the versatility of Dha by further functionalising the newly 
incorporated double bond through the conjugate addition of nucleophiles. 
Phosphorylated and glycosylated protein derivatives were just a few of a number of 
selectively modified products successfully obtained.30,31  
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1.1.3.3 Alkylation of Cysteine  
Alkylation is a common and straightforward route to the functionalisation of cysteine. A 
variety of different suitable electrophiles have been explored with the α-halocarbonyls 
(5, Scheme 1.3) being the first and one of the most commonly employed.32 
Iodoacetamide was originally the most popular reagent due to its high reactivity, 
however competing side reactions with lysine and histidine meant that chloroacetamide 
often prevails as the reagent of choice.33 
 
 
 
 
 
Scheme 1.3: Alkylation of cysteine (1) using a haloacetamide (5). 
 
Such reagents have been effectively used for conjugation of proteins to other molecules 
such as fluorescein34 and oligosaccharides.35 
 
Another chemical functionality commonly employed in cysteine alkylation is maleimide 
6. The chemistry of this group facilitates the conjugate addition of a nucleophile,27 such 
as the thiolate of a cysteine residue.17 The resultant product is the reduced succinimide 
7. 
 
 
Scheme 1.4:  Reaction between cysteine (1) and a maleimide (6). 
 
These maleimides react rapidly due to the highly electrophilic nature of the alkene; this 
electrophilicity is caused by the electron withdrawing effects of the neighbouring 
carbonyl groups. When used at physiological pH, maleimides have also demonstrated 
high selectivity towards cysteine thiols over other nucleophilic sites in proteins; the ε-
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amino of lysine or the imidazole of a histidine residue for example.19,36 Another 
important characteristic of these motifs is the presence of the second point of attachment 
at the maleimide nitrogen, enabling facile conjugation of the maleimide complex to 
another biomolecule or functional moiety. Recent examples in the literature demonstrate 
the versatility of this concept whereby fluorophores, polymer chains and enzymes have 
all successfully been linked to proteins or carbohydrates via a maleimide (Figure 1.3).37-
40  
 
 
 
 
 
Figure 1.3: Possible uses for maleimide conjugation. 
 
Despite its strengths for highly reactive and selective cysteine modification, maleimides 
still suffer limitations. Loss of the double bond through succinimide formation means 
that there is a limit to the extent of conjugation; only one biological or chemical entity 
can be attached to the protein of interest.11 In addition, it would often be beneficial if the 
maleimide motif could be removed at a desired point, for instance, once the protein had 
reached a certain destination within the cell. The succinimide linkage was originally 
thought to be completely irreversible, however more recently it has been found to 
disassemble, by a retro-conjugate addition, over several days in vivo.41 A more ideal 
situation would be complete and controlled disassembly at a desirable location. 
 
There has also been evidence of some reactivity towards lysine residues where the 
maleimide is present in significant excess, or where the pH of the reaction is 
significantly increased above neutral.42 These, however, are easily avoidable using 
reaction conditions that favour cysteine selectivity. 
 
1.1.4 A New Class of Maleimides 
Recent work by the Baker and Caddick groups (both UCL) has described a new class of 
reagents, the bromomaleimides 8, as a next generation of maleimides, which have the 
ability to act as double conjugate acceptors.19,24,43 It was proposed that incorporating a 
leaving group onto the double bond of the maleimide would facilitate an addition-
elimination sequence. Addition of a cysteine thiolate occurs at the maleimide double 
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bond which results in the subsequent elimination of bromide and formation of the 
thiomaleimide 9 (Scheme 1.5). Maintaining the double bond means that a second 
nucleophile can attack and, by the same mechanism, facilitate the elimination of the 
cysteine substituent.43 This makes reversibility of the cysteine modification possible. 
 
Scheme 1.5: Reaction between cysteine thiolate and bromomaleimide. 
 
The Baker group have undertaken much research into bromomaleimide to examine its 
efficacy. It was first reacted with a model cysteine system, N-Boc-Cys-OMe (10), which 
led to the expected thiomaleimide 11 in a very fast and clean reaction; quantitative yield 
in less than 1 minute (Scheme 1.6).43  
 
 
 
 
 
 
 
Scheme 1.6: Reaction between bromomaleimide (8) and N-Boc-Cys-OMe (10). 
 
Competition experiments between maleimide 6 and bromomaleimide 8 in the presence 
of the model cysteine showed bromomaleimide to react faster.43 Selectivity experiments 
were also conducted whereby bromomaleimide 8 was reacted with a 1:1 mixture of 
cysteine and propylamine. The result was the formation of the thiomaleimide  product 
11 exclusively,43 showing strong selectivity for the thiol over the amine. Perhaps the 
most exciting finding was that when the thiomaleimide 11 was treated with the common 
reducing agent tris(2-carboxyethyl)phosphine (TCEP), its nucleophilic nature served to 
enable the elimination of the N-Boc-Cys-OMe in 98% yield.43 This clearly 
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demonstrated the reversibility of the reaction suggesting that, when applied to a peptide 
or protein, the modification could be temporary. 
 
Following these initial findings, through a collaboration between the Baker and Caddick 
groups, bromomaleimide 8 was then assessed on a protein – namely the SH2 domain of 
the Grb2 adaptor protein with a single point mutation (L111C) resulting in a domain 
with a single cysteine residue (12, Scheme 1.7).19 Treatment with 1 equivalent of 
bromomaleimide led to total, selective modification of the single cysteine residue 
present to produce thiomaleimide 13.19 Due to retention of the maleimide double bond, 
it was predicted that a second conjugate addition could take place. To test this, 1 
equivalent of glutathione was added to the thiomaleimide complex. The expected 
dithiosuccinimide 14 product was formed.19  
 
Scheme 1.7: Modification of the Grb2 SH2 domain (L111C) (12) with N-methyl-3-
bromomaleimide (8). 
 
From these findings it was proposed that using a 3,4-disubstituted reagent, such as 
dibromomaleimide 15, would lead to the formation of the dithiomaleimide product 16 
with retention of the double bond. The above reaction was repeated and this theory 
proven (Scheme 1.8). Retention of the double bond meant that the conjugation reaction 
is reversible as other nucleophiles (such as TCEP, β-mercaptoethanol or glutathione) 
can be employed to cleave the substituents; it is believed this is again via a conjugate 
addition-elimination sequence.19 
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Scheme 1.8: Reversible cysteine modification using dibromomaleimide (15). 
 
The ability of excess glutathione to facilitate the cleavage of the maleimide conjugates 
led to the intriguing possibility that the reducing conditions of the cytoplasm of cells 
may be ideal to facilitate this process. In passing from the extracellular to the 
intracellular region, the glutathione concentration increases from ~0.01 mM to 1–11 
mM respectively.44 Experimental results proved even 1 mM glutathione enough to give 
complete cleavage of thiomaleimide 17 and reformation of the unmodified protein 12 
(Scheme 1.9).  
 
 
 
 
 
Scheme 1.9: Protein cleavage in conditions mimicking the intracellular environment. 
 
The considerable thiol concentration difference across the cell membrane, and the 
cleavage that results upon crossing it, was promising as it suggested the possibility of 
controlling the location at which the original peptide is released. Drugs that are inactive 
upon administration but that become pharmacologically active when they reach their 
required destination, as a result of an enzymatic or chemical modification, are termed 
pro-drugs.45 The search for such drugs is of great importance as they show promise in 
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reducing the unwanted side-effects common to many drugs currently available. 
Recently, using maleimides bearing a rhodamine-green fluorescent protein (GFP) 
fluorescence resonance energy transfer (FRET) pair, the ability of maleimide conjugates 
to undergo intracellular cleavage in mammalian cytoplasm was demonstrated. This 
highlighted the potential use of such conjugates in the targeted delivery of therapeutic 
cargo which is released upon internalisation into the cell.46 
 
1.1.5 Targeting Disulfide Bonds as Sites of Modification 
As previously mentioned, many peptides and proteins contain one or more disulfide 
bonds, serving to both confer stability and maintain the precise tertiary structure vital to 
biological activity (Table 1.1). Both therapeutic proteins and those synthesised for 
excretion into the extracellular environment commonly have disulfides; in these cases 
significant protein stability is essential.1  
 
These naturally occurring disulfides are also a very attractive target for protein 
modification reactions as they remove the need for introducing free cysteines artificially 
which often suffers limitations such as low expression yields and unwanted dimerisation 
of proteins.47  
Table 1.1 Examples of therapeutic proteins displaying one or more solvent-accessible disulfide 
bonds48. 
  
Non-covalent interactions between amino acid side chains and the formation of 
disulfide bonds is coupled with resultant protein folding. In biological systems this is 
facilitated by the presence of two enzymes: protein disulfide oxidoreductase and protein 
disulfide isomerase.49,50 Due to the rigidity of the peptide bond, neighbouring cysteine 
residues cannot couple to form a disulfide. This is also true for the case in which the 
Protein Disulfide Linkage(s) Medical Application 
IFN-β Single intra-chain 
Treatment of multiple 
sclerosis 
IL-2 Single intra-chain 
Treatment of certain 
cancers 
TNF-α Single intra-chain 
Treatment of soft tissue 
carcinoma 
Hirudin 
 
Two intra-chain Anti-coagulant 
Insulin 
Two inter-chain and one 
intra-chain 
Treatment of diabetes 
Antibodies 
 
Two inter-chain and two 
intra-chain 
Various 
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two cysteines are separated by just one other residue (C-X-C). Due to the nature of both 
the α-helix and β sheet arrangement of an amino acid chain, cysteines are only able to 
form disulfides when spaced by at least two other residues (C-X-X-C) resulting in a 
viable cysteine-cysteine alignment.20  
 
The reactivity of the disulfide bond, and that of the two cysteine residues produced upon 
reduction, has been found dependant upon both the immediate local environment51,52 
and its accessibility within the protein structure.53  Both Wang et al. and Britto et al. 
describe findings whereby cysteine residues in proximity to basic amino acid residues 
such as arginine, histidine and lysine had enhanced reactivity. They conclude that the 
positive charges on these basic residues may help promote deprotonation of the cysteine 
thiol (-SH) to the significantly more reactive thiolate (-S-). Conversely, a negatively 
charged local environment, caused by proximity to acidic residues such as aspartic acid 
and glutamic acid, led to suppression of thiol dissociation and a resultant decrease in 
cysteine reactivity.51,52 
 
With regards to disulfide accessibility, it has been found that disulfide bonds residing in 
the hydrophobic core of a protein are significantly less reactive.54 This, however, is a 
necessary characteristic as these disulfide bonds are often integral to the function and 
tight packing of the protein and modifying these buried disulfides may lead to undesired 
effects such as unfolding and loss of biological activity.23 Accessible disulfides on the 
other hand, such as those on the surface of the protein, tend to contribute mainly to the 
stability of a protein and hence are not so fundamental to protein structure and 
function.23,55 Consequently, these accessible disulfides present themselves as a more 
attractive target for modification. Reduction of such disulfides leads to the formation of 
a pair of very reactive thiolate nucleophiles whose reactivity holds great potential for 
subsequent modification reactions. 
 
The chemical modification strategies described in Section 1.1.3 and 1.1.4 were designed 
for the modification of single cysteine residues, either naturally occurring, artificially 
inserted or from the reduction of a disulfide to form two modifiable cysteines. In the 
case of the latter, loss of the disulfide bond removes any structural integrity that it 
previously conferred which could be detrimental to protein function in many cases. This 
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will be most significant in cases where the disulfide bond is in proximity to the 
pharmacophore of the peptide or protein.  
 
A recent alternative to modification of the individual cysteines of a reduced disulfide 
bond is the idea of ‘re-bridging’ the two cysteines whilst simultaneously incorporating 
the desired functionality. Research into the re-bridging of an accessible disulfide bond 
as a protein modification strategy was originally pioneered by Brocchini et al., who 
aimed to exploit the reactivity of both the sulfur atoms of the reduced disulfide. They 
developed the polyethylene glycol (PEG) linked mono-sulfone 18 which, by means of 
sequential addition-elimination reactions, served to install a three-carbon bridge 
spanning the original disulfide bond to produce the PEGylated product 19. The 
proposed mechanism of the reaction is shown in Scheme 1.10.23  
 
 
 
Scheme 1.10: Disulfide modification using a PEG-linked monosulfone (18) to connect cysteines 
via a three-carbon bridge. 
  
Brocchini et al. found that, through using these reagents, the fundamental tertiary 
structure of a peptide could be maintained, despite incorporation of an unnatural 
cysteine-cysteine linkage. They demonstrated this on a number of peptides, such as 
somatostatin, L-asparaginase, glutathione, interferon α-2b and an anti-CD4 antibody 
fragment. Only in the case of L-asparaginase was any reduction in biological activity 
observed, presumed to be as a result of the steric hindrance caused by the extended PEG 
component.23,56 
 
 A 
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Brocchini also commented on the use of mild reduction conditions to selectively target 
only the accessible disulfides in situations where multiple bridges are present. This 
helps to reduce the number of possible products obtained, making purification easier, as 
well as further reducing the chances of abolishing biological activity by modifying 
integral disulfides crucial to protein structure and function.23,56 
 
Following this work, in 2010 Baker et al. realised the potential of dibromomaleimide, 
which was previously employed for single cysteine modification, in the selective 
targeting of disulfides.  It was envisaged that dibromomaleimide could circumvent the 
undesireable formation of an additional chiral centre and would result in a sulfur-sulfur 
linkage formed with just two carbon atoms,19 rather than the three reported above.  
 
1.1.6 3,4-disubstituted Maleimides as Disulfide Modification Reagents 
Research by Baker et al. progressed to examine the ability of dibromomaleimide 15 to 
modify a disulfide bond by addition of both cysteine thiolates upon its reduction. 
Somatostatin 20, which is discussed in greater detail in Section 1.3, was employed as a 
suitable peptide model on which to test this. Native somatostatin is produced in the 
body to serve as a regulatory hormone in the pancreas and gastrointestinal tract, a 
neurotransmitter in the central nervous system and an inhibitor of hormone release at 
the pituitary.57 Somatostatin is a cyclic peptide of 14 amino acids formed by proteolytic 
cleavage from a larger peptide precursor.57 Most importantly, it contains a single, 
accessible disulfide bond. Somatostatin 20 was treated first with 1 equivalent of TCEP 
to reduce the disulfide, followed by 1.1 equivalents of dibromomaleimide 15 at pH 6.2. 
This resulted in complete conversion to the maleimide-bridged construct 21 (Scheme 
1.11). Subsequent treatment with β-mercaptoethanol led to reversal back to the reduced 
peptide, confirming the reversibility of the modification.19 These results were promising 
and presented dibromomaleimide as the first known reagent for selective and reversible 
disulfide bridging. 
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Scheme 1.11: Reversible disulfide bridging of somatostatin (20) by dibromomaleimide (15). 
 
Following this, the prospect of using the maleimide nitrogen as a third point of 
attachment was investigated. N-fluorescein-dibromomaleimide was synthesised and 
reacted with somatostatin; the fluorescently labelled, bridged peptide was formed 
efficiently.19 In addition, N-PEG dibromomaleimide has also been synthesised and used 
in the bridging of somatostatin. PEGylation is a common strategy employed to help 
improve water-solubility and in vivo half-life and to reduce potential antigenicity of a 
protein12 - such a reagent could be invaluable in the site-specific PEGylation of 
therapeutic peptides and proteins.  
 
Both reagents have shown comparable biological activity to native somatostatin.24 
These results give great promise for use of these maleimides in the field of 
bioconjugation.  
 
Research in the Baker group later turned to overcoming one of the more restricting 
problems with dibromomaleimide and its derivatives - the significant time the reduced 
disulfide bond is left un-bridged before addition of the maleimide moiety. This is 
problematic as it can lead to protein unfolding and loss of tertiary structure or, if more 
than one accessible disulfide is present, scrambling of the disulfides, both potentially 
resulting in loss of protein function.24,58 If, upon reduction of a protein’s disulfide 
bonds, its tertiary structure is largely maintained, the proximity of the free thiolates 
increases the chances of correct cysteine connectivity upon re-bridging. However, if the 
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reduction process leads to a large disruption of the tertiary structure and the free thiols 
move too far apart, then the propensity to form the correct cysteine pairs is greatly 
reduced.  
 
To overcome this, the ideal protocol would be an in-situ approach, where a reducing 
agent and a bridging reagent could be present at the same time to facilitate rapid 
bridging upon reduction. Attempts to achieve this with dibromomaleimide failed as it 
was found to have substantial reactivity towards TCEP, the commonly used reducing 
agent, and therefore was not suitable for in-situ use.24 Instead, dithiomalemides were 
presented as an alternative reagent that might be more resistant to attack by the reducing 
agent. Comparison in-situ reactions of somatostatin 20 with dibromomaleimide and 
dithiophenolmaleimide 22 were conducted. While dibromomaleimide appeared to be 
attacked by TCEP leading to incomplete somatostatin bridging, the use of 
dithiophenolmaleimide 22 led to quantitative conversion to the bridged peptide 21 
within 20 minutes (Scheme 1.12).24 These findings presented dithiophenolmaleimide as 
the first known disulfide bridging reagent for effective use in an in-situ protocol.24 
 
Scheme 1.12: The in-situ protocol with TCEP for disulfide bridging of somatostatin. 
 
TCEP cross reactivity promoted a screen of other potential reducing agents suitable for 
use in an in-situ protocol. While DTT and mercaptoethanol were incompatible due to 
their thiol-based nature causing them to react with the maleimides themselves, 
benzeneselenol proved efficient when used in conjunction with dithiophenolmaleimide. 
Control reactions revealed that the released thiophenol serves as a reducing agent itself, 
achieving efficient disulfide cleavage in the presence of benzeneselenol.15 
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1.1.7 Towards Novel Bioconjugates by Disulfide Bridging 
The scope of the in-situ protocol using 3,4-disubstituted maleimides for disulfide 
modification continues to be investigated. Most recently, its application to the 
modification of the disulfide bonds of antibodies and antibody fragments has been 
optimised and published. In this work, a disulfide-stabilised single chain variable 
fragment (sscFv) was employed, namely shMFE 23, which displays carcinoembryonic 
antigen (CEA) specificity. Pre-incubation of shMFE with as little as 2 equivalents of 
dithiophenolmaleimide-based bridging reagents before addition of 25 equivalents of the 
reducing agent benzeneselenol led to quantitative conversion to the functionalised 
antibody fragment 24 (Scheme 1.13).59 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.13: In situ disulfide bridging of the disulfide bond of shMFE (23). R = PEG, 
fluorescein, biotin or spin label. 
 
Remarkably, the binding affinity of the bridged sscFv fragments was not just retained 
but actually increased, as determined by ELISA. The observed increase in binding 
affinity is postulated to be as a result of the release of some of the strain associated with 
the incorporated disulfide bond, altering the geometry of the protein in such a way as to 
facilitate improved antigen binding.59 Subsequent to these promising results, 
functionalization of the sscFv fragment was achieved by employing maleimides 
incorporating fluorescein, biotin, PEG and a nitroxide spin label. Pleasingly, rapid 
conversion to the desired products was observed in all cases, with yields of homogenous 
product of between 80-90%. All analogues produced exhibited the same improved 
binding as observed previously. Subjecting the functionalised derivatives to reducing 
agents or intracellular concentrations of glutathione led to the regeneration of the 
unmodified sscFv 23 through cleavage of the maleimide bridge.59 This highlights the 
possibility of selective and controlled intracellular delivery using such functionalised 
antibody fragments. 
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Following this success, work has focused on the production of antibody-drug conjugates 
(ADCs) using this chemistry. This is a rapidly expanding area owing to the great 
demand for targeted delivery of cytotoxic drugs to cancerous cells in order to minimise 
undesirable side effects common to current cancer therapeutics. Minimising side effects 
will undoubtedly lead to improved patient tolerability and compliance.60 Preliminary 
work utilising this chemistry in this area, published by Castañeda et al., involved the 
synthesis of a dithiophenolmaleimide derivative linked to a cytotoxic drug; doxorubicin 
was chosen as the first anticancer warhead of choice. Synthesis of the functionalised 
maleimide 25 (Figure 1.4) was straightforward and produced excellent overall yields.61 
 
 
 
 
 
 
 
 
Figure 1.4: N-doxorubicin dithiophenolmaleimide (25). 
 
Conjugation of this reagent was tested on the antigen binding fragment (Fab) of the 
monoclonal IgG1 antibody trastuzumab (marketed as HerceptinTM) as this fragment has 
one inter-chain disulfide bond and is known to internalise upon binding to its target, the 
HER2/neu receptor. In this case, the disulfide bond of the Fab fragment 26 was first 
reduced with 3 equivalents of TCEP for 1 hour before addition of 5 equivalents of the 
doxorubicin-linked maleimide 25 to produce the desired conjugate 27 in near-
quantitative yields within 1 hour (Scheme 1.14).61 
 
 
Scheme 1.14: Disulfide bridging of the trastuzumab Fab fragment using N-doxorubicin 
dithiophenolmaleimide. 
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ELISA analysis suggested no loss of binding affinity when comparing native 
trastuzumab-Fab 26 to that functionalised by maleimide 25. In addition, incubation of 
the Fab conjugate 27 in lysosome-mimicking conditions (37 °C, pH 4.5) led to 
continued release of the cytotoxic cargo over time.61 This demonstrates the potential of 
such conjugates in the targeted delivery and controlled release of anti-cancer drugs 
which could make a valuable contribution to the expanding field of ADCs. 
 
Another area in which disulfide bridging using functionalised maleimides has been used 
effectively is in the improvement of the pharmacodynamic properties of therapeutic 
proteins. Palanki et al. recently published their work on their progress towards 
formulating a long acting growth hormone receptor agonist.62 In order to treat the 
effects of growth hormone deficiency, recombinant growth hormone is administered 
daily to patients via subcutaneous injection; this is as a result of its short serum half-life 
(20-30 minutes). A stabilised derivative which could be administered weekly is highly 
sought after. Palanki et al. developed a conjugate of human growth hormone connected, 
via the disulfide bridging linker 28, to an aldolase carrier antibody. In this way, the 
antibody serves to improve the pharmacokinetics and biodistribution of the growth 
hormone in order to increase its circulatory lifetime. Linker 28 consists of the 
dithiophenolmaleimide moiety at one end, for insertion into the disulfide bonds of 
growth hormone, and an electrophile at the other end, designed to react selectively with 
a free lysine on the aldolase antibody (Figure 1.5).62 
 
 
 
 
 
 
Figure 1.5: The linker used in the work by Palanki et al.62 
 
The group successfully managed to isolate their desired conjugate in around 30% yield. 
Interestingly, despite the presence of two disulfide bonds in human growth hormone, 
they found they achieved 95% selectivity for one disulfide over the other.62 With 
subsequent analysis of their conjugate, they found that conjugation of the protein by 
disulfide bridging had lowered its affinity for the growth hormone receptor. Its cellular 
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response is still elicited to a certain extent, but a lesser amount is internalised and, thus, 
satisfactory circulatory levels of growth hormone are maintained for longer. In addition, 
conjugation of growth hormone to the aldolase antibody gives protection from 
proteolysis, further improving the half-life of the protein. Animal studies have given 
promising evidence to suggest that, after administration of the conjugate, weight 
stabilisation is achieved for at least five days.62 Pre-clinical studies continue on this 
promising therapeutic candidate. 
 
1.1.8 Fine Tuning the Maleimide Reagents 
Tuning the groups attached to the maleimide is also proving to be a powerful method 
for controlling the reactivity and utility of the reagent. It was recently reported by 
Marculescu et al. that substituting the thiophenol moieties for phenol leads to a bridging 
reagent with attenuated reactivity, postulated to aid selectivity in some 
bioconjugations.63 In addition, the phenoxymaleimides were found to efficiently install 
a succinimide bridge within the disulfide bond of somatostatin; a result not possible 
with the more reactive mono-substituted maleimides such as bromomaleimide 8. 
Addition of 1.5 equivalents of phenoxymaleimide 29 to reduced somatostatin led to 
complete conversion to the succinimide bridged peptide 30 (Scheme 1.15) in 1 hour.63  
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.15: The succinmide bridging of somatostatin (20) using phenoxymaleimide (29).  
 
Such succinimide bridges were expected to have differing reactivity towards thiols in 
comparison to their maleimide equivalent. In fact, thiol reactivity of the succinimide 
bridge was found to be dependent upon the system in which it was employed; a 
succinimide bridged ds-scFv showed complete resistance towards thiol cleavage, 
whereas succinimide bridged somatostatin 30 was fully cleavable.63 This differential 
stability is reasoned to be as a result of the local environment of the disulfide. The 
succinimide bridge presents itself as a novel disulfide bridging reagent with properties 
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distinct from that of the maleimide bridge. It has already demonstrated its applicability 
in the dual labelling of a peptide in an efficient one-pot procedure.63 
 
Another method of tailoring the maleimides is by the means of attachment of moieties 
to the maleimide nitrogen. Although the reversible modification of peptides and 
proteins is both novel and invaluable, there are undoubtedly circumstances in which a 
permanent modification is desired. Recently, bromomaleimides have been synthesised 
whose stability can be controlled by a simple hydrolysis procedure.64 In this way, 
protein bioconjugates can be designed to be either stable or cleavable in the presence of 
excess thiol. It was found that an N-linked aromatic moiety on the maleimide (Scheme 
1.16) led to reagents that hydrolyse rapidly at pH 8; the resulting maleamic acid 32 
being no longer cleavable by excess thiol.64 Incorporating such reagents into proteins 
produces conjugates in which the stability can be tempered to achieve reversible or 
irreversible modification as desired. This could prove useful in the synthesis of labelled 
proteins, where reversibility may be a hindrance. 
 
 
Scheme 1.16: From reversible to irreversible modification using N-phenylbromomaleimide in 
the modification of somatostatin. 
 
1.1.9 Summary 
In summary, the potential of protein and peptide modification for various applications 
has been described and the current methods for modification introduced. Modification 
of native, accessible disulfide bonds by re-bridging presents itself as a new and efficient 
method for selective and controlled functionalisation. With the advent of in-situ 
modification protocols, retention of tertiary structure and biological activity is possible. 
Careful design of the modification reagent and protocol employed has proven to 
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facilitate broad application of this chemistry. The project herein continues to evaluate 
the scope of this chemical modification strategy. The peptides to be investigated in this 
project will now be introduced. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 34 
1.2 Tertiapin Q & its Applications 
 
1.2.1 Introduction to Toxins 
A toxin is a poisonous substance produced by the natural metabolic activity of a number 
of living organisms.65 They have evolved in plants, animals and microbes as a means of 
catching prey and as a self defence mechanism.66 Toxins are usually small peptides, of 
between 8 and 70 amino acids, with a very compact structure and are usually associated 
with the ill-effects that occur as a result of absorption and accumulation into body 
tissues, owing to their significant toxicity. Peptide toxins are usually found in animal 
venom, and by association with specialised envenomation apparatus, they are delivered 
into the soft tissue via intravenous or subcutaneous routes66. Evolution had helped fine-
tune these peptides to elicit great stability, potency and target selectivity. 
 
It has long been realised that a substance is only poisonous at a specific dose, a 
threshold dose, and above this almost any substance could be classified as 
“poisonous”67 It is with this knowledge that poisons and toxins began to establish 
themselves as valuable therapeutic and analytical tools. Studies in toxicology have 
facilitated the determination of the level at which the toxin becomes poisonous and 
elicits its undesirable effects and, as a result, much research has been focused on 
exploitation of these substances at low doses for beneficial applications. 
 
Ion channels are a common target for many plant and animal toxins and play a 
fundamental role in cellular signalling within the body; modification or disruption of 
this can have dramatic effects. Furthermore, studies have shown toxins to be highly 
selective for their particular channel target, to have low immunogenicity, little 
accumulation in organs and high chemical and thermal stability.68 Combined, these 
factors make toxins very promising candidates for channel-targeting therapeutics for a 
range of human diseases and disorders. The pharmaceutical industry has increasingly 
begun to employ toxin mimetics as therapeutics for cancer,69 pain,70 epilepsy71 and both 
neurological and cardiovascular disorders66,72; a variety of these are currently in clinical 
trials. 
 
In addition to drug discovery, a second invaluable application of such toxins is the 
characterisation of the channels and receptors to which they are targeted.68 They have 
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proven highly effective as pharmacological probes to help elucidate the structure and 
consequent function of various ion channels. An example is the characterisation of the 
nicotinic acetylcholine receptor where initially the peptide neurotoxin α-bungarotoxin, 
from a Taiwanese banded krait, to which it selectively binds, was used to isolate the 
receptor in an affinity chromatography assay.73 Following this a second toxin, α-
conotoxin, derived from the Conus family, was employed to characterise the receptor.74 
 
1.2.2 Tertiapin and Its Structure and Function 
Tertiapin is a twenty one amino acid neurotoxin derived from the venom of the honey 
bee. It was isolated over thirty years ago when it was believed that bee venom contained 
substituents with anti-arthritic properties75. In the search for these substituents many 
small peptides, including tertiapin, were isolated and examined for their biological 
activity.75 Since its isolation, a significant amount of work on the structure and 
biological activity has been undertaken. In 1993, Xu and Nelson published their work 
presenting the solution structure of the peptide determined by two-dimensional NMR 
and circular dichroism.76 Superimposition of the data showed tertiapin to be a very rigid 
and compact molecule, owing to the strong interactions between amino acid side chains. 
Four cysteine residues form two disulfide bonds adding further to the stability of the 
molecule. Within the structure are an α-helix and a Type 1 reverse turn connected by a β 
strand (Figure 1.6).76-78  
 
  
 
 
 
 
 
 
 
Figure 1.6: Three-dimensional solution structure of tertiapin determined by NMR. Disulfide 
bonds (cys3-cys14 and cys5-cys18) shown (PDB code: 1TER).78 
 
In the elucidation of the biological role of the small peptides isolated from the bee 
venom, tertiapin was found to selectively inhibit a particular class of potassium (K+) 
channel, namely the G protein-gated inwardly rectifying K+ (GIRK) channel.76,77,79 
These channels are activated by muscarinic M2, α2 adrenergic, D2 dopaminergic, 
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histamine, adenosine A1, GABAB and somatostatin receptors.
80 Upon neurotransmitter 
release, these receptors are activated, leading to the dissociation of the Gβδ subunit of a 
G-protein from the Gα subunit. It is the binding of this Gβδ to the C- and N- termini of 
the GIRK channel which directly activates it.80,81 To date, four different GIRK subunits 
have been identified, GIRK1-4, and these are found as dimers differentially distributed 
within the body. GIRK1 is found almost invariably in all GIRK-expressing tissues 
whilst GIRK2 is widely expressed in neurons and GIRK4 found mainly in the cardiac 
tissue.82 The name ‘inward rectifier’ comes from the propensity of the GIRK channels 
to allow movement of a large flux of K+ ions in the inwards direction, and only a 
comparatively small amount in the outwards direction. The mechanism for selective 
current flow direction in GIRK channels was for a long time unknown. There is now 
significant evidence to suggest that it is the blocking of the channel from the 
intracellular side by Mg2+ ions and polyamines which prevent outward K+ flow.83,84 
 
GIRK1/2 channels (a channel made up of both GIRK1 and GIRK2 subunits) play an 
important role in regulating action potential firing in the central nervous system. They 
allow movement of a small amount of K+ in the outwards direction in order to maintain 
a hyperpolarized state and consequently decreased neuronal excitability.85 The crucial 
role of the GIRK channels has been demonstrated by experiments on weaver mice 
which carry a mutation in the pore region of the GIRK2 subunit. The mutation has been 
proven to cause decreased K+ selectivity and loss of channel function, leading to 
seizures and neuronal cell death.86,87  In the heart, GIRK1/4 channels are activated by 
acetylcholine in response to vagus nerve stimulation. Here, the small outward K+ 
current through the GIRK channels serves to slow the heart rate by elongating the 
refractory period of cardiomyocytes.88,89 
 
GIRK channel subunits have just two transmembrane domains (M1 and M2 in Figure 
1.7) with a pore-forming loop between the two, as depicted in Figure 1.7. Four of these 
subunits assemble to form the complete channel.90 In recent years, research has been 
carried out to further elucidate the structure and resultant function of the inward-
rectifying channels. The role of particular residues of the pore-forming loop as an ion 
selectivity filter,91  the mechanism by which the channel pore is opened for K+ flux92 
and the secondary structure of the N- and C-terminal regions forming the cytoplasmic 
pore93 have all been studied.   
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Figure 1.7: A GIRK subunit showing the two transmembrane segments (M1 and M2), the pore 
forming loop (P) and the interaction with G-protein.94 
 
However, due to a lack of high-affinity ligands that selectively bound to GIRK 
channels, some areas of the pharmacology and the functioning of the channel remained 
relatively unknown. In 1998, Jin and Lu ran a screen of venoms from various sources 
for their inhibitory action against the channel and, once a successful candidate was 
found, isolated the component which was active.75 Searching protein databases revealed 
this active component to have the same structure as tertiapin. Comparison studies 
between the isolated peptide and synthetic tertiapin led to complete confirmation that 
the isolated peptide was tertiapin. Tertiapin was found to inhibit the GIRK channel with 
an IC50
i of 8.5 nM.79,95  
 
It was later found that one of the methionine residues in tertiapin, number 13 (Figure 
1.8), is readily oxidised by air and that this greatly hinders the peptide’s ability to bind 
to the channel.  
 
 
 
 
Figure 1.8: Tertiapin (33), amino acid chain representation (methionine 13 highlighted). 
 
In 1999, Jin et al. aimed to overcome this problem by making mutants of the peptide;  
replacing the methionine residue, one at a time, with fourteen other amino acids before 
testing their activity and affinity for the channel (Table 1.2).79 
                                                 
i The IC50 of a substance is defined as the half-maximum inhibitory concentration. 
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Table 1.2:  The Kiii values for wild type tertiapin 33 and fourteen mutants.
79 
Species Mean Ki (nM) 
Standard 
Error of the 
Mean 
Number of 
Experiments 
wt 2.04 0.02 50 
M13A 19.31 2.51 4 
M13D 21.54 1.82 4 
M13E 299.63 17.65 4 
M13F 33.74 1.98 3 
M13G 96.81 6.32 4 
M13I 7.21 0.45 8 
M13L 16.23 1.91 4 
M13N 40.41 3.04 4 
M13Q 1.25 0.01 50 
M13S 38.93 4.25 4 
M13T 21.41 2.06 4 
M13V 12.54 1.08 4 
M13W 40.14 2.34 3 
M13Y 27.12 1.65 3 
 
        
From this screen, it was found that replacing methionine with glutamine produced a 
variant that had specificity and affinity comparable to that of wild type tertiapin but was 
not susceptible to spontaneous oxidation in air. This variant, named tertiapin Q, 
presented itself as an effective new pharmacological probe.  
 
Work on tertiapin and tertiapin Q progressed to determine how they elicit their 
inhibitory action. Experiments, again by Jin et al., included an alanine scan whereby 
each residue (except for the four cysteines involved in disulfide bonding) of the peptide 
was mutated, in turn, to alanine and the activity of the mutant tested. It was found that 
mutating histidine 12, lysine 17 or lysine 20 resulted in a much greater IC50 value.
77 It 
was hypothesised that these residues were integral to channel binding. Based on the fact 
that residues 12-19 make up the α-helix of the peptide’s secondary structure, this 
                                                 
ii The Ki of a substance is the inhibition constant and is the concentration required to occupy 50% of the 
target channel or receptor. 
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evidence strongly suggests that this region was primarily responsible for the interaction 
with the channel surface. Mutagenesis studies on the channel itself showed residues in 
the channel pore to be involved in the channel-toxin interaction. From a combination of 
these, a hypothesis arose whereby the toxin blocks the channel by insertion of its α-helix 
into the pore, leaving the remainder protruding into the extracellular environment.77 
 
It was recently found that tertiapin Q is not completely selective for GIRK channels and 
that it also has an inhibitory effect on voltage-dependent Ca2+ activated large 
conductance K+ (BK) channels.96 Studies by Khanjan et al. show that the inhibition 
characteristics vary between GIRK and BK channels; inhibition of BK channels by 
tertiapin has proven to be much slower, voltage dependent and has a lower IC50 of 5.8 ± 
1.0 nM.96 
 
1.2.3 Application of Tertiapin Q 
There is increasing demand for high affinity probes to elucidate the pharmacology of 
different ion channels. Tertiapin Q has already been presented as a good candidate and 
has been put to use as an analytical tool for studying GIRK channels. For example, a 
tertiapin Q derivative radiolabelled with 125I was synthesised by Felix et al.97 They 
decided to attach the label at the N-terminus as this is known not to be involved in the 
interaction with the GIRK channel. They found their derivative to be of very similar 
potency to tertiapin Q and suggest its use in quantifying cell surface channel 
expression.97 Whilst a novel product resulted, its synthetic route had its drawbacks. Site-
directed mutagenesis was required to incorporate a tyrosine residue as native tertiapin Q 
lacks these. Tyrosine was chosen as its reactivity enables further functionality, covalent 
attachment of 125I in this case.  Additionally, the conversion to the iodinated product 
was not quantitative, with both the native peptide and the di-iodinated peptide also 
formed meaning subsequent purification by HPLC was required.97 No further attempts 
at functionalising tertiapin Q appear to have been reported. 
 
In addition to pharmacological probes, tertiapin Q, like many other toxin peptides, has 
been proposed as a potential therapeutic due to its notably high channel selectivity. 
Recent studies have proposed that targeting GIRK channels could be an effective way 
of treating atrial fibrillation, a common cardiac arrhythmia.98 Constitutively active 
GIRK1/4 channels in the heart have been observed and have shown to sustain the 
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arrhythmia and, therefore, controlled inhibition of the GIRK channels has been 
proposed at a therapeutic possibility. Tertiapin Q has good inhibitory potential, and 
selectively inhibits GIRK1/4 channels of cardiac tissue at low nanomolar 
concentrations.99 Experiments have demonstrated that tertiapin Q can efficiently 
terminate vagus nerve-induced atrial fibrillation in canines99,100 and reduce GIRK1/4 
current in the atrial myocytes from patients with chronic atrial fibrillation.98  
 
Despite promising results, tertiapin Q has unwanted pharmacological characteristics, 
such as immunogenicity and short serum half-life, which could prevent its use as a 
therapeutic.4,5 It is these factors which have previously led to a shortage of peptide-
based therapeutics, regardless of their advantages over small molecule drugs. Increasing 
realisation of the advantages of utilising peptides, such as their ease of synthesis and 
high target specificity and affinity, has gone hand-in-hand with advances in chemical 
synthesis techniques and methods to overcome poor physiochemical properties.5 As a 
result, prospects for peptide-based therapeutics have begun to, and look set to continue 
to, improve.  
 
1.2.4 Summary 
In summary, tertiapin Q presents itself as an ideal candidate for bioconjugation. Its 
nanomolar affinity for its target makes it ideal for use as a probe to study the 
pharmacology of the GIRK channel family; incorporation of a visualisation agent could 
greatly advance research in this area. In addition, the inhibitory activity of tertiapin Q 
could be exploited for the treatment of atrial fibrillation provided the discussed 
limitations can be overcome. Despite this potential, progress in this area is minimal and 
not widely reported on in the literature.  
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1.3 Somatostatin, its Analogues & their Applications 
 
 
1.3.1 Somatostatin and Its Structure and Function  
Somatostatin is a natural cyclic peptide hormone originally discovered and isolated 
from the bovine hypothalamus. There are two natural forms, somatostatin-14 (Figure 
1.9, 20) (sst-14) and somatostatin-28 (sst-28); sst-28 consists of the same 14 amino 
acids as sst-14, but with an extra 14 amino acids extending from its N-terminus. 
Although there is some evidence to suggest that sst-28 is a precursor to sst-14, it is also 
known to act as a hormone in its own right, with very similar pharmacological actions 
to sst-14.101 The two forms of somatostatin are commonly expressed in both the central 
nervous system (CNS), where it acts as a neurotransmitter, and in the gastrointestinal 
tract, acting as an inhibitor of growth hormone, glucagon, insulin and gastrin release.102 
 
 
 
 
 
 
 
Figure 1.9: Amino acid sequence of somatostatin-14 (20). 
 
Somatostatin targets the somatostatin receptor which has been located in the CNS, the 
gastrointestinal tract and in many cells of neuroendocrine function. Recently, five 
human receptor subtypes have been cloned and identified (sst1-5) with largely variable, 
tissue-dependant expression suggesting significant diversity in the function of the 
receptor in each tissue type.103  The somatostatin receptors form a distinct subset of the 
G-protein coupled receptor (GPCR) superfamily; they comprise the characteristic 
seven-helix membrane-spanning structure, where the extracellular domain binds the 
associated ligand and the intracellular domains are responsible for signal transduction 
inside the cell.103 All 5 receptor subtypes bind the two natural forms of somatostatin and 
do so with low nanomolar affinity. In addition, the subtypes share common intracellular 
signalling pathways upon activation by somatostatin, namely the activation of 
phosphotyrosine phosphatase (PTP), inhibition of adenylyl cyclase, activation of 
K+/Ca2+ channels and the modulation of mitogen-activated protein kinase (MAPK). It is 
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these pathways that mediate the subsequent inhibitory effects on hormone release and 
cell growth, which are the effects characteristically associated with somatostatin.103,104 
 
It is well accepted that the binding of somatostatin to its receptors is predominantly 
through amino acid residues 7-10; these residues together comprise the hormone 
pharmacophore.  Only very minor modifications can be made to these residues without 
incurring a huge loss in biological activity – threonine can be exchanged for valine and 
tryptophan exchanged for its enantiomer with little effect, but lysine must always be 
conserved.105,106 There is a disulfide bond between the two cysteine residues of 
somatostatin (3 & 14) which, like with most cyclic peptides, is fundamental to the 
structural integrity, rigidity and function of the hormone. The two phenylalanines (6 and 
11) neighbouring the pharmacophore have been shown exhibit a stabilising effect on the 
peptide structure, potentially by means of a non-covalent aromatic interaction of the 
amino acid side chains, but do not directly interact with the receptor.105 
 
Somatostatin receptors are known to be over-expressed in various pathologies, perhaps 
most importantly in cancers; ovarian, kidney, breast, thyroid and neuroendocrine 
tumours are a few examples. As a consequence of this, there is great interest in 
exploiting this differential receptor expression and the pharmacological action of 
somatostatin for clinical applications.104 The ability of somatostatin to control the 
release of active peptide hormones that are being over-produced by these receptor-
bearing tumours makes somatostatin an ideal candidate as an anti-proliferative 
therapeutic. However, the short in vivo half-life (2-3 minutes in plasma) due to rapid 
enzymatic degradation, along with the relatively low selectivity of the peptide for one of 
the five receptor subtypes, are considerable drawbacks making somatostatin itself not 
ideal for use in the clinic.101,102  
 
1.3.2 Somatostatin Analogues  
Efforts to circumvent these drawbacks through the synthesis of analogues with 
improved pharmacokinetic properties have been ongoing since the 1980’s. Importantly 
it was discovered that, by exchanging L-tryptophan for the D- enantiomer, the half-life 
of the peptide could be significantly improved. This is believed to be because of the 
more favourable interaction between the indole ring of D-tryptophan with the side chain 
of the neighbouring lysine residue; when in the D- configuration, tryptophan is more 
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able to shield the aliphatic chain of lysine. It was found that exchanging these 
enantiomers led to minimal alteration to the overall conformation and architecture of the 
peptide, but rather served to increase structural stability by stabilising the hair-pin turn 
motif.105 In addition, D-amino acids are known to confer greater resistance towards 
proteases, further adding to prolonged in vivo half-life.101,105 In addition to this, 
shortening of the chain length of the peptide also had beneficial effects. Removal of 
amino acids from either side of the pharmacophore, with exception of the two cysteines 
required for maintenance of the disulfide bond, lead to derivatives with a smaller ring 
size and decreased flexibility.105 This served to increase the potency and specificity of 
the peptide; native somatostatin has almost no specificity for any of the 5 receptor sub-
types.104,105 These significant improvements to the pharmacokinetic properties of the 
peptide made it a more attractive candidate for use in the clinic, and recently a few of 
these synthetic analogues have successfully made it onto the market for treatment of 
somatostatin receptor positive tumours. These are displayed in Table 1.3. 
 
Table 1.3: The pharmacokinetic properties of somatostatin and its analogues (adapted from 
publication by Veber et al.).106 
 
Name Size 
Half-
life 
Target receptor 
Administrative 
route 
Development 
stage 
Somatostatin 
(20) 
14/28 
amino 
acids 
~3 min sst1-5 IV - 
Octreotide 
(34) 
8 amino 
acids 
2 h 
Primarily sst2 
(partially sst5) 
IV, SC, IM 
Approved & 
marketed 
Lanreotide 
8 amino 
acids 
2 h 
Primarily sst2 
(partially sst5) 
SC, IM 
Approved & 
marketed 
Pasireotide 
6 amino 
acids 
12 h 
Primarily sst5 
(partially sst1-3) 
SC, IM 
Approved & 
marketed 
(IV: intravenous, SC: sub-cutaneous, IM: intramuscular) 
 
Perhaps the most well-documented of all analogues to date is octreotide 34; originally 
synthesised and reported by Wilfried Bauer in 1979 and today marketed by Novartis 
Pharmaceuticals under the brand name Sandostatin® (Figure 1.10).107 
 
 
 
 
 
 44 
 
 
 
 
 
 
 
 
 
Figure 1.10: The amino acid sequence of octreotide (34) (Sandostatin®) with the 
pharmacophore depicted in orange. 
 
Octreotide binds almost exclusively to sst2 and has shown to be 20 times more potent 
than native somatostatin.104,107 It has been approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of patients with various types of 
neuroendocrine tumours (NETs). NETs have been found to overexpress the sst2 
receptor at high levels, making octreotide an ideally targeted therapeutic.104 The 
bioavailability of octreotide is good, approximately 100% for a sub-cutaneous 
administration, and distribution of the peptide is rapid.101 More recently, long-acting 
formulations of the peptide have been designed by incorporation of octreotide into 
micropsheres made from a biodegradable polymer. This variant, known as Sandostatin-
LAR® (long-acting release), was shown to release low levels of octreotide for about 7 
days after administration before slowly increasing its release rate over the subsequent 
week and maintaining its maximal concentration for 28-35 days.104,108 
 
1.3.3 Somatostatin Analogues as Imaging Agents 
1.3.3.1 Radiolabelled Derivatives 
As well as being used as a therapeutic in its own right, octreotide has also been 
investigated as a targeting agent by conjugation of the peptide to another active 
biomolecule. One such example is the coupling of octreotide to a radioactive isotope to 
allow imaging and localisation of somatostatin receptor positive tumours. One of the 
first labelled variants synthesised was 123I-labelled tyr3-octreotide 35 by Krenning et al. 
in 1989 - here the phenylalanine residue at position 3 was substituted for a tyrosine; a 
structurally similar amino acid which would facilitate attachment of 123I (Figure 
1.11).109   
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Figure 1.11: The structure of Oct-tyr-123I (35). 
 
Successful radioiodination allowed visualisation of receptor positive tumours in vivo 
with use of a gamma camera.109 However, this imaging agent was found to suffer 
drawbacks such as poor bioavailability due to rapid clearance by the liver and relatively 
short radioactive half-life (~13 hours).10,110 
 
The next generation of octreotide-based imaging agents designed to overcome these 
drawbacks comprised a chelating group attached at the peptide termini. The first and 
most well established example of this is 111In-pentetreotide 36, developed by Bakker et 
al., which has diethylene triamine penta-acetic acid (DTPA) conjugated to the N-
terminus of octreotide. DTPA is a chelating group which allows radiolabelling by 
chelation with indium-111 (Figure 1.12).111 111In-pentetreotide was found to be very 
effective in visualisation of a variety of somatostatin receptor positive tumours and was 
marketed as a radiopharmaceutical by Mallinckrodt Medical Inc. under the commercial 
name of OctreoScan®. 
 
 
 
 
 
 
 
Figure 1.12: The structure of OctreoScan® (36). 
 
In comparison to 123I-octreotide, OctreoScan was found to have a significantly longer 
half-life of ~68 hours and to be cleared predominantly by the kidneys. These superior 
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kinetics and biodistribution profiles help reduce background interference and false 
positives from accumulation in normal healthy gut structures.10,110 An average dose of 
6.0 mCi of OctreoScan is given to a patient before whole-body imaging by scintigraphy 
is carried out to produce 2D images like those in Figure 1.13 below. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: Scintigram obtained 4 h after injection with OctreoScan (36). Arrow shows tracer 
accumulation at the liver, while the arrow head shows accumulation in an area of the pancreas.  
(Normal tissue accumulation is also seen in the kidneys and bladder as a result of normal tracer 
clearance).112  
 
This imaging is easily interpretable and allows the localisation and assessment of 
tumours – clinicians are then able to decide on subsequent treatment and whether 
somatostatin or octreotide therapy could prove effective.110 The main limitation with 
this construct is that the DPTA chelating agent is restricted to the binding of gamma-
emitting particles only, it has poor affinity for beta-emitting particles such as 60Y and 
186Re; these are known as ‘bone seekers’ and, if not tightly bound by a chelator, will 
accumulate in the bone marrow and cause irreparable damage.10  
 
To overcome this limitation, Heppelar et al. designed a new chelator comprising of 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) which can bind a 
number of different radiometals. This was subsequently conjugated to octreotide to 
create DOTATOC 37 shown below in Figure 1.14.113 
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Figure 1.14: The structure of DOTATOC (37). 
 
Careful choice of the radiometal added to DOTATOC produces constructs suitable for 
varying applications; 67Ga  and 111In can be used for single photon emission tomography 
(SPET), 68Ga and 86Y for positron emission tomography (PET) and 90Y, 68Ga and 177Lu 
for peptide receptor radionucleotide therapy (PRRT). Different radiometals have 
different physical properties, for example the emission products of their decay and the 
energy at which these are emitted. This in turn affects the degree of tissue penetration 
possible and, therefore, the therapeutic potential. 111In emits gamma-radiation and 
Auger electrons; these are low energy and lead to minimal tissue penetration (0.02-10 
µm) making 111In-based constructs suitable for imaging but not for radiotherapy. 
Radiometals such as 90Y, however, emit beta-radiation which is of much higher energy 
and hence facilitates much deeper tissue penetration (up to 12 mm).114 Investigations 
into the use of 90Y-DOTATOC as treatment for somatostatin receptor positive tumours 
gave promising results (tumour size stabilisation or regression in many cases).113,115 
This is owed, in part, to the ‘cross-fire effect’ which is pronounced when using 
radiometals with such high tissue penetration levels and is the term used to describe the 
elimination of cells that had not come into direct contact with the radiotherapeutic agent 
itself. This can, however, be a drawback if this cross-fire effect causes unwanted 
toxicity to neighbouring organs. 177Lu emits intermediate-range beta-radiation resulting 
in a tissue penetration of around 2 mm, presenting this radiometal as an ideal choice for 
medium-sized or surrounded tumours.114 The versatility of the DOTA chelating agent 
gives it great value as both an imaging agent and a radiotherapeutic and thorough 
consideration of the radiometal employed facilitates tailoring of the construct for each 
individual patient case.  
 
A drawback to the discussed routes to radiolabelled octreotide derivatives is the 
synthetic strategy required to create them. Octreotide is routinely produced by means of 
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solid phase peptide synthesis, however the presence of a nucleophilic lysine residue 
within the pharmacophore of the peptide makes functionalization more challenging. In 
order to avoid attaching the chelating moiety to this lysine residue, which would 
undoubtedly be detrimental to the biological activity of the peptide, a protected lysine 
must instead be incorporated. Addition of the chelating group is then restricted to the N-
terminal NH2 group, but a subsequent deprotection step is then required to regain the 
natural lysine residue.116 An example is shown in Scheme 1.17, showing the 
incorporation of DTPA onto the N-terminus of octreotide. The peptide is first treated 
with di-tert-butyl-dicarbonate ((Boc)2O) to protect the inter-chain lysine residue before 
coupling of DTPA-dianhydride at the N-terminus selectively. This is then purified on 
silica gel to remove the unwanted doubly substituted DPTA derivative and un-reacted 
starting material before deprotection of the lysine residue using TFA. Finally, another 
purification step was added to obtain the desired homogenous product in a low yield of 
10%, even before the final radiolabelling step.111,116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.17: The synthetic route to OctreoScan® (36). 
 49 
1.3.3.2 Fluorescent Derivatives 
Fluorescence detection presents itself as another attractive method by which to image 
tumours for early stage tumour diagnosis. The high sensitivity of this method means 
that femtimolar quantities of a near-infra red fluorescent dye can be detected with ease. 
In addition, it removes the need for the patient to be exposed to the ionising radiation 
present in radiometal imaging techniques.117 Cyanine dyes have been widely 
investigated for use as a contrast agent in optical imaging; the first receptor targeting 
molecules employed with these dyes were monoclonal antibodies that bound to 
receptors known to be expressed on the surface of tumour cells.118 Despite the high 
specificity of the antibody-receptor binding, the drawback with utilising antibodies as a 
targeting moiety is their significantly long in vivo half-life and high immunogenicity.  
 
In 2001, Becker et al. reported the use of indocarbocyanine dyes linked to octreotide at 
the N-terminus forming the fluorescent conjugate 38 (Figure 1.15). Their synthetic 
strategy involved synthesising the octreotide chain with a Boc-protected inter-chain 
lysine and trityl-protected cysteine residues. With this in hand, the carboxylic acid-
functionalised cyanine dye was coupled to the N- terminal amine of octreotide by means 
of a classic HBTU facilitated coupling. Following this, the protected residues were 
deprotected using TFA and the peptide cyclised by disulfide bond formation before 
finally being purified by HPLC.119 Final yields were not reported. 
 
 
 
 
 
 
 
Figure 1.15: The structure of indodicarbocyanine dye-linked octreotide (38). 
 
In this key publication, they effectively demonstrated that this conjugate displayed 
specific and long-lasting targeting of tumours whilst maintaining desirable 
pharmacokinetic properties.117 The figure below shows the contrast between tumour and 
normal tissue in a mouse bearing a RIN38/SSTR2 tumour before and 6 hours after 
administration of the conjugate. Localisation of the tumour is very effective due to high 
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accumulation in the tissue over-expressing the somatostatin receptor. In addition, 
contrast enhancement was found to be rapid, with ~75% maximum contrast reached 
within 1 hour post injection. Interestingly, the group also investigated the effect of 
exchanging the two cysteines of octreotide with methionine – in this mutant, which 
resultantly lacks its disulfide bond, the binding and accumulation of the dye-linked 
conjugate was significantly reduced shown by the lack of contrast in panels B and D of 
Figure 1.16.117  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16: In vivo fluorescent images of RIN38/SSTR2 tumour bearing mice both before 
(panels A and B) and after 6 hours (panels C and D) administration of the conjugate 38. Panels 
A and C show the effect of the conjugate using native octreotide, panels B and D show the 
effect of a double mutant of octreotide (C2M, C7M).117 
 
This finding further demonstrates the crucial structural contribution of the disulfide 
bond, as discussed at the start of this chapter. Fluorescent octreotide 38 proved to be a 
highly selective and sensitive method for visualisation of tumours by optical imaging. 
One of the few drawbacks with this method, however, is the low penetration levels of 
near infra-red light in living tissue, limiting the use of such conjugates to superficial 
lesions, breast carcinomas or gastric cancers rather than tumours in deeper set 
organs.117,120 
 
Octreotide has been linked to other fluorophores with similar success. Recently Fottner 
et al. synthesised a 5-carboxy-fluorescein linked octreotate derivative which they used 
with a miniaturised confocal laser scanning microscope, facilitating, for the first time, 
the morphological and functional imaging of somatostatin receptor positive tumours in 
real time. This allowed for instantaneous, high-resolution, hisopathological evaluation 
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of organs in vivo. This novel technique is envisaged to be of use in confocal endoscopy, 
facilitating intraoperative visualisation of tumours during surgery.121 
 
1.3.3.3 Multimodal Derivatives 
Employing two complimentary imaging techniques synergistically can allow for more 
accurate staging and localisation of tumours and is a concept that has started to be 
explored. Administering two separate imaging agents carries problems as both will have 
differing pharmacokinetic properties to consider and the toxic effects of each 
component may well be additive. To circumvent this, incorporation of multiple imaging 
agents into nanoparticles, micelles and liposomes has been investigated,122,123 however, 
these carry their own drawbacks as such large molecules have inherently slow diffusion 
rates into the target tissue and rapid uptake by the liver. Most recently, efforts have been 
focused on incorporating the desired imaging agents into one, relatively small entity. 
Monomolecular multimodal imaging agents (MOMIAs) are single molecules consisting 
of two or more imaging agents in a 1:1 signalling ratio, both providing different but 
complimentary information.124 Coupling optical imaging with a radionuclear method 
allows for the drawbacks of each individual method to be negated. Deep tissue tumours 
can be detected using a short-lived radioisotope without the depth limitations of optical 
imaging and subsequently, once the diseased region had been located, precise imaging 
of the tumour can be carried out by optical imaging outside of radioactivity exposed 
areas.124,125 The challenge lies in incorporation of the two active molecules onto a 
targeting moiety, without disrupting the activity, efficiency or selectivity of any of the 
components.  
 
In 2008, Edwards et al. reported on their octreotate derivative LS172 (39) which 
incorporates the DOTA chelating group at the N-terminus for binding of either 177Lu or 
64Cu and the near-infrared fluorescent dye cypate conjugated at the C-terminus of the 
peptide.125 Carefully controlled protection and deprotection steps throughout the solid 
phase synthesis procedure were required to form the desired product shown in Figure 
1.17.  
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Figure 1.17: The LS172 MOMIA (39). 
 
They found that binding of the radiometal to the chelator affected binding affinity of the 
conjugate, for example, binding of 64Cu to DOTA reduced the affinity of LS172 by 
approximately 5-fold. Despite this, their experiments demonstrated excellent correlation 
in the biodistribution of the MOMIA with both optical and radionuclear imaging 
techniques and high binding affinity for the somatostatin receptor. A detrimental 
problem they encountered with LS172 was low tissue accumulation owing to poor 
receptor internalisation upon receptor binding.125 Accumulation of the contrast agent is 
essential for precise tumour assessment and, as a result, this will hinder the potential use 
of LS172 as a MOMIA in the clinic.  
 
1.3.4 Summary 
In summary, radio- and fluorophore-labelled somatostatin derivatives are a valuable tool 
in the diagnosis and, in some cases, treatment of somatostatin receptor positive tumours. 
Despite their usefulness, synthetic routes to these conjugates are indirect and hence 
often low yielding.  
 
Research into utilising octreotide as a targeting moiety for a MOMIA continues. 
Efficient and straightforward routes to enable the incorporation of the imaging moieties 
onto the peptide are required for the concept to progress. 
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1.4 An Introduction to the Patch Clamp Technique 
 
1.4.1 General Introduction 
The plasma membrane of a cell is a semi-permeable barrier, less than 10 nm in 
thickness, which separates the cytoplasm and intracellular organelles from the 
extracellular environment. This membrane is predominantly formed of a phospholipid 
bilayer within which proteins are embedded; these proteins are fundamental for cell 
recognition and the transport of chemicals and ions, both into and out of the cell.126 
Knowledge on this system is vast and well-documented but not within the scope of this 
introduction.  
 
The aforementioned proteins responsible for ion transport are channels that span the 
entire plasma membrane to allow effective transport of ions from one side to another. 
These channels show ion-type selectivity and are gated by either changes in pH, ligands, 
mechanical stress or by changes in electrical potential.126 Through precise regulation of 
ion transport, these channels are responsible for an extensive array of physiological 
processes, from control of hormone secretion to maintaining the heart beat. As a result 
of this, extensive research continues to be conducted into understanding the properties 
and functions of the various channel families and the pharmacological treatment of 
diseases associated with them. 
 
1.4.2 Studying Ion Channels Using the Patch Clamp Technique 
Patch clamp is a very powerful, high-resolution technique used to measure ionic 
currents across a cell membrane. It was originally developed by Erwin Neher and Bert 
Sakmann who demonstrated how the technique could be used to measure incredibly 
small electrical currents passing through a single ion channel in a patch of frog skeletal 
muscle127,128; for this work, and for pioneering the patch clamp method, they were 
awarded the Nobel Prize in Physiology and Medicine in 1991.129  
 
The original method by Neher and Sakmann describes gently pressing the blunt tip of a 
heat polished micropipette onto the surface of a single cell, as depicted in Figure 1.18. 
The small (0.5-2 µm) tip diameter, when in contact with the plasma membrane, creates 
a megaohm (MΩ) seal allowing isolation of a tiny patch of membrane; this can contain 
as little as one single ion channel. It is through this that the electronic recordings were 
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then made.129 Since its original development, the patch clamp technique has been 
greatly refined and is responsible for a wealth of information on the biophysics of ion 
channels and the cell membrane. A seminal discovery leading to significant 
improvement of the accuracy of recordings was that gentle suction, or negative pressure, 
applied to the pipette could create a seal in the gigaohm (GΩ) range – this led to 
reduced ion leak.130  
 
 
 
 
 
 
 
Figure 1.18: The basic patch clamp technique.131 
 
Formation of this high-resistance seal leads to complete electric isolation of the patch of 
membrane beneath the pipette tip; this ensures that any ions that flow through this patch 
of membrane will enter the pipette and be recorded.132 The pipette is filled with a 
solution of desired ionic composition allowing the extracellular environment to be 
completely controlled by the operator. Recording in this fashion is known as the ‘cell-
attached’ configuration and is the most non-invasive of all patch clamp methods, with 
the cell remaining attached throughout the experiment.131,132 With this method, single 
channels can be isolated, as depicted in Figure 1.19, but the intracellular environment 
cannot be controlled. 
 
 
 
 
 
 
 
 
 
Figure 1.19: The ‘cell-attached’ patch clamp mode.131 
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If, subsequent to seal formation, the negative pressure is significantly increased, the 
patch of membrane under the pipette can rupture and access to the intracellular region is 
gained. Upon membrane rupture, the solution and the electrode within the pipette come 
into contact with the cell cytoplasm. The volume of the cell is negligible relative to the 
volume of the micropipette and so the intracellular composition is said to be that of the 
pipette solution and, thus, is completely controlled by the operator.132 In this way, both 
the intra- and extracellular environments can be controlled by tailoring of the pipette 
solution and bath solution respectively. This method is known as the ‘whole-cell’ 
configuration and allows for recordings from all ion channels within the cell membrane 
as depicted in Figure 1.20.78,131,132 
 
 
 
 
 
 
 
 
 
Figure 1.20: The ‘whole-cell’ patch clamp mode.131 
 
Recording is done using a silver electrode within the micropipette which is connected to 
a very sensitive amplifier. The rate of ion flow through an ion channel is typically 
around ten million ions per second; this equates to a current of just a few picoamperes 
and hence highly sensitive detection and amplification is fundamental for precise 
recordings.132 A second electrode is connected to form a circuit and is maintained in the 
extracellular bath solution, this is the bath (or ground) electrode. This can be modelled 
by the equivalent circuit illustrated in Figure 1.21 for the whole-cell configuration. 
 
 
 
 
 
 
 Ion flux 
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Figure 1.21: The whole-cell mode setup.133 
 
Within the circuit formed there is an observable resistance from the pipette, shown in 
Figure 1.21 as serial resistance (Rs), and also the resistance from the cell membrane 
itself, shown as membrane resistance (Rm). The latter is the largest of the two and, with 
formation of a complete circuit, the current through Rm can be determined.
134 The 
whole-cell configuration is the most commonly employed and two modes are available: 
the voltage-clamp mode facilitates the holding of the membrane potential at a set 
voltage, allowing for the quantification of membrane current as the sum of the total ion 
flux though the cell membrane (i.e. through Rm) whilst in the current-clamp mode, the 
membrane current is held constant while changes in membrane potential are 
observed.132 
 
Besides the original cell-attached and most common whole-cell configurations, there are 
a few less common variants that can be employed as alternatives. Adding pore-forming 
agents (commonly antibiotics such as amphotericin B) to the pipette solution while in 
the cell-attached configuration creates a partially permeable membrane under the pipette 
tip; this facilitates the ionic continuity between the pipette solution and cytoplasm 
whilst ensuring intracellular proteins stay within the cell. This is known as the 
‘perforated-patch’ method and is depicted in Figure 1.22.131,132 
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Figure 1.22: The perforated patch clamp mode.131 
 
It is also possible to make recordings using a small patch of membrane rather than the 
whole cell. This again allows for both the intra- and extracellular environment to be 
controlled and increases the chances of obtaining recordings through single channels. In 
the ‘inside-out’ configuration (Figure 1.23a), the cytosolic face of an excised patch of 
membrane is exposed, allowing for the study of the effect of intracellular ligands on the 
ion channel of interest. Conversely, in the ‘outside-out’ configuration (Figure 1.23b), 
the extracellular face is exposed and the effect of extracellular ligands then 
studied.131,132  
 
 
 
 
 
 
 
 
Figure 1.23: The a) ‘inside-out’ and b) ‘outside-out’ patch clamp modes.131  
 
1.4.3 Membrane Potential and Capacitance 
The intra- and extracellular media possess a number of different inorganic ions in 
varying concentrations. The gross distribution of these ions is relatively consistent 
among a vast number of cell types and is displayed in Table 1.4 below. 
 
 
 
Amphotericin B 
a) Inside-out b) Outside-out 
 58 
Table 1.4: The ionic distribution across the animal cell membrane.132  
 
Ion 
Species 
Intracellular concentration 
range (mM) 
Extracellular concentration 
range (mM) 
Na+ 5.00-20.0 130-160 
K+ 130-160 4.00-8.00 
Ca2+ 0.05-1.00x10-3 1.20-4.00 
Mg2+ 10.0-20.0 1.00-5.00 
Cl- 1.00-60.0 100-140 
 
The differences in ion distribution create a concentration gradient across the plasma 
membrane for each ion species. These concentration gradients lead to the diffusion of 
ions down this gradient, from higher to lower concentration environments.132 This 
diffusion of ions changes the existing electric potential across the membrane (the 
membrane potential).  This new potential creates an electric force on the ions which 
opposes the diffusion force on the ions. As the diffusion of the ionic species continues, 
the electric potential gradient opposing the diffusion gets steeper. Once these two 
opposing forces are equal, equilibrium is reached and there is no net movement of ions 
across the membrane.134    
 
 The relationship which describes the electrical potential at which an ionic gradient is at 
equilibrium is given by the Nernst equation:132,134  
 
 
 
Where E is the equilibrium potential for a given ion, R is the universal gas constant (8.31 J mol-1 K-1), T is 
temperature in Kelvin, z is the oxidation state of the given ion, F is the Faraday constant (9.65 x 104 C 
mol-1) and [ion]o and [ion]i are the extra- and intracellular concentrations of the given ion respectively. 
 
The potential difference across the cell membrane, i.e. the membrane potential, is due to 
both the overall distribution of ions and the relative permeability of the plasma 
membrane to each ionic species at any one moment. At rest, the typical membrane 
potential is around -50 to -80 mV.132 
 
If the membrane potential is not equal to the equilibrium potential for a given ion at any 
one moment, then that ion will move across the membrane accordingly. This movement 
of ions is a movement of charge and, in electronic terms, is expressed in current:132 
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Where I is current in amperes (A) and dQ/dt is the change in charge over time in coulomb (C). 
 
The current caused by ion flux is dependent upon two variables: the net electrical 
potential acting on the ion, which is the difference between the membrane potential and 
the equilibrium potential, and the resistance from the membrane. The fewer channels 
open for transport of the ion, the greater the resistance imposed by the membrane 
(Rm).
132  
 
The membrane also exerts a capacitance effect, meaning it has the ability to store 
charge. It does so by accumulating ions of opposite charge on the inner and outer faces 
of the membrane by forces of attraction. It follows that the larger the surface area of the 
membrane, the greater the capacitance of the cell as there is greater area over which to 
accumulate ions. As a result of this capacitance associated with the plasma membrane, a 
change in membrane potential will always come into effect with some delay; the change 
must first overcome the stored charge present at that given moment.132 
 
The resistance, capacitance and potential of a cell membrane are all factors that are 
taken into consideration when conducting electrophysiological experiments to study 
ionic currents and there are methods to quantify and compensate for them accordingly.  
 
1.4.4 Application of the Patch Clamp Technique 
 
Patch clamp is a valuable technique employed when approaching physiological 
questions about ion channels. Patch clamp can be carried out on cultured cells, excised 
dissociated cell samples or on tissue slices; the latter creating the most physiologically 
relevant environment133. In addition, the ion channel of interest can be heterogeneously 
introduced and expressed by transfection of a stable cell line. The patch clamp 
technique is used in many areas of research, most notably in the area of neuroscience 
and the research into the physiology of excitable cells. Methods for efficient cell 
isolation have broadened the scope of possibilities through patch clamp. Recently, high 
resolution recordings from brain slices were obtained135 and even recordings from the 
brain in vivo have been conducted successfully.136 The great significance of this 
advance in the patch clamp technique is demonstrated in its recent use to study 
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fundamental electrophysiological processes such as electrical transmission at 
synapses136,137 and the study of vital ion channels in neurones of the brain.138,139 
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1.5 Project Aims 
 
 
As discussed in the introduction, maleimides present themselves as one of the most 
commonly employed motifs for the chemical modification of cysteine. Most recently, 
their utility in the re-bridging of a reduced disulfide bond as a strategy for protein 
modification has been realised and, as a result, is becoming a rapidly expanding and 
exciting field.  
 
A preliminary aim of this project is to broaden the library of 3,4-disubstituted 
maleimide reagents available; careful design of the chemistry of these reagents should 
allow their reactivity, properties and functionality to be fine-tuned. We plan to explore 
the effect of varying the substituents of the 3,4-disubstituted maleimides in order to 
either increase or decrease reactivity, or to tailor the chemical properties of the reagents 
(Scheme 1.18). Perhaps most significantly, a solution to the issue of the poor water-
solubility associated with the currently available maleimides is sought. The 
modification protocols devised thus far all employ significant amounts of organic 
solvents which are known to disrupt non-covalent interactions and which may have a 
detrimental effect on protein structure.140,141 Improving the water-solubility of our 
reagents could be greatly beneficial and widen the scope of their utility. 
 
 
 
 
Scheme 1.18: From dibromomaleimide 15 to novel next generation maleimides. 
 
We are also interested in probing the selectivity of the maleimides; site-selectivity in the 
field of bioconjugation is a fundamental criteria but one that can prove challenging to 
achieve. Many peptides and proteins of therapeutic interest have disulfide bonds, often 
multiple. Thus far, research within the group had been restricted to systems with a 
single disulfide bond. Those with multiple disulfides present themselves as more 
challenging targets. We aim to probe the ability of our maleimide reagents to selectively 
target a disulfide by exploiting the differential accessibility and reactivity of the bonds. 
Recently published work by Brocchini et al. describes similar studies on their disulfide-
bridging monosulfone reagents with promising results56; we are interested in how well 
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3,4-disubstituted maleimide reagents compared in the pursuit for truly site-selective 
disulfide modification reagents.  
 
An in situ protocol for maleimide modification has recently been reported, which serves 
to immediately re-bridge two cysteine residues upon reduction, effectively minimising 
the opportunity for protein or peptide unfolding and aggregation.24 In the case of 
multiply disulfide bonded systems, this protocol is hypothesised to reduce the likelihood 
of disulfide scrambling – an important consideration for these more complex systems. 
We plan to examine the scope of this in situ protocol in overcoming such limitations 
associated with the presence of more than one disulfide bond within a target. 
 
In order to examine the aforementioned concepts, we have chosen the small peptide 
neurotoxin tertiapin Q 40 as a target (Scheme 1.19). This peptide has two disulfide 
bonds in relatively close proximity. As described, this peptide has potential for use as an 
ion channel probe or as a therapeutic for atrial fibrillation; success in the selective 
modification of the disulfide bond/s of tertiapin Q could open the doors to the formation 
of novel, functional bioconjugates for such applications. 
 
 
 
 
 
 
Scheme 1.19: Towards a maleimide modified derivative of tertiapin Q (40). 
 
We aim to accurately assess the effects of the incorporation of an unnatural two-carbon 
bridge within the disulfide bond/s of tertiapin Q. To accomplish this, we plan to use the 
electrophysiological technique of patch clamp to assess any alterations to the binding 
and resultant effects of maleimide modified tertiapin Q on its target, namely the GIRK 
channel family. If biological activity is successfully maintained, work will focus on the 
synthesis of the desired, functional bioconjugates. 
 
Concurrent with this, we plan to examine the scope of the small peptide octreotide as a 
target for maleimide modification. Octreotide has considerable coverage in the literature 
as both a therapeutic in its own right, and as a precursor for bioconjugation. Its high 
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affinity for the somatostatin receptor makes it the ideal candidate for the diagnosis and 
treatment of somatostatin-receptor positive tumours, of which there are numerous. We 
hope to use maleimide modification to contribute to this field, by the design and 
synthesis of some novel, next-generation bioconjugates (Scheme 1.20). Of particular 
interest is whether we could create a functional diagnostic MOMIA via an efficient 
synthetic route. 
 
Scheme 1.20: Towards novel bioconjugates of octreotide (34). 
 
Subsequent to the preliminary yet promising research carried out by the Baker and 
Caddick groups, and alongside the complimentary work conducted by the Brocchini 
group, this project will investigate the 3,4-disubtituted maleimides as reagents for 
disulfide modification. Of key interest is their efficacy when used on therapeutically 
relevant targets and those with multiple disulfide bonds – a challenging idea but one that 
would vastly broaden the scope of the maleimide modification technique. A primary 
goal is to devise sound methods for both accurate structural analysis and biological 
activity testing of our modified products. Finally, we aim to create useful and innovative 
bioconjugates from our chosen target peptides, with the vision of creating products that 
fulfil gaps within the clinical market. 
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Chapter 2: Results & Discussion 
2.1 Maleimide Synthesis & Reactivity  
 
2.1.1 Maleimide Synthesis 
After promising results from research in the Baker group on dibromomaleimide and, 
perhaps more significantly, dithiophenolmaleimide, it was proposed that a family of 
modified thiophenolmaleimide reagents be synthesised and examined.24 Altering the 
substituents on the aromatic ring of dithiophenolmaleimide should serve to tune the 
reactivity of the compounds. The target molecules first envisaged were designed to vary 
in their substituents in the ortho- position on the thiophenol ring. Introducing steric bulk 
at these positions was postulated to help decrease susceptibility towards unwanted 
attack by bulky nucleophilic reducing agents employed in the disulfide bridging 
protocols. Dithiophenolmaleimide 22 and the ortho-substituted derivatives 41-43 were 
chosen and synthesised using dibromomaleimide and the corresponding substituted 
thiophenols, both of which commercially available (Scheme 2.1). In each case, the 
synthesis was straightforward and yielded a solid product with varying yellow 
colouration.  
 
 
 
 
 
 
 
Scheme 2.1: Synthetic route to maleimides 22 and 41-43. 
 
All syntheses were very fast; all starting material had reacted within 15 minutes in each 
case, as confirmed by thin-layer chromatography (TLC). The yield of maleimide 43 is 
significantly lower; this was reasoned to be as a result of the competing side reaction in 
this synthesis, the formation of the disulfide, which was not isolated due to its tendancy 
to elute alongside maleimide 43 during attempts at purification. 
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2.1.2 Addition of Cysteine to Maleimides 
To examine how efficient these new maleimides would be at reacting with thiols via the 
addition-elimination reaction, a preliminary test was carried out using a protected 
cysteine analogue, N-Boc-Cys-OMe (10) (Scheme 2.2).  The reaction was carried out in 
pH 6.2 phosphate buffer in order to mimic conditions suitable for use with proteins. 
After protocol optimisation, DMF (15%) was employed in order to facilitate the 
solubilisation of the maleimides. 
 
 
 
 
 
 
 
 
 
Scheme 2.2: The reaction of maleimides 22 and 41-43 with N-Boc-Cys-OMe (10). 
 
Table 2.1: Yield of dicysteine-maleimide obtained for maleimides 22 and 41-43. 
 
Maleimide Reaction time (min) Yield of Product 44 
(%) 
22 (X=H) 30 85 
41 (X=Me) 120 37 
42 (X=Cl) 60 49 
43 (X=COOMe) 30 86 
 
In the case of maleimides 22 and 43, the reaction was fast; all starting material had 
reacted within 15 minutes, affording good yield of the product 44 after purification. In 
contrast, with maleimides 41 and 42, starting material remained, even after elongated 
reaction times of over an hour, and it appeared that no further reaction was taking place. 
This is consistent with the fact that maleimides 41 and 42 contain electron donating and 
sterically encumbering groups respectively, which will serve to reduce the rate of 
nucleophilic substitution. This may also lead to competing reactions, such as disulfide 
formation, which would prevent full conversion to the desired product.  
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2.1.3 TCEP Cross Reactivity with Maleimides 
As described in Chapter 1, a potential limitation of targeting disulfide bonds in protein 
modification is the likelihood of scrambling, aggregation or unfolding during the 
reduction process. The ideal bridging protocol adopts an in situ approach whereby the 
bridging reagent and the reducing agent must be present together in order to decrease 
the time the reduced disulfide is left unbridged. For this to be possible however, the 
maleimides must be resistant to cross reactivity with the reducing agent employed. Due 
to the fact that dithiothreitol (DTT) and β-mercaptoethanol (BME) are thiol-based, they 
have been found to be, as expected, inefficient at disulfide reduction when used in 
combination with thiophenolmaleimide 22 due to their propensity to react with the 
maleimide itself.24 As a result, the phosphine-based reducing agent TCEP has routinely 
been employed thus far. Reactivity towards TCEP has been observed for 
dibromomaleimide and, to a lesser extent, for thiophenolmaleimide. This decreased 
susceptibility of cross-reactivity with dithiophenolmaleimide is perhaps due to the 
increased steric hindrance imparted by the aromatic rings, blocking the access of TCEP. 
To examine the reactivity of maleimides 22 and 41-43 towards TCEP they were reacted 
together in pH 6.2 phosphate buffer for 15 minutes (Scheme 2.3) and the yield of 
recovered maleimide calculated. The results obtained are shown in Table 2.2. 
 
 
 
 
 
 
 
Scheme 2.3: Reaction conditions to determine cross reactivity of maleimides 22 and 41-43 with 
TCEP. 
 
 
Table 2.2: Yield of maleimide recovered after cross-reactivity experiment. 
 
Maleimide Yield Recovered (%) 
22 (X=H) 94% 
41 (X=Me) 100% 
42 (X=Cl) 96% 
43 (X=COOMe) 95% 
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All maleimides tested seemed to exhibit resistance towards cross reactivity with TCEP. 
Variation between the recovered yields is negligible, suggesting the extent of cross 
reactivity is not dependent upon the protection by the substituent on the aromatic ring. 
 
2.1.4 Bridging Somatostatin in a Step-wise Protocol 
Work progressed onto testing the disulfide bridging capability of the maleimide 
reagents on a model peptide system. Somatostatin 20, a 14 amino acid peptide hormone 
discussed in detail in Section 1.3, was employed. Somatostatin has a single, accessible 
disulfide bond and proved simple to prepare and characterise by the desired analytical 
methods. Initially, utility of the maleimides 22 and 41-43 in the step-wise bridging 
protocol was investigated.24 This is a two stage process, the first being reduction of the 
disulfide bond using TCEP to reveal the two nucleophilic cysteine thiols. The second 
stage is addition of the maleimide reagent to install a two-carbon bridge between the 
cysteines, as depicted in Scheme 2.4, creating maleimide bridged somatostatin 21.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.4: Step-wise bridging of somatostatin (where X = H (22), Me (41), Cl (42) or COOMe 
(43)). 
 
After addition of 1.4 equivalents of TCEP and incubation at room temperature for 1 h, 
somatostatin was fully reduced. This was determined by apparent conversion by LC-
MS. Successful reduction was identified by the increase in mass from m/z 1638 to m/z 
1640 accounting for the protonation of both cysteine sulphurs. A subsequent mass 
increase to m/z 1733 was observed upon addition of the maleimide reagents accounting 
for the incorporation of the bridge between the two cysteine residues and formation of 
bridged somatostatin 21. The species were commonly observed as the doubly charged 
ions; typical mass spectra are shown in Figure 2.1 A-C. 
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Figure 2.1: A-C: ESI mass spectrum of A) peak at m/z 819.38 corresponding to the doubly 
charged ion of native somatostatin 20 (expected mass = m/z 818.95). B) peak at m/z 820.34 
corresponding to the doubly charged ion of reduced somatostatin (expected mass = m/z 819.95) 
and (C) peak at m/z 866.90 corresponding to the doubly charged ion of maleimide-bridged 
somatostatin 21 (expected mass = m/z 866.50). 
 
LC-MS readings were taken at 1, 10 and 60 minutes, and despite all of the maleimides 
showing rapid bridging, there were some noticeable differences between their rates of 
reaction. Apparent conversion to the bridged product 21 over time for each of the four 
maleimide reagents is shown in Figure 2.2. Conversion percentages are determined by 
peak height in the LC-MS spectra and are normalised accordingly if more than one 
A B 
C 
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species is detected. Such analysis is not perfectly quantitative, but gives a good 
representation of conversion rates and product ratios. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Percentage conversion to bridged somatostatin 21 over time for maleimides 22 and 
41-43. 
 
From Figure 2.2, it is apparent that the rate of conversion to modified somatostatin 21 
follows the trend 43 > 22 > 42 > 41. This is as expected and supports the observations 
from the previous experiment using protected cysteine. Maleimide 43 reaches 
quantitative conversion to the bridged product 21 within 1 minute, owing, as previously 
discussed, to the effects of the electron withdrawing methyl-ester group on the aromatic 
ring, increasing its reactivity towards the cysteine thiolate. Conversely, maleimide 41 
had only reached 70% conversion to bridged product 21 in this time; the electron 
donating methyl substituent decreasing the reactivity of the maleimide and therefore 
slowing the rate of reaction. Maleimides 22 and 42, with their thiophenol and 
chlorothiophenol substituents respectively, have intermediate bridging speeds, the un-
substituted and halogenated aromatic rings having a lesser effect on the maleimide 
reactivity.  
 
Maleimide 43 presents itself as a very effective bridging reagent capable of complete 
conversion to bridged somatostatin within 1 minute. When compared to maleimide 22 
which was found, both in this study and in previous literature, to afford complete 
conversion within 10 minutes7, this further heightens the potential for 43. Increased 
speed of the bridging reaction consequently means that the free cysteines of the reduced 
disulfide have less opportunity to participate in disulfide scrambling, or for the 
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structural integrity of the peptide or protein to be lost by unfolding, both of which could 
be detrimental.  
 
2.1.5 Bridging Somatostatin in an In Situ Protocol 
Following these promising results, the utility of these maleimides in the in situ protocol 
described was assessed. In this procedure, the peptide is pre-incubated with the 
maleimide reagent prior to addition of the reducing agent. It should follow that, as soon 
as the disulfide bond is cleaved, there is a maleimide present to immediately re-bridge 
the free cysteine thiols. In reference to a previously published protocol,24 5 equivalents 
of maleimides 22 or 41-43 were added to somatostatin 20 before 3 equivalents of TCEP 
(Scheme 2.5). LC-MS recordings were taken after 1, 5, 10, 20 and 30 minutes.  
 
 
 
 
 
 
 
 
Scheme 2.5: In situ bridging of somatostatin (where X = H (22), Me (41), Cl (42) or COOMe 
(43)). 
 
Apparent conversion to the bridged product 21 over time is plotted in Figure 2.3.  
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Percentage conversion to bridged somatostatin 21 over time for maleimides 
22 and 41-43 (3 equiv TCEP). 
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From these results, it is apparent that the difference between maleimides 22 and 41-43 
in the rate of conversion to the bridged product 21, which was seen in the step-wise 
protocol, is no longer apparent and the rate of conversion is almost identical in each 
case. For all maleimides tested, only 40-50% conversion was observed after 1 minute, 
which is significantly less than the conversion observed using the step-wise protocol. 
This suggests that it is in fact the reduction of the disulfide by TCEP that is the rate 
limiting step in this reaction sequence, rather than the speed at which each maleimide 
can re-bridge the free thiols. Interestingly, it took longer than the 20 minutes previously 
reported using thiophenolmaleimide 22 to reach complete conversion to the bridged 
product 21 in such a protocol1. With exception to maleimide 41, all other reagents led to 
the desired product within 60 minutes. 
 
2.1.6 Towards Reagent Stoichiometry in the In situ Protocol 
Ideally, a stoichiometric system would exist, whereby there are no unused reagents 
remaining after complete conversion to the bridged product; this facilitates the ease of 
product purification and minimises the likelihood of any undesirable side reactions 
occurring. Using dibromomaleimide this is difficult to achieve due to the previously 
observed cross reactivity with TCEP. As previously demonstrated, the thiophenol-based 
maleimide reagents show much greater resistance and therefore could potentially be 
applicable to a stoichiometric system. Experiments were carried out in an attempt to 
reduce the amounts of each reagent employed. 
 
 
By initially employing TCEP as the limiting reagent, somatostatin was incubated with 5 
equivalents of maleimide 22 for 10 minutes, before addition of 1 equivalent of TCEP. 
The reaction was monitored over 90 minutes by LC-MS. Product formation is shown in 
Figure 2.4. 
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Figure 2.4: Percentage conversion to bridged somatostatin 21 over time using the in situ 
protocol with 5 equivalents of maleimide 22 and 1 equivalent of TCEP.       
 
Using a stoichiometric (with respect to the number of disulfide bonds) amount of 
reducing agent revealed a very fast initial reaction, with 55% conversion to the bridged 
product 21 within 1 minute. Subsequent to this, the rate of reaction drops significantly. 
Maximal product formation is seen soon after 30 minutes, and from this point onwards 
there is negligible increase. To determine the exact stoichiometry at which full 
conversion to bridged somatostatin is obtained, a second experiment was conducted 
whereby 1 equivalent of TCEP was added primarily as before, and then, as the 
percentage of conversion stopped increasing over time, 0.1 equivalents of TCEP were 
then added incrementally. Product formation is shown in Figure 2.5. 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Conversion to bridged somatostatin 21 over time using the in situ protocol with 5 
equivalents of maleimide 22 and 1 equivalent of TCEP, followed by 0.1 equivalents at 25, 40 
and 70 minutes.       
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A further 0.3 equivalents of TCEP is required to push the conversion to completion by 
full disulfide bond reduction. This may be as a result of a very small degree of cross 
reactivity with the maleimide reagents. Nevertheless, 1.3 equivalents of TCEP is 
pleasingly close to the stoichiometric ideal.  
 
Turning next to the minimisation of bridging reagent employed in the in situ protocol, 
somatostatin was pre-incubated with a minimum amount of maleimide 22 before 
addition of TCEP. Product formation is shown in Figure 2.6. It was found that with as 
little as 1.1 equivalents of maleimide 22 used in conjunction with 1.3 equivalents of 
TCEP, full conversion to bridged somatostatin 21 could be obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Conversion to bridged somatostatin over time using the in situ protocol with 1.1 
equivalents of maleimide 22 and 1.3 equivalent of TCEP. 
 
In comparing this to the results in Figure X where 5 equivalents of maleimide are 
employed, it is apparent that this only serves to increase the rate of the reaction; 80% 
conversion to the bridged product 21 is achieved within 5 minutes in this case.  
 
Again this gives promise that cross-reactivity between the reagents used is very low, 
and that near-stoichiometric amounts of reducing agent and maleimide can be employed 
with minimal compromise on the rate of the disulfide bridging reaction.   
 
2.1.7 An In situ Protocol using Benzeneselenol-Catalysed Reduction 
As previously mentioned, at pH 6.2, the common reducing agents DTT and BME are 
not compatible in an in situ protocol, due to their thiol-based nature. In the search for 
alternatives, it was found that selenol-based reagents were used to catalyse the reduction 
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of disulfide bonds with great efficiency.24 When a catalytic amount was used in 
conjunction with DTT in the reduction of the disulfide bond of α-chymotrypsinogen, 
disulfide reduction rates were increased by a factor of ~100.142 In light of this, previous 
studies in the group investigated the use of benzeneselenol alongside 
dithiophenolmaleimide 22 and such a protocol proved effective in the rapid in situ 
modification of the disulfide bond of somatostatin.24 The devised protocol was repeated 
using maleimides 22 and 41-43; pre-incubation with 10 equivalents of the maleimide 
before addition of 5 equivalents of benzeneselenol (Scheme 2.6). Conversion to the 
bridged peptide 21 was monitored over time.  
 
 
 
 
 
 
 
 
 
Scheme 2.6: In situ bridging of somatostatin using catalytic benzeneselenol (PhSeH) (where X = 
H (22), Me (41), Cl (42) or COOMe (43)). 
 
The apparent conversions to bridged peptide 21 by LCMS are shown in Figure 2.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Percentage conversion to bridged somatostatin 21 over time for 22 and 41-43 (5 
equiv. benzeneselenol). 
 
All maleimides reach quantitative conversion to bridged somatostatin 21 and, with the 
exception of 42, do so within 5 minutes with negligible variation in rate of reaction. 
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This suggests that benzeneselenol has dramatically increased the rate of disulfide 
reduction in comparison to TCEP. The speed of the bridging itself is also increased, but 
can be accounted for by the excess (10 equivalents) of maleimide present. In 
conclusion, benzeneselenol presents itself as an efficient alternative to TCEP to 
facilitate very rapid disulfide reduction. 
 
2.1.8 Towards an Organic Solvent-Free In Situ Protocol 
The four maleimide compounds tested thus far, although efficient in the bridging 
protocol, were found to be somewhat insoluble. Because of this, acetonitrile (40% v/v) 
and DMF (2.5% v/v) were routinely added to the buffer in which somatostatin is 
dissolved in order to aid solubility of the maleimide compounds once added. This is 
highly undesirable when trying to mimic physiological reaction conditions.140,143 
Organic solvents such as these have been found to have a detrimental effect on protein 
structure and function.144 For this reason, maleimide 45 where X = COOH was 
synthesised (Scheme 2.7), on the premise that the carboxylic acid should greatly 
increase the solubility of the whole compound. Deprotonation to form a charged 
carboxylate moiety should improve its dissolution in water. 
 
 
 
 
 
 
 
Scheme 2.7: The synthetic route to maleimide 45. 
 
Pleasingly, maleimide 45 was found to be soluble in pH 6.2 phosphate buffer, with no 
added organic solvents, up to a concentration of 7 mM. This concentration is suitable 
for the disulfide modification experiments. The reactivity of this reagent was 
comparable to that of the other thiophenolmaleimide derivatives. 1.1 equivalents of this 
compound were used in the in situ bridging of somatostatin, alongside 1.3 equivalents 
of TCEP and full conversion to the bridged product 21 was seen within 60 minutes 
(Scheme 2.8).  
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Scheme 2.8: In situ bridging of somatostatin 20 using maleimide 45 in organic solvent-free 
conditions. 
 
Maleimide 45 proved to be the first example of a disulfide bridging reagent compatible 
with a completely organic solvent-free system. This reagent, and other water soluble 
maleimide derivatives, could prove invaluable in cases where the peptide or protein 
shows sensitivity towards organic solvents.63 
 
2.1.9 Summary of Results 
In summary, new functionalised thiophenolmaleimides with differing chemistry have 
been synthesised successfully. They varied in their reactivity depending on the nature of 
the group in the ortho position of the aromatic ring, electron withdrawing groups aiding 
faster rates of reaction; maleimide 43 presented itself as the fastest acting bridging 
reagent to date. Results confirmed that maleimides 22 and 41-43 are all unreactive 
towards the reducing agent TCEP, as desired. The maleimides were all capable of 
bridging the disulfide bond of somatostatin in both the step-wise and in situ protocol 
with TCEP as the reducing agent. Near-stoichiometric conditions can be achieved, 
minimising the amount of unused reagent remaining and aiding product purification. 
Employing benzeneselenol as a reducing agent in the in situ protocol lead to improved 
reduction rates compared to those observed with TCEP. Incorporation of a carboxylic 
acid moiety on the aromatic rings of the maleimide serves to improve water-solubility to 
such an extent that completely organic solvent-free conditions can be achieved with 
maleimide 45.  
 
Tuning of the reactivity of the maleimides goes further than that studied in this project, 
and is the focus of other members of the group. In continuation of this study, the effect 
of altering the location of the ring substituent to the meta- and para- positions would be 
of interest but was not within the scope of this project. 
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2.2 Modification of Tertiapin Q 
 
 
From initial experiments with somatostatin giving promise that our 3,4-disubstituted 
maleimide reagents could effectively re-bridge an accessible disulfide bond, we wished 
to examine the scope of this modification strategy. Somatostatin presented itself as a 
relatively simple model owing largely to the fact it consists of a single disulfide bond. 
We were intrigued by how this chemistry would translate to more complex systems; 
those with multiple disulfide bonds were a key interest. As discussed in Chapter 1.1, 
disulfide bonds are prevalent in many extracellular or surface-exposed peptides and 
proteins where they play fundamental roles in conferring structure and stability and in 
the tuning of biological function.1  Examples of those containing multiple disulfides are 
also numerous. For the purpose of our study, we chose a small 21 amino acid 
neurotoxin peptide called tertiapin Q. This peptide is discussed in detail in Chapter 1.2, 
but most notably it consists of two disulfide bonds which serve to maintain its rigid and 
compact structure and consequently help confer great affinity for its GIRK channel 
target.76 We hypothesised exploring the scope of the maleimide reagents on this system; 
to determine whether sufficient control of the bridging could be obtained to allow 
selective disulfide modification whilst retaining the correct cysteine connectivity, to 
examine to what extent the biological activity of the peptide is altered as a result of 
modification and to synthesise novel, functional bioconjugates of tertiapin Q for various 
applications.   
 
2.2.1 Dose-Response Analysis of Native Tertiapin Q 
It is a well-known concept that the response elicited by a given substance is dependent 
upon the concentration. Substances such as toxins often show the characteristic dose-
response relationship whereby, at very low doses, the substance is non-toxic, at 
intermediate doses a response is seen and the level of which steeply increases and, at 
very high doses, the effect tends to plateau as the effect reaches its maximum.145 
  
Analysis of the effect of increasing doses of native tertiapin Q on the inhibition of both 
inwards and outwards flux of K+ through the GIRK1/4 channel would serve as control 
with which to compare the biological activity of any modified derivatives. Whole-cell 
patch clamp experiments were conducted on HEK293 cells stably expressing the GIRK 
1/4 channel subtype.146 This subtype was chosen as, in cardiac cells, these predominate 
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and therefore is the most physiologically relevant system to employ in out experiments. 
The typical current traces for a recording of GIRK1/4 currents at both rest and after 
application of tertiapin Q are shown in Figure 2.8. 
 
Figure 2.8: Current recordings of A) the resting GIRK1/4 channel and B) GIRK1/4 channel 
inhibition by tertiapin Q (100 nM). Current was recorded over 20 mV voltage steps, over a 
range of -120 to +40 mV from a holding potential of -50 mV. 
 
 
These representative recordings show the large inwards currents and smaller outwards 
currents of the GIRK1/4 channel at rest (Figure 2.8A). Immediate current activation is 
observed following capacitive transient spikes. Upon administration of tertiapin Q, 
inhibition of the GIRK1/4 channel is seen by reduction in both the inwards and 
outwards currents (Figure 2.8B).  
 
Recordings were taken at regular intervals whilst increasing doses of tertiapin Q 
(ranging from 1 nM to 100 nM) were subjected to the cells via continuous perfusion. 
A 
B 
A 
B 
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This allows for the recording of the total amount of current from K+ flux through all 
GIRK1/4 channels in the cell membrane. The results obtained are shown in Figure 2.9. 
 
Figure 2.9: Current-voltage relationship: average K+ current (pA/pF) over a range of membrane 
potentials (-120 to +40 mV) in response to changing concentrations of tertiapin Q. The error 
bars shown are calculated as the standard error of the mean. 
 
Figure 2.9 shows the change in K+ current over the full range of membrane potentials 
tested. The graph shows the characteristic trace of an inwardly rectifying channel – a 
significantly large inwards K+ current, seen between -120 and around -40 mV, and a 
smaller outwards K+ current seen between around -40 and +40 mV.147 The point at 
which the lines cross the x-axis is where the ion flux switches from being in the inwards 
direction to being outwards. The expected value of this for a particular ion, known as 
the reversal potential, has the same numerical value as the equilibrium potential of that 
ion. This is defined by the Nernst equation: 
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The Nernst equation where R is the universal gas constant (8.31 Jmol-1 K-1), T is the 
temperature in Kelvin, z is the oxidation state of the ion, F is the Faraday constant (9.65x104 
Cmol-1) and [ion]o and [ion]i are the extracellular and intracellular concentrations of the ion of 
interest respectively. 
 
For K+, at a temperature of 298 K, the physiological equilibrium potential is calculated 
as -83.7 mV. In this investigation, the compositions of the intracellular and extracellular 
solutions produce an equilibrium potential of -48.0 mV. In the patch clamp protocol 
used, the holding potential is -50 mV, close to the equilibrium potential calculated 
where there is no net movement of ions across the cell membrane. Experimentally, 
Figure 2.9 shows the reversal potential to be between around -40 mV prior to the 
addition of tertiapin Q. The small discrepancy is due to endogenous currents present in 
HEK293 cells,148 and also some small current leak as a result of the whole-cell patch 
clamp procedure. Figure 2.9 also shows that tertiapin Q inhibits the GIRK channels at 
all membrane potentials tested, confirming that its effect is voltage independent, 
concurrent with previous literature.96  
 
At the lowest tertiapin Q concentration, 1 nM, there is very little change in the level of 
K+ current passing through the GIRK channels, although a very small inhibitory 
response is still seen. Increasing the concentration from 1 nM to 5 nM sees a dramatic 
increase in the inhibitory response, shown by the large drop in the level of K+ current 
recorded. This effect continues up to 30 nM, but increasing the concentration above 30 
nM leads to no further increase in channel inhibition. Even with tertiapin Q 
concentrations as high as 100 nM, the current level does not seem to reach 0, where 
there is no flux of K+; this residual current has also been noticed in similar experiments 
by Kanjhan et al..96 
 
In order to obtain a numerical value to quantify the potency of tertiapin Q as an 
inhibitor, the IC50 value should be determined. In this case, this is the concentration at 
which half maximum inhibition of the GIRK channel is obtained. To do this, the 
average degree of channel inhibition, as a percentage, by each concentration of tertiapin 
Q tested is plotted (Figure 2.10). From this, the concentration for half maximum 
inhibition can be determined. 
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Figure 2.10: Mean current inhibition (%) with increasing concentration of tertiapin Q (plotted 
as log [tertiapin Q (µM)]. The sigmoidal fit line (red) was produced using a fit with function y = 
Bottom+(Top-Bottom)/(1+10^(X-LogIC50)). R2 = 0.9976. X at Y50 = -2.32. The error bars 
shown are calculated as the standard error of the mean. Raw data in Appendix Table 1. 
 
 
The sigmoid shape of the graph in Figure 2.10 is highly characteristic of a dose-
response study. The equation used to fit the data assumes a Hill slope of -1.0; this 
corresponds to a 1:1 ratio of ligand to receptor binding and can be utilised in this 
analysis due to extensive literature precedent confirming this stoichiometry to be true.145 
The IC50 value was calculated to be 4.78 nM. This is similar to the value quoted in the 
literature which is 8.5 nM.79 With an R2 of 0.9976, the data values fit well within the 
sigmoid trend line suggesting the IC50 value obtained can be taken with confidence. 
 
From this analysis, it is clear that tertiapin Q is a potent inhibitor of GIRK1/4 channels, 
eliciting its effects at concentrations as low as 1 nM. This potency, along with its great 
selectivity, makes tertiapin Q an ideal candidate for studying the characteristics and 
physiology of these channels.   
 
2.2.2 Tertiapin Q Wash-Out Analysis 
It is often the case that ion channel inhibitors that physically block the channel by 
binding in the pore region act reversibly and that washing out the inhibitor can lead to 
recovery of original function.145 Chemical modification of tertiapin Q also has the 
potential to alter not only the inhibitory potential of the toxin, but also the ability for the 
inhibition to be reversed by washing out the toxin from the channel pore. If toxins such 
as tertiapin Q are to be used for analytical or medical applications then these 
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characteristics are important. To test this, after the maximum concentration of tertiapin 
Q had been administered to the cells and maximal GIRK channel inhibition observed, 
perfusion was switched to extracellular solution and currents monitored for return to 
resting levels. Figure 2.11 shows the current recovery after administration of 100 nM 
tertiapin Q. After GIRK channel inhibition by the maximum concentration of tertiapin 
Q, some recovery of K+ flux is possible with continuous wash-out with extracellular 
solution. At the most negative membrane potential, -120mV, there is about 35% current 
recovered. Resting current levels were not fully regained. 
 
Figure 2.11: K+ current (pA/pF) inhibition over a range of membrane potentials (mV) with 
100nM tertiapin Q and K+ current recovery after washing with extracellular solution. 
 
 
These particular results were recorded after 25 minutes of perfusion with extracellular 
solution which suggests that current recovery is significantly slow. This experiment was 
repeated with similar results; only between 25-45% of the baseline current levels were 
ever observed. These findings are concurrent with others in the literature95; however 
there are also cases where more complete recovery is seen88. This variation is most 
probably due to the differing cell types employed and the limiting amount of time that 
patch-clamp recordings can be taken for as the seal on the cell membrane is easily lost.  
 
This analysis of native tertiapin Q serves as a control for comparison with any modified 
derivatives synthesised. 
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2.2.3 Maleimide Modification of Tertiapin Q 
With our study on native tertiapin Q complete, we turned to examining the scope of 
maleimide modification on this doubly disulfide bonded system. Initial studies 
employed non-functionalised maleimides for simplicity and ease of purification and 
analysis; if biological activity is retained using these then the desired functionalised 
maleimides could subsequently be employed. The products in Figure 2.12 were 
envisaged. 
 
Figure 2.12: The envisaged products from bridging tertiapin Q disulfide/s with maleimide 
reagents: Singly modified products 46 and 47 and doubly modified product 48. 
 
2.2.4 Probing Disulfide Reactivity 
Solvent accessibility of a disulfide bond within a peptide or protein is variable and 
sequence dependent and is an important factor to consider when attempting to modify a 
peptide or protein at this site. Increased accessibility often equates to increased 
reactivity as reagents can often reach the disulfide more easily.53 In the case of tertiapin 
Q, being formed of only 21 amino acids means it has only limited tertiary structure; it 
lacks the hydrophobic core created in larger polypeptides and proteins during protein 
folding which helps bury the disulfide bonds and shield them from surrounding solvent.  
When studying the published NMR solution structure shown below in Figure 2.13, both 
disulfide look relatively solvent accessible but the C3-C14 disulfide perhaps a little 
more so. Only so much information can be taken from such an image however, and to 
what extent this expected accessibility is observed experimentally was of interest. 
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Figure 2.13: Three-dimensional solution structure (ball and stick representation) of tertiapin 
determined by NMR. Cysteines (cys3-cys14 and cys5-cys18) shown in yellow.78 
 
In order to assess the accessibility of the two disulfides within the tertiary structure of 
tertiapin Q, an initial experiment was conducted to find out whether they were both 
solvent accessible and reactive.  As in the step-wise protocol, the reducing agent is first 
added to the peptide and left to reduce for a given amount of time before 10 equivalents 
of dibromomaleimide 15 were subsequently added in each case to re-bridge any reduced 
disulfides (Scheme 2.9). The reducing agents TCEP and DTT were both tested for their 
efficacy in reduction, and were tested in varying equivalents. The effect of pH on the 
reactivity of the disulfides was also investigated.  
 
 
 
 
 
 
Scheme 2.9: Reduction and modification of the disulfide bond/s of tertiapin Q using TCEP or 
DTT (varying equivalents) in conjunction with maleimide 15 (10 equivalents) at pH6.2 or 8. 
 
Formation of the singly modified products 46 and/or 47 and doubly modified product 48 
were recorded by monitoring apparent conversion by LC-MS. The reaction mixture was 
injected into the LC-MS instrument and all product peaks from the LC trace selected for 
mass analysis. From the obtained mass spectrum, containing peptide ions in multiple 
 C3 C14 
 C5 
C18 
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charge states, a deconvolution algorithm was run to facilitate ease of interpretation. A 
typical LC trace, mass spectrum and deconvoluted mass spectrum are shown in Figure 
2.14 and 2.15 A and B – these are for reduced tertiapin Q, but are typical of all peptide 
species analysed. 
 
 
 
 
 
 
 
 
Figure 2.14: The LC chromatogram of reduced tertiapin Q. Peak eluting at 0.89 min was 
selected for mass analysis. 
 
 
Figure 2.15: A) ESI mass spectrum of the chromatographic peak eluting at 0.89 min (Figure 
2.14) corresponding to the +2, +3, +4 and +5 reduced tertiapin Q ions of m/z 1228.79, 819.38, 
614.73 and 491.96 respectively. B) Deconvolution of spectrum A. Peak at m/z 2457 
corresponding to reduced tertiapin Q (Expected mass = m/z 2456.29). 
 
Upon reduction, the expected mass increase from m/z 2452 to m/z 2456 is observed 
upon protonation of the free cysteine thiolates. Incorporation of one maleimide bridge to 
produce product 46 and/or 47 sees a subsequent mass increase to m/z 2547, while 
incorporation of two maleimide bridges to produce the doubly modified product 48 sees 
+2 
 +3 
+4 
+5 
B   A 
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a mass increase to m/z 2642. Product formation was normalised to a total of 100%; the 
observed ratios are shown below in Table 2.3. 
 
 
 
 
 
 
 
 
 
Scheme 2.10: Experimental conditions of the reduction study of tertiapin Q 40 using the 
reducing agents TCEP or DTT (1, 3 or 5 equiv.) for 1 h before addition of excess 
dibromomaleimide 15. 
 
Table 2.3: Reduction study of tertiapin Q: apparent conversion to singly modified peptide 46 
and/or 47 and doubly modified peptide 48 under varying reaction conditions. 
 
 
With a significant excess (10 equivalents) of dibromomaleimide present, it should 
follow that any disulfide that is reduced will be subsequently bridged. When an excess 
of the reducing agent TCEP is used, both disulfides are modified; even 3 equivalents of 
TCEP is enough to fully reduce both bonds (experiments 2 and 5). This suggests that 
both disulfides are solvent accessible and can be reduced and re-bridged. This is as 
initially expected from studying the NMR structure of tertiapin Q (Figure 2.13). 
 
In an attempt to reduce and modify just a single disulfide, the effect of adding sub-
stoichiometric (with respect to disulfide bonds) amounts of TCEP was tested. The major 
products in these cases are the double-modified peptide 48 and the native peptide 40 
Experiment Reducing Agent 
Time left 
reducing 
pH 
Amount of 
native 
TPNQ 
40(%) 
Amount of 
46/47 (%) 
Amount of 
48 (%) 
1 TCEP (1 equiv.) 1h 6.2 37% 18% 45% 
2 TCEP (3 equiv.) 1h 6.2 0% 0% 100% 
3 TCEP (5 equiv.) 1h 6.2 0% 0% 100% 
4 TCEP (1 equiv.) 1h 8 50% 0% 50% 
5 TCEP (3 equiv.) 1h 8 0% 0% 100% 
6 TCEP (5 equiv.) 1h 8 0% 0% 100% 
7 DTT (2 equiv.) 3h 6.2 69% 0% 31% 
8 DTT (5 equiv.) 3h 6.2 41% 0% 59% 
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(experiments 1 and 4). Interestingly, very little of the single modified peptide is 
observed. This suggests that selective reduction of a single disulfide is not possible. The 
fact that formation of the double bridged peptide 48 is favourable suggests that when 
one disulfide is reduced the second then becomes more reactive to reduction. This could 
be reasoned by the slight alteration of the conformation of the peptide upon reduction of 
one disulfide bond, causing a slight change in the local environment of the second and 
resulting in a more favourable situation for its reduction. Alternatively, due to the 
proximity of the disulfide bonds in tertiapin Q, thiol-disulfide exchange reactions could 
potentially occur, whereby upon reduction of one disulfide to form two reactive cysteine 
thiolates, these could subsequently attack a cysteine residue of the neighbouring second 
disulfide, leading to its reduction.149 Scheme 2.11 shows one permutation of this, but of 
course there would be multiple. 
 
 
 
 
Scheme 2.11: One example of a thiol-disulfide exchange reaction occurring between two 
disulfides (R1S-SR2 and R3S-SR4). 
 
Within such a system, the equilibrium constants of the disulfide exchange reactions 
depend on the differences in stability between the possible disulfide connectivities. 
Such intramolecular reactions are fast and naturally occur during the process of protein 
folding whereby the most stable disulfide arrangement is sought.149 In this case, such 
exchange reactions would limit the selectivity that TCEP may have had for one 
disulfide over the other. 
 
The effect of altering pH on the disulfide reactivity of tertiapin Q was tested. 
Environmental pH plays an important role in determining the reactivity of a disulfide; at 
a pH above the pKa of the cysteine thiol (-SH), which is approximately ~8.2 (depending 
on the structural context), the cysteine prefers to reside in its more reactive thiolate (-S-) 
form. The thiolate is known to be (5x1010)-fold more reactive than the protonated thiol 
and hence participates in reactions involving nucleophilic attack more readily.150 When 
considering the conditions for site-selective modification, a compromise has to be made 
however. At pH 8, although cysteine reactivity is increased, the likelihood of other 
nucleophilic sites within the peptide or protein also increasing in reactivity is 
heightened. Lysine residues, for example, with a pKa of approximately 10.5, could 
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potentially react with a Michael acceptor such as a maleimide and cause unwanted side 
products. In the case or tertiapin Q, where there are four lysine residues within the 
amino acid sequence, this could potentially be a significant problem.151 The 
experimental results show that increasing the pH to 8 has no significant effect on 
disulfide reactivity in the case of tertiapin Q, and so employing a pH 6 system will be 
more ideal. This will help prevent any unwanted lysine modification occurring. 
 
Also notable from the results table is that DTT does not show greater efficacy in 
reduction of the disulfides in comparison to TCEP. This is a beneficial result as, due to 
the fact that DTT is itself a thiol and will therefore react with a maleimide reagent, it 
would have to be removed from the reaction prior to maleimide addition to ensure an 
efficient reaction and complete conversion to the desired product. To remove unwanted 
reagents, a purification method is needed, during which re-oxidation to the disulfide is 
an unwanted but likely result.151 Instead employing TCEP removes the issues of 
maleimide cross-reactivity. 
 
To conclude from this analysis, the most significant observation is that, despite sub-
stoichiometric amounts of reducing agent, both disulfides on tertiapin Q appear 
accessible and, as a result, are reactive towards the reducing agents and bridging 
reagents used in this project. 
 
2.2.5 Step-Wise Modification of Tertiapin Q 
From the reactivity study, it was apparent that obtaining solely the singly bridged 
products 46 and/or 47 was going to be challenging. For this reason, we concentrated on 
obtaining complete conversion to the doubly bridged product 48. Providing that the 
cysteines are joined in the native connectivity and that the incorporation of a two carbon 
bridge between the two residues does not have a detrimental effect on the structure of 
the peptide, incorporating two maleimides as opposed to one was not envisaged to pose 
a problem. The step-wise protocol employed in Section 2.2.4 proved efficient in 
formation of the desired product. In order to facilitate ease of purification and reduce 
chances of reagent cross reactivity, a dithiophenolmaleimide reagent was chosen. 
Maleimide 45 presented itself as ideal due to its high reactivity previously observed 
with somatostatin modification, and also its water-solubility. Employing this reagent 
meant that tertiapin Q was successfully converted to the doubly modified derivative 48, 
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using minimal equivalents of reagent in completely organic solvent-free conditions 
(Scheme 2.12) 
 
Scheme 2.12: The step-wise modification protocol: reduction using TCEP (2.6 equiv.) for 1 h 
followed by addition of maleimide 45 (2.2 equiv.). 
 
Using this protocol, clean conversion to the doubly bridged product 48 (Figure 2.16) 
was observed within 10 minutes of addition of maleimide 45 to the reduced peptide.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16: Deconvoluted mass spectrum of the reaction mixture. Peak at m/z 2642 
corresponding to doubly modified tertiapin Q 48 (Expected mass = m/z 2642.27). 
 
Despite almost stoichiometric reagent ratios, for accurate characterisation and future 
biological testing, purification of the desired product was required. Attempts to use 
dialysis to filter off any remaining TCEP and maleimide and to remove the salts from 
the buffer employed were unsuccessful. The yield of recovered product dropped by 70-
80% repeatedly. This was hypothesised to be due to the small and hydrophilic nature of 
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the peptide making it difficult to retain. RP-HPLC purification presented itself as a 
superior method, providing further analysis of the modification reaction as well as a 
means of purification. Injection of the reaction mixture onto the C18 RP-column 
allowed the separation of four different species. The LC chromatogram from the 
reaction mixture is shown below in Figure 2.17, with the species labelled A-D. 
 
Figure 2.17: LC chromatogram of the reaction mixture (Retention time of A: 6.0 min, B: 9.5 
min, C: 10.5, D: 18.5-19.0 min). 
 
A more complex mixture of product than expected was observed in the chromatogram. 
In order to determine the nature of these products they were isolated, concentrated under 
vacuum and characterised by MALDI mass spectrometry. Peaks C and D appeared not 
to consist of peptide-based products. Surprisingly, both peaks A and B proved to be the 
doubly modified product 48, as shown in the mass spectra in Figure 2.18. 
 
Figure 2.18: MALDI mass spectra of peaks A and B from the LC chromatogram in Figure 2.17. 
Peaks at m/z 2640.3 and m/z 2640.0 respectively correspond to the doubly modified peptide 48 
(Expected mass = m/z 2642.26). 
 B 
D 
 A 
C 
A 
B 
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The fact that both peaks represented species of the same mass, yet were differentially 
eluted from the column, suggests they vary in configuration or conformation. It was 
hypothesised that A and B could be regioisomers from differing cysteine-cysteine 
connectivity. In the protocol used, the disulfide bonds are left to reduce for one hour in 
which time tertiapin is able to unfold, facilitated further by its limited secondary 
structure which would normally help keep the peptide together. It seems, therefore, not 
unlikely that upon addition of the maleimide reagent, incorrect cysteine pairing could 
result as a consequence of partial or complete unfolding. In addition, if the previously 
proposed thiol-disulfide exchange reactions are occurring during reduction, then this 
again would also facilitate the bridging of a non-native pair of cysteines. Subsequent to 
isolation and concentration, the modified peptide in both A and B was reconstituted in 
distilled water and the peptide concentration determined using the absorbance at 280 
nm. A was found to have a concentration of 136 μM and B of 306 μM and, from this, a 
yield of 23% and 52% was calculated respectively. This suggests the latter was the more 
predominantly formed product from this reaction, with the cumulative yield of doubly 
modified peptide 48 calculated to be 75% after RP-HPLC purification.  
 
Following these findings, efforts focussed on determining whether biological activity of 
the modified peptide had been retained. Whole-cell patch clamp experiments were 
undertaken, analogous to those carried out on native tertiapin Q. HEK293 cells stably 
expressing the GIRK1/4 channel were again employed. The modified tertiapin Q 
samples A and B were kept separate at all times and prepared over a range of 
concentrations (from 1 nM to 100 nM). These solutions were perfused over the cells in 
a sequential manner with increasing concentration. Negligible inhibition of the 
GIRK1/4 channels by either sample A or B was seen in this case, as shown in Table 2.4.  
 
Table 2.4: Changes to K+ current levels through GIRK1/4 channels after administration of 100 
nM A or 100 nM B. 
 
Experiment 
Current remaining 
after addition of 
100 nM of A (%) 
Current remaining 
after addition of 
100 nM of B (%) 
1 98 95 
2 96 98 
3 98 92 
Average 97 95 
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From the results in Table 2.4, almost maximal current is observed in each case; the 
doubly modified derivatives appeared unable to block the GIRK1/4 channel and K+ 
flux. To ensure that this was not due to very low channel expression, native tertiapin Q 
was also tested on the cells (data not shown) and the expected current inhibition was 
observed confirming the GIRK1/4 channel was present and functional.  
 
To ensure that the loss of inhibitory activity of the peptide was not a result of the 
purification method, a simple control was conducted. Low pH environments caused by 
addition of acid to the solvents in HPLC protocols can lead to protein unfolding and 
denaturation in some cases.152 In our protocol, 0.1% TFA is added to both eluents, 
lowering the pH to around pH 2. Perhaps this caused unfolding of the peptide. To 
examine whether the RP-HPLC procedure caused loss of activity, native tertiapin Q was 
subjected to the same RP-HPLC protocol as employed above and was concentrated and 
prepared for testing identically. Results showed that the ‘purified’ native peptide 
retained biological activity (data not shown) concluding that, as expected, the 
purification method was not an issue. 
 
It therefore seemed conclusive that the inactivity of the modified peptide was a result of 
maleimide modification of the disulfide bonds. Even small distortions to a peptide or 
protein’s tertiary structure can be detrimental and perhaps tertiapin Q cannot tolerate 
such modification. In addition, if the maleimides have bridged the cysteine residues in 
incorrect pairs then this is likely to abolish biological function; this can be easily 
reasoned in this case where a step wise protocol was employed. An in situ method was 
sought in order to overcome the problem. 
 
2.2.6 In Situ Modification of Tertiapin Q 
Preliminary in situ method development began - maleimide 45 was again employed so 
that aqueous conditions could be used in every attempt to not perturb the tertiary 
structure of tertiapin Q. Tertiapin Q was firstly incubated with 5 equivalents of 
maleimide 45, before addition of varying amounts of TCEP as shown in Scheme 2.13. 
Product formation was again monitored by apparent conversion by LC-MS. An 
unexpected side product was observed during the reaction. Results are displayed in 
Table 2.5.  
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Scheme 2.13: The in situ modification protocol using maleimide 45 (5 equiv.) and TCEP (2-4 
equiv.). 
 
Table 2.5: Product formation (by apparent conversion by LC-MS) after 5 minutes using 
maleimide 45 (5 equiv.) with varying equivalents of TCEP (2-4 equiv.). 
 
No. of 
equivalents 
of TCEP 
Native 
TPNQ (%) 
Singly 
Bridged 
TPNQ 
46/47 (%) 
m/z 2798 
product 
(%) 
Doubly 
Bridged 
TPNQ 48 
(%) 
2 37 43 - 20 
3 9 9 77 5 
4 8 9 77 6 
 
 In this case, formation of the doubly bridged product 48 appears to be hindered by the 
formation of a side product. Deconvolution of the recorded mass spectra revealed this 
product to be of m/z 2798. It was predicted that this could be as a result of one of two 
products, the first arising from addition of TCEP to the singly bridged product and has 
m/z 2797 (49), and the second from retention of thiosalicylic acid on the doubly bridged 
product with m/z 2796 (50) (Figure 2.19). 
 
 
 
 
 
 
 
 
Figure 2.19: The possible adducts 49 and 50 formed in the in-situ reaction. 
 
In order to determine for certain the nature of this adduct, the in situ experiment was 
carried out using thiophenolmaleimide 22. If the adduct is formed by retention of the 
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eliminated leaving group, which is now thiophenol, then in this case the mass of the 
adduct formed will be m/z 2751. As before, 5 equivalents of maleimide 22 were 
incubated with tertiapin Q before addition of TCEP, 2 equivalents in this case, and the 
reaction monitored over time. The results are shown in Table 2.6. 
 
Table 2.6: Product formation (by apparent conversion by LC-MS) over time using maleimide 22 
(5 equiv.) with 2 equivalents of TCEP. 
 
No. of 
equivalents 
of TCEP 
Reaction 
Time 
(mins) 
Native 
TPNQ 
(%) 
Singly 
Bridged 
TPNQ 
46/47 (%) 
m/z 2751 
product 
(%) 
Doubly 
Bridged 
TPNQ 48 
(%) 
2 1 81 19 - - 
2 15 32 23 - 45 
2 30 5 0 - 100 
 
From these results we can confirm that the adduct cannot be from attack by TCEP, as 
none of the m/z 2798 adduct is observed. However, there was also no evidence of the 
m/z 2751 adduct corresponding to retention of a thiophenol moiety. This suggests that 
the adduct formed using maleimide 45 is characteristic of that maleimide reagent solely. 
This is postulated to be as a result of the ability of the carboxylic acid group, when 
existing as the carboxylate, to form a stabilising salt bridge with the maleimide nitrogen.   
This may well limit its utility in an in situ protocol.  
 
Undeterred by this, we revised our in situ protocol. We decided to compromise on an 
organic solvent-free system in order to use a maleimide with no side reactivity. We also 
decided to investigate benzeneselenol as reducing agent; this requires organic solvent to 
keep it in solution, unlike TCEP which is water soluble, however it showed significantly 
rapid bridging speeds on previous experiments with somatostatin in Section 2.1.7. 
Maximising the speed at which the disulfides are re-bridged upon reduction should help 
to reduce the likelihood of peptide unfolding and disulfide scrambling.24   
 
Analogous to the benzeneselenol protocol employed with somatostatin, we employed 
maleimide 22 as the bridging reagent. 20 equivalents of maleimide 22 were added to 
tertiapin Q before addition of 1.1 equivalents of benzeneselenol. Product formation was 
monitored over time by LC-MS. Results are shown in Figure 2.20. 
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Figure 2.20: Product formation of singly modified product 46/47 and doubly modified product 
48 over time using 1.1 equivalents of benzeneselenol. 
 
Similarly to TCEP, using 1.1 equivalents of benzeneselenol does not give selective 
modification of a single disulfide; formation of the doubly modified product 48 is 
observed as soon as after 1 minute. This sub-stoichiometric amount of benzeneselenol 
appears not to be sufficient to push the reaction to completion. Despite being catalytic in 
disulfide reduction, selenols have the propensity to oxidise to form the diselenide when 
exposed to air which hinders their reductive potential. As a result, an excess is often 
required to compensate for this. As disulfide selectivity appeared again not possible, the 
reaction was repeated using 5 equivalents of benzeneselenol in order to achieve 
complete conversion to the doubly modified peptide 48. Results are shown in Figure 
2.21. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.21: Product formation of singly modified product 46/47 and doubly modified product 
48 over time using 5 equivalents of benzeneselenol. 
 
Using 5 equivalents of benzeneselenol gave efficient conversion to the doubly modified 
product 48, with no unwanted side products observed. In these reactions, 20 equivalents 
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of maleimide 22 were used; further experiments revealed that as little as 5 equivalents 
gave the same efficient conversion (data not shown). 
 
With the desired product in hand, it was purified by RP-HPLC to remove any excess 
reagents, buffer salts and organic solvents. Chromatographic separation revealed three 
products, A-C. The LC chromatogram is shown in Figure 2.22.                             
 
Figure 2.22: LC chromatogram of the reaction mixture (Retention time of A: 17.25 min, B: 18.5 
min, C: 23.75 min). 
 
The LC chromatogram showed one main product (peak B) believed to be the desired 
doubly modified product 48. To determine whether peak A or C was unreacted peptide, 
the reaction mixture was co-injected with native tertiapin Q 40. The LC chromatogram 
is shown in Figure 2.23. 
 
Figure 2.23: LC chromatogram of the co-injection of the reaction mixture and native tertiapin Q 
(Retention time of N: 17.0 min, A: 17.25 min, B: 18.5 min, C: 23.75 min). 
 
Native tertiapin Q (peak N) does not appear to directly co-elute with either A or C. 
Peaks A-C were carefully isolated before characterisation by MALDI mass 
B 
A 
C 
B C 
A 
N 
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spectrometry. Peaks A and C appeared not contain peptide-based products and the 
spectra obtained were messy and uninterpretable. The spectrum of peak B is shown in 
Figure 2.24, and confirms the formation of the desired doubly modified peptide 48. 
 
Figure 2.24: MALDI mass spectra of peak B from the LC chromatogram in Figure 2.22. Peak at 
m/z 2642.3 corresponds to the doubly modified peptide 48 (Expected mass = m/z 2642.26). 
 
 
Pleasingly, a very clean mass spectrum was obtained from the RP-HPLC purification 
and this product was taken on for biological testing to determine whether inhibitory 
activity had been retained by disulfide modification through the in situ protocol. Whole-
cell patch clamp experiments were conducted. HEK293 cells stably expressing the 
GIRK1/4 channel were again employed. The modified tertiapin Q was prepared at a 
concentration of 100 nM and perfused over the cells whilst monitoring for inhibition of 
the K+ currents. Again, disappointingly, negligible inhibition of the GIRK1/4 channels 
was observed, as shown in Table 2.7. 
 
Table 2.7: Changes to K+ current levels through GIRK1/4 channels after administration of 100 
nM native tertiapin Q or 100 nM of purified B (doubly modified product 48). 
 
 
 
 
 
 
 
 
 
 
 
 
Similarly to tertiapin Q modified by the step wise protocol, biological activity of the 
peptide appears to have been abolished by incorporation of the maleimide bridges. An 
Experiment 
Current remaining 
after administration of 
100 nM native TPNQ 
(%) 
Current remaining 
after administration of 
100 nM B (%) 
1 17 87 
2 12 92 
3 14 104 
Average 14 94 
 98 
average of 94% of the resting current was recorded even after continuous perfusion with 
the modified peptide. This suggests that this in situ protocol, which has been designed 
to reduce potential disulfide scrambling by facilitating rapid bridging upon reduction, 
does not maintain the correct tertiary structure of tertiapin Q. 
 
We were interested in deciphering whether the loss of activity was due to the structural 
influence of the maleimide bridge on the peptide structure or rather as a result of 
disulfide scrambling from incorrect cysteine-cysteine connectivity. The former seemed 
less likely as maleimide modification of somatostatin, which again is a small peptide 
with limited tertiary structure, demonstrated retention of biological activity.24 It should 
be noted, however, that the concentration of modified somatostatin tested in this case 
was 20 µM – more than an order of magnitude greater than the EC50iii of the native 
peptide, making it not truly comparable to the native situation. The relatively small size 
of the maleimide in comparison to the peptide itself also adds to the premise that it 
should not significantly interfere with tertiary structure. All systems should be seen as 
unique, however, and this should not be overlooked as a possibility.  
 
For these reasons, disulfide scrambling was the more probable scenario, thus, we 
decided to focus our efforts on trying to establish whether this had occurred. For this, 
we turned to tandem mass spectrometry. Initially, we collaborated with Dr. Kostas 
Thalassinos, UCL. Using their equipment and expertise, we were able to conduct ion-
mobility-tandem mass spectrometry (IM-MS/MS) analysis on a hybrid quadrupole-ion 
mobility-orthogonal acceleration time-of-ﬂight (oa-TOF) mass spectrometer (Synapt 
HDMS, Waters).153 
 
Tandem mass spectrometry (MS/MS), as its name implies, utilises two mass 
spectrometers in tandem. The first detects all species within the introduced sample, the 
species of interest (parent ion) is then selected and subsequently fragmented within a 
collision cell to produce a series of fragments (daughter ions) which are detected in the 
second mass analyser (Figure 2.25). The end result is a mass spectrum containing ions 
characteristic of the selected peptide species from which information regarding the 
structure and amino acid sequence can be obtained.154 
 
                                                 
iiiThe EC50 of a substance is defined as the half-maximum effective concentration. 
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Figure 2.25: The stages of MS/MS analysis; after sample introduction, the species are ionised 
prior to m/z separation at MS1. After manual selection for the species of interest, the species is 
fragmented in a collision cell filled with an inert gas. A second round of m/z separation occurs 
before fragment ions arrive at the detector and are recorded. 
 
MS/MS has become an increasingly useful and popular technique for the structural 
characterisation and analysis of complex molecules as a result of its great accuracy, 
efficiency and sensitivity. In addition, the information obtained from such a technique 
allows for the localisation of post-translational or chemical modifications at the amino 
acid residue level.155,156 In theory, it should be possible to unequivocally locate the site 
of maleimide modification within the sequence of tertiapin Q, providing good 
fragmentation can be achieved. 
 
Fragmentation of peptides requires the involvement of a proton at the cleavage site, in 
other words it is ‘charge-directed’. It therefore follows that, if an amino acid side-chain 
tightly binds or ‘sequesters’ that proton, increased energy will be required to move that 
proton from the basic side-chain to the peptide backbone, in order to induce the 
dissociation event. The nomenclature of the daughter ions generated during such 
fragmentation was originally established by Roepstorff and Fohlmann,157 and later 
revised by Biemann,158 and describes the fragments extending from the N-terminal as b-
ions and those extending from the C-terminal as y-ions (Figure 2.26).  
 
 
 
 
 
 
 
Figure 2.26: Fragmentation paths yielding b- and y-ions characteristic of an amino acid chain.  
Sample 
introduction 
 
 Ion 
source 
 MS1  Fragmentation  MS2 
 Detector  Computer 
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A peptide species will have a characteristic fragmentation pattern which is governed 
largely by its amino acid sequence and depends on how readily the peptide can be 
cleaved at each site within this sequence.156 In order to assess the intrinsic fragmentation 
pattern of tertiapin Q, MS/MS analysis of the native peptide was undertaken, both in the 
oxidised and reduced state. As can be expected, the oxidised tertiapin Q did not 
fragment well owing to the compact and rigid nature of the peptide; the disulfide bonds 
serving to limit the number of possible dissociation sites. Conversely, reduced tertiapin 
Q exists in a much more open and extended conformation, making fragmentation easier 
and, thus, more complex yet conclusive MS/MS spectra are obtained. The peptide was 
introduced to the instrument by direct infusion ESI and the full mass spectrum was 
recorded. The spectrum yielded the doubly, triply, quadruply and quintuply charged 
ions, as shown in Figure 2.27. 
 
Figure 2.27: Full MS of reduced tertiapin Q recorded at a peptide concentration of ~500 pg/µL 
in water + 0.1% formic acid. Peaks correspond to the +2, +3, +4 and +5 reduced tertiapin Q ions 
of m/z 1228.74, 819.82, 614.32 and 492 respectively. 
 
After isolation of the species of interest, this was subjected to manually controlled 
collision energies in order to fragment the peptide. The resulting fragments were then 
conveyed to a TOF-mass analyser and the MS/MS spectra was recorded. If few 
fragments were detected by the mass analyser, the collision energy was increased 
  +2 
 +3 
 +4 
+5 
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accordingly to produce spectra with maximum information. The MS/MS spectrum of 
the doubly charged reduced peptide ion at m/z 1228.74 is presented in Figure 2.28, 
showing the fragments b9, b10, b11, b13, b14, b15, b16, y11, y12, y13 and y14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.28: MS/MS spectrum of the +2 reduced tertiapin Q ion at m/z 1228.74. Shown in the 
inset is the peptide’s amino acid sequence, b- and y-ions are formed by peptide bond cleavage 
with charge retention on the N- and C-termini. 
 
The reduced peptide fragments well, with the most intense fragment peaks being those 
of the b10 and b11 ions, which are the sites either side of the proline-11 residue. This 
suggests the amide bonds connecting proline are significantly more labile. With the 
characteristic fragmentation of native tertiapin Q examined, work progressed on to 
locating the maleimide modification in our product. A mass increase corresponding to 
the monoisotopic mass of a maleimide bridge should be observed within the spectra.  
 
Work began by determining the possible number of regioisomers that could arise from 
inserting two maleimide bridges in between the four cysteine residues of tertiapin Q. 
Similarly to natural disulfide formation through oxidation, the number of possible 
connectivities increases with increasing number of cysteine residues. Sela and Lifson159 
described the formula for the number of regioisomers (i) formed when n cysteine 
residues oxidise to form p disulfide bonds as: 
b9 
b10 
b11 
b13 
b14 
b15 
b16 
y11 
y12 
y13 y14 
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n! 
p!(n-2p)!2p 
 
This is assuming all cysteines are in an appropriate environment and are suitably close 
enough to form a bond. In the case where all cysteine residues within the peptide or 
protein participate in disulfide bonding, the formula can be simplified to: 
n! 
(n/2)!2(n/2) 
 
In the case of tertiapin Q with its four cysteine residues, there are three possible 
disulfide regioisomers and, thus, three possible ways in which a maleimide could bridge 
the fully reduced peptide. These are shown schematically in Figure 2.29. 
 
C3-C14/C5-C18 (native) connectivity: 
 
 
 
 
 
 
 
 
 
C3-C5/C14-C18 connectivity: 
 
 
 
 
 
 
 
 
 
 
C3-C18/C5-C14 connectivity: 
 
 
 
 
 
 
 
 
 
Figure 2.29: The three possible cysteine-cysteine connections in a doubly maleimide modified 
tertiapin Q 48 (native connectivity) and 51 and 52 (scrambled connectivities).  
i = 
i = 
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Using these predictions, a library of possible peptide fragments which could occur from 
each cysteine-cysteine connection was created. This was done by taking each case, and 
removing amino acids consecutively from both the N-terminus (creating y-ions) and C-
terminus (creating b-ions) and accurately calculating the mass of each of these 
theoretical fragment species.   
 
With this library in hand (see Appendix Tables 3, 4 and 5), experimental analysis began. 
As before with native tertiapin Q, the purified product 48 was introduced to the 
instrument by direct infusion ESI and the species of interest is then selected for. The 
triply, quadruply and quintuply charged ions were observed, as shown in Figure 2.30. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.30: Full MS of doubly modified tertiapin Q 48 recorded at a peptide concentration of 
~500 pg/µL in water + 0.1% formic acid. Peaks correspond to the +3, +4 and +5 modified 
tertiapin Q ions of m/z 881.93, 661.89 and 529.86 respectively. 
 
Subsequent fragmentation of the m/z 881.93, 661.89 and 529.86 ions generated MS/MS 
spectra. Analysing the MS/MS spectra of the triply charged peptide ion gave quite 
conclusive results. From searching our fragment library for species that correspond 
exclusively to one of the three possible regioisomers, a number of matching masses 
were identified.160 The data suggested in was in fact one of the scrambled variants 
  +3 
 +4 
+5 
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produced, specifically the C3-C5/C14-C18 regioisomer. From the MS/MS spectrum in 
Figure 2.31, the b8, b9, b10, y10 and y11 ions can be seen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.31: MS/MS spectrum of the +3 modified tertiapin Q ion at m/z 881.93.  
 
In addition to the species labelled in the spectrum, other fragment species were also 
identified and are listed in Table 2.8. In this case, the monoisotopic masses calculated 
and the mass ions experimentally observed incorporate the mass of a maleimide bridge. 
The way in which the modified peptide fragments well between cysteine 5 and cysteine 
14, and that the fragments within this region all incorporate the exact mass associated 
with addition of a maleimide bridge give sound evidence to prove the incorrect bridging 
connectivity. The C3-C5/C14-C18 regioisomer (51) appears to be the product formed 
from the modification reaction. 
 
 
 
 
 
 
 
 
 
 
 
b8 
b9 
b10 
y10 
y11 
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Table 2.8: The expected and observed fragment peaks from the MS/MS spectra of doubly 
modified tertiapin Q. (+ mal = + mass of maleimide bridge). 
 
Fragment Sequence 
Regioisotope 
connectivity 
Expected 
monoisotopic 
mass (m/z) 
Observed 
mass 
(m/z) 
b5 ALCNC + mal C3-C5/C14-C18 598.18 598.17 
b6 ALCNCN + mal C3-C5/C14-C18 712.22 712.23 
b7 ALCNCNR + mal C3-C5/C14-C18 868.32 868.34 
b8 ALCNCNRI + mal C3-C5/C14-C18 981.40 981.35 
b9 ALCNCNRII + mal C3-C5/C14-C18 1094.49 1094.43 
b10 ALCNCNRIII + mal C3-C5/C14-C18 1207.57 1207.44 
b11 ALCNCNRIIIP + mal C3-C5/C14-C18 1304.62 1304.67 
b12 ALCNCNRIIIPH + mal C3-C5/C14-C18 1441.68 1441.71 
b13 ALCNCNRIIIPHQ + mal C3-C5/C14-C18 1569.74 1569.77 
y10 KKGCKKWCQH + mal C3-C5/C14-C18 1337.64 1337.47 
y11 KKGCKKWCQHP + mal C3-C5/C14-C18 1434.69 1434.54 
y12 KKGCKKWCQHPI + mal C3-C5/C14-C18 1547.75 1547.78 
 
This is depicted in Figure 2.32. The product fragmented in a similar fashion to the 
reduced, native peptide analysed previously, suggesting the structure is relatively open 
and extended. Sites in-between the maleimide bridged cysteines, which would have 
given the fragments corresponding to b3 and b4 (or y17 and y18) and b14- b17 (or y4-y7), 
are not observed, which would be expected if this cysteine connectivity be true. 
 
 
 
 
 
 
 
 
 
 
Figure 2.32: The C3-C5/C14-C18 connectivity of regioisomer 51 and the sites of fragmentation 
observed. 
 
This suggests the maleimides bridge two cysteine residues before the peptide re-folds 
into its native conformation, preventing the formation of the desired product 48. Had the 
maleimides bridged tertiapin Q in the correct, native fashion, we would have expected 
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minimal fragmentation, owing to the compact nature of the peptide as previously 
discussed. Only the few terminal residues from the N- and C- terminus are expected to 
be cleaved in this case. Good fragmentation was observed in our experiments, again 
suggesting that the correct regioisomer was not the product formed. 
 
 
 
 
 
 
 
 
 
 
Figure 2.33: The native C3-C14/C5-C18 connectivity of desired doubly modified product 48 
and the expected possible sites of fragmentation. 
 
These results would provide a good explanation for the loss of biological activity of 
modified tertiapin Q as disulfide scrambling is often detrimental to the biological 
activity of peptides and proteins. As discussed in the introduction, disulfide bonds play 
a fundamental role in maintaining a precise and unique tertiary structure which is 
crucial to defining activity. We decided to investigate further this idea of disulfide 
scrambling in the tertiapin Q model. 
 
Molecular modelling is a technique commonly used to visualise molecules and proteins 
and analyse their structure and behaviour. In order to gain a better understanding of 
what happens to the structure of teriapin Q during the modification protocol, the 
modelling program Chimera was used with the PDB file for tertiapin (1TER).78 As 
described in the literature, tertiapin has a very compact and rigid structure, with the two 
disulfide bonds connecting the C-terminal α-helix and the more extended N-terminal β-
strand (Figure 2.34).   
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Figure 2.34: NMR solution structure (cartoon representation) of tertiapin. Cysteines are 
highlighted and the distance between the thiol atoms indicated. (PDB code: 1TER) 
 
From the NMR structure, we see that in the native state both the C3-C14 and C5-C18 
disulfide bonds span a distance of about 2 Å whilst the disulfide pairs themselves are 
between about 6.4 to 8.7 Å away from each other. Removing the disulfide bonds and, 
using the energy minimisation tool in Chimera, letting tertiapin adopt its lowest energy 
state effectively mimics the effect of disulfide reduction during the maleimide 
modification protocols. The energy minimised conformation is shown in Figure 2.35. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.35: NMR solution structure (cartoon representation) of tertiapin Q after energy 
minimisation and the resultant distances between cysteine residues. 
 
It is apparent that, when the disulfide bonds are reduced, the peptide will unfold into a 
more extended conformation and the cysteine residues move into very different 
proximities. The native pairs C3-C14 and C5-C18 are now around 8.8 and 6.7 Å apart 
C18 
C14 
C3 
C5 
2.010 Å 
    8.675 Å 6.448 Å 
2.017 Å 
C3 
C5 
C14 
C18 
8.839 Å 
7.591 Å 
6.687 Å 
5.512 Å 
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respectively; markedly greater than the 2 Å at which they are held at before reduction. 
In contrast, the C14 and C18 residues, which are 8.7 Å apart in the native state, move 
significantly closer together with about 5.5 Å distance now between them. This is in 
fact the closest pair of cysteine residues as a result of the change in peptide 
conformation. This further supports the hypothesis that the disulfide bonds could have 
scrambled as a result of maleimide modification as the cysteines appear to no longer 
reside in distances which would favour the native C3-C14/C5-C18 connectivity. In 
addition, the fact that residues C14 and C18 are now significantly closer would add 
weight to the evidence from the fragmentation study above, that in fact C3-C5 and C14-
C18 are now bridged pairs. 
 
This theoretical analysis correlates well with some further results obtained from the IM-
MS/MS work. Prior to fragmentation in the instrument, the peptide moves through an 
ion mobility separation chamber. Ion mobility can separate species dependant on shape; 
it has the ability to separate species of the same mass-to-charge (m/z) ratio existing in 
different conformations. Complementary to NMR and x-ray crystallography, it is used 
to study three-dimensional protein structure and for analysis of complex mixtures.161 
Ion mobility is based on the time taken for individual species to transverse the mobility 
chamber which contains an inert gas and is under the influence of a weak electric field. 
This time, known as drift time (td), is related to the mass, charge and collision cross 
section of the ion species. The collision cross section is the area of an ion that is 
accessible for the carrier gas molecules to strike. The smaller this collision cross-
section, meaning the smaller and more compact the species ion, the less area available 
for carrier gas to collide with and impede the ion’s drift. As a result, the ion requires 
less time to migrate through the drift chamber.153,161 
 
Experimentally, the td of both native and doubly modified tertiapin Q was recorded 
(Figure 2.36 A and B). This data was then converted into a corrected collision cross 
section using a calibration curve. This calibration curve was constructed using two 
calibrants, cytochrome c and myoglobin, which both have known cross sections existing 
in a variety of charge states (Appendix Figure 1). Using this calibration curve and the 
known td values, a corrected, rotationally averaged collision cross section was 
determined for tertiapin Q. Absolute collision cross sections were derived from these 
figures by correcting for the charge of the species.  
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Figure 2.36: Ion mobility spectra showing collision cross section obtained for A) native 
tertiapin Q and B) doubly bridged tertiapin Q. 
 
From the experimental data obtained, native and doubly modified tertiapin Q have 
collision cross sections of 435 and 473 Å2 respectively. The fact that there is such a 
difference between these values suggests that they have quite different tertiary 
structures. Furthermore, the increased cross section size of the modified peptide in 
comparison to the native peptide implies that the modified peptide has now adopted a 
more extended, open conformation, which served to increase its td. These 
A 
B 
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experimentally obtained cross sections can be compared to theoretical values calculated 
using MOBCAL from the PDB file. Here the theoretical cross section of the native 
peptide was calculated to be 427 Å2; not dissimilar to the experimentally obtained value 
for native tertiapin Q, but again significantly different to that of the modified peptide. 
This adds evidence to suggest that the tertiary structure has certainly been perturbed by 
the modification in such a way that its structure is no longer so compact. 
 
All of our structural information obtained suggests that the maleimides have bridged the 
cysteine residues in non-native pairs. Fragmentation patterns, ion mobility analysis and 
modelling experiments suggest that C3-C5/C14-C18 is the preferential regioisomer 
formed, i.e. regioisomer 51. Tertiapin Q is believed to elicit its inhibitory activity 
towards the GIRK channel family by means of insertion of its α-helix into the pore of 
the channel.77 The fact that two of the cysteine residues we are targeting reside within 
the α-helix itself suggests that such disulfide scrambling observed would not be well 
tolerated. Such modification would be expected to have a detrimental effect on 
biological activity. 
 
The propensity to form such a scrambled product suggests that either a) both disulfides 
are reduced before maleimide bridging occurs or b) reduction of the first disulfide 
initiates thiol-disulfide exchange reactions, effectively scrambling the peptide before it 
is bridged by a maleimide. In order to try and overcome these issues, we must carefully 
control reduction whilst maximising the speed of the bridging reaction. If we could 
selectively reduce and immediately re-bridge just one disulfide at a time, one would 
hope a correct native pair could be targeted.23 
 
2.2.7 Towards Controlled Disulfide Reduction  
As thiol-based reducing agents are unsuitable in our in situ protocol due to cross 
reactivity issues they were not suitable for this work, despite potentially having the 
desired attenuated reductive potential. Benzeneselenol is also unsuitable as it has been 
found to be catalytic and reduce disulfides very rapidly as a result. For these reasons, we 
returned to TCEP. In order to try and slow the reduction by TCEP it was postulated that 
incremental addition of very small amounts of the reducing agent may be the only way 
to slow reduction. We continued to employ the fast reacting maleimide 22; envisaging 
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that, if added in significant success, we could promote immediate bridging during a 
slow and controlled reduction process. 
 
Twenty equivalents of maleimide 22 were pre-incubated with tertiapin Q 40, prior to 
addition of 0.3 equivalents of TCEP every 15 minutes (Scheme 2.14) and product 
formation monitored by LC-MS. 
 
 
 
 
 
 
 
 
Scheme 2.14: The in situ modification protocol using maleimide 22 (20 equiv.) and incremental 
addition of TCEP (0.3 equiv. every 15 min). 
 
In this case, we were not focused on pushing the reaction to completion, rather 
assessing whether or not the correct product was being formed. For this reason, when 
suitable conversion to singly modified products 46 and/or 47 or doubly modified 
product 48 was observed, the sample was immediately taken on to MS/MS analysis. For 
this point onwards, a different MS instrument was utilised - in this case, a capillary-LC-
MS/MS; this allows for separation by chromatography prior to MS/MS analysis. As a 
result, RP-HPLC purification of any product was not essential before analysis and the 
mixture could be introduced into the instrument directly. Once again, the doubly, triply 
and quadruply charged ions of the doubly modified product 48 were recorded (data not 
shown) and subsequent fragmentation of the doubly and triply charged peptide ions 
provided the most conclusive information. The MS/MS spectrum of this doubly charged 
peptide ion at m/z 1322.13 after fragmentation is shown below in Figure 2.37. 
 
The fragments observed in both spectra are listed below in Table 2.9. Once again, 
results suggest formation of the undesired C3-C5/C14-C18 regioisomer. High 
abundance of the b10 and b11 fragment ions especially suggests ease of fragmentation at 
these sites, indicative of the scrambled, open conformation. 
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Figure 2.37: MS/MS spectrum of the +2 modified tertiapin Q ion at m/z 1322.13.  
 
 
Table 2.9: The expected and observed fragment peaks from the MS/MS spectra of doubly 
modified tertiapin Q. (+ mal = + mass of maleimide bridge). 
 
Fragment Sequence 
Regioisotope 
connectivity 
Expected 
monoisotopic 
mass (m/z) 
Observed 
mass (m/z) 
b8 ALCNCNRI + mal C3-C5/C14-C18 981.40 981.35 
b9 ALCNCNRII + mal C3-C5/C14-C18 1094.49 1094.43 
b10 ALCNCNRIII + mal C3-C5/C14-C18 1207.57 1207.41 
b11 ALCNCNRIIIP + mal C3-C5/C14-C18 1304.62 1304.21 
b12 ALCNCNRIIIPH + mal C3-C5/C14-C18 1441.68 1441.53 
b13 ALCNCNRIIIPHQ + mal C3-C5/C14-C18 1569.74 1569.63 
y10 KKGCKKWCQH + mal C3-C5/C14-C18 1337.64 1337.47 
y11 KKGCKKWCQHP + mal C3-C5/C14-C18 1434.69 1434.47 
y12 KKGCKKWCQHPI + mal C3-C5/C14-C18 1547.78 1547.77 
 
It appears that even attempts to attenuate the reduction speed during the reaction do not 
lead to formation of the desired product. Even though conversion to modified tertiapin 
is slower, selectivity for the correct disulfide is not achieved. Once again this suggests 
b10 
b11 
b13 
y11 
y12 
b12 
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that either the reduction is still not achieving selectivity for a single disulfide, and/or the 
re-bridging by the maleimide reagent is not fast enough to prevent the process of thiol-
disulfide exchange leading to the isomerisation of the disulfide bonds and therefore 
allowing the formation of the undesired C3-C5/C14-C18 product 51(Figure 2.38). 
 
 
 
 
 
 
 
 
Figure 2.38: The C3-C5/C14-C18 connectivity (regioisomer 51) and the sites of fragmentation 
observed. 
 
Another consideration during this part of the project was whether tertiapin Q had an 
intrinsic propensity to scramble and misfold during synthesis. Of course in vivo there 
are cellular mechanisms including molecular chaperones to aid peptide and protein 
folding and to ensure correct tertiary structure is obtained.49,50 Although the in vitro 
situation is very different, the tertiapin Q employed in this project was made 
synthetically by means of solid phase synthesis. During this procedure, there are various 
protection and deprotection steps to ensure correct bonding between desired residues, 
including the disulfide bonds. We were interested to determine whether tertiapin Q, 
once reduced, refolds into its native state when unaided by such chaperones and 
protection strategies. Often the secondary structure of a peptide or protein is sufficient 
to facilitate the templating of the amino acids into the correct conformation162; as 
frequently drawn upon in this study, however, every system will behave differently and 
should be considered individual.  
 
Tertiapin Q in pH 6.2 buffer was fully reduced using TCEP before being left at room 
temperature for 72 hours to re-fold and re-oxidise. Analytical RP-HPLC was used to 
monitor the product formation of the reaction. The resulting chromatograms are shown 
in Figure 2.39.  
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Figure 2.39: LC chromatogram of A) native tertiapin Q (Retention time: 17.75 min), B) reduced 
tertiapin Q (Retention time: 18.50 min) and C) tertiapin Q after 72 h re-oxidation (retention 
time: 17.75 min). 
 
From the chromatograms, an increased retention time is observed upon reduction of the 
peptide. Upon re-oxidation, the retention time of the re-folded peptide appears to be 
exactly that of the original native peptide. This suggests the same conformation has 
been achieved. Additionally, there appears to be just one peak formed implying this is 
the sole product. The effect of organic solvent on this process was also considered. This 
A 
B 
C 
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analysis was repeated using the solvent conditions routinely employed in our 
modification protocols, pH 6.2 buffer with 40% MeCN and 2.5% DMF (Figure 2.40). 
 
Figure 2.40: LC chromatogram of A) native tertiapin Q (Retention time: 17.75 min), B) reduced 
tertiapin Q (Retention time: 18.50 min) and C) re-oxidised tertiapin Q after 72 h (retention time: 
17.75 min) in organic solvent. 
 
In this case, the same increased retention time is seen upon reduction of the peptide. The 
re-oxidation is slower than in organic solvent-free conditions; some reduced peptide still 
remains after 72 hours. However, after re-oxidation the peptide appears to, once again, 
A 
B 
C 
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adopt the native conformation. The organic solvents do not seem to hinder the 
templating of the peptide suggesting they shouldn’t have had a negative effect in the 
modification protocols.  
 
Results suggest that, during natural disulfide formation, tertiapin Q has the ability to 
adopt the correct structure, suggesting correct disulfide connectivity. Scrambling does 
not therefore appear to be an inherent problem during peptide folding.163 It seems 
conclusive that the, thus far unavoidable, issue of incorrect cysteine-cysteine bridging 
during maleimide modification is as a result of the reagents and protocols employed in 
the strategy. Selective reduction of a single disulfide bond is not achievable and 
therefore facilitates formation of an unwanted product.  
 
2.2.8 Towards Controlled Disulfide Modification 
The thiomaleimides are known to react very fast; it was hypothesised that a less reactive 
reagent may be more effective at selectively targeting a single disulfide. To this point, 
using thiophenol-based maleimides has always resulted in formation of the doubly 
modified product, even when sub-stoichiometric amounts of reagent were employed. 
The aryloxymaleimides have been reported to display attenuated reactivity towards 
cysteines.63 Compared to the thiophenol, aryloxy substituents contribute an increased 
mesomeric effect into the maleimide ring, reducing their electrophilicity. It was 
envisaged that such reagents could aid modification selectivity in some systems.  
 
Investigation into whether such reagents could be of use in the selective modification of 
tertiapin Q began; if one of the disulfides was even slightly more accessible or reactive 
then perhaps it could be targeted using an aryloxymaleimide. Synthesis of maleimide 53 
was straightforward but relatively low-yielding (Scheme 2.15). After the first addition 
of phenol to form N-methyl mono-bromo, mono-phenoxymaleimide, addition of the 
second phenol group was slow. Attempts to increase reaction time from 48 to 72 hours 
and increase reaction temperature from room temperature to 60 °C did not lead to 
increased yields. 
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Scheme 2.15: The synthetic route to N-methyl di-phenoxymaleimide 53. 
 
Efforts to optimise the synthesis were not in our interest at this point, so work 
progressed onto the utility of this reagent in the in situ modification of tertiapin Q. 
When considering which reducing agent to employ it was decided that benzeneselenol 
was unsuitable; its catalytic nature proved to favour the reduction and modification of 
both disulfides significantly. For this reason, we chose to return to TCEP. Starting with 
less than 2 equivalents of both maleimide 53 and TCEP (Scheme 2.16), the reaction was 
monitored for product formation over time, by LC-MS analysis. 
 
 
 
 
 
 
 
 
 
 
Scheme 2.16: The in situ modification protocol using maleimide 53 (1.5 equiv.) and TCEP (1.5 
equiv.). 
 
Significant amounts of the singly modified peptide 46 and/or 47 were observed during 
this reaction. When formation of the singly modified product started to plateau, 0.5 
equivalents of TCEP were added to the reaction in attempt to maximise the yield. The 
results of the analysis are displayed in Table 2.10. 
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Table 2.10: Formation (by apparent conversion by LC-MS) of the singly modified product 46 
and/or 47 and the doubly modified product 48 over time. 
 
Total 
Reaction 
Time (h) 
Total 
equivalents 
of TCEP 
Total 
equivalents 
of 
Maleimide 
Native 
TPNQ 40 
(%) 
Singly 
Bridged 
46/47 (%) 
Doubly 
Bridged 
48 (%) 
1 1.5 1.5 59 41 0 
2 1.5 1.5 55 45 0 
3 2.0 1.5 37 63 0 
4 2.0 1.5 35 65 0 
5 2.5 1.5 23 77 0 
 
Pleasingly, using maleimide 53 in conjunction with TCEP yielded almost 80% of the 
singly modified product, with no evidence of the doubly modified product forming, 
even after 5 hours reaction time. An example of the LC-MS spectra observed is shown 
in Figure 2.41. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.41: Deconvoluted mass spectrum of the reaction mixture, over the mass range m/z 
2000-4000. Peak at m/z 2456 corresponding to reduced tertiapin Q (expected mass = m/z 
2456.29) and m/z 2564 corresponding to singly modified peptide 46/47 (expected mass = m/z 
2563.29). 
 
This is the first time the single bridged peptide has been observed without concurrent 
formation of the double bridged product. The attenuated reactivity of the maleimide can 
be clearly observed by the amount of unreacted native peptide remaining in each case. 
In order to determine whether incremental addition of the reducing agent was a 
necessary procedure to aid single modification, the established in situ protocol using 
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TCEP was repeated, but this time the reducing agent was added as a single portion. The 
results are shown in Table 2.11. 
 
Table 2.11: Product formation (by apparent conversion by LC-MS) from the in situ 
modification of tertiapin Q with addition of TCEP in a single portion. 
 
Total 
Reaction 
Time (h) 
Total 
equivalents 
of TCEP 
Total 
equivalents 
of 
Maleimide 
Native 
TPNQ 40 
(%) 
Singly 
Bridged 
46/47(%) 
Doubly 
Bridged 48 
(%) 
1.5 2.5 1.5 20 69 11 
 
Although the singly bridged peptide was formed faster (70% conversion in 1.5 hours 
compared to 4-5 hours previously), a small amount of the doubly bridged peptide was 
also formed. Incremental addition of TCEP appears to be beneficial. In order to make 
subsequent purification of the desired product easier, the number of species should be 
minimised, therefore we chose the incremental TCEP addition protocol as standard. 
 
Intrigued by the efficient formation of a singly modified product, localisation of the 
maleimide bridge was the next task. Despite facilitating single modification, whether or 
not maleimide 53 has been selective for a particular disulfide remained to be 
determined. In this case, there are 6 possible regioisomers that could be formed as a 
result of bridging just two cysteines. After its conclusive results previously, MS/MS 
analysis was again employed to determine which regioisomer, or combination thereof, 
had been formed. The possible regioisomers are depicted in Figure 2.42. 
 
 
 
 
 
 
 
 
 
 
 
 
 120 
C3-C14 or C5-C18 (native) connectivity: 
 
 
 
 
 
 
C3-C5/C14-C18 connectivity: 
 
 
 
 
 
 
 
C3-C18/C5-C14 connectivity: 
 
 
 
 
 
 
 
 
 
Figure 2.42: The six possible cysteine-cysteine connections in a singly modified species. 
Regioisomers 54 and 55 (native connectivity) and 56-59 (scrambled connectivities). 
 
A new library of possible fragments that could arise from each of regioisomer was 
constructed (see Appendix Tables 6-11), again by sequentially removing each amino 
acid in turn and calculating the monoisotopic mass of the resultant fragment. Figure 
2.43 shows the full mass spectrum of the singly modified product. The doubly, triply 
and quadruply charged peptide ions were all recorded. 
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Figure 2.43: Full MS of singly modified tertiapin Q recorded at a peptide concentration of ~500 
pg/µL in water + 0.1% formic acid. Peaks correspond to the +2, +3 and +4 modified tertiapin Q 
ions of m/z 1282.81, 855.51 and 642.02 respectively.  
 
After selecting the parent ion of the desired singly modified product, it was fragmented 
as before and the resulting MS/MS spectra analysed. In this case, the doubly and triply 
charged ions yielded the most conclusive information. The spectrum from 
fragmentation of the doubly charged ion of m/z 1282.81 is shown in Figure 2.44. 
 
Although fewer fragments were observed in these experiments, there was conclusive 
evidence to suggest incorrect cysteine-cysteine connectivity once again. The fragments 
observed that suggest this are listed below in Table 2.12. 
 
 
+2 
+3 
+4 
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Figure 2.44: MS/MS spectrum of the +2 modified tertiapin Q ion at m/z 1282.81. 
 
Table 2.12: The expected and observed fragment peaks from the MS/MS spectra of singly 
modified tertiapin Q. (+ mal = + mass of maleimide bridge). 
 
Fragment Sequence 
Regioisotope 
connectivity 
Expected 
monoisotopic 
mass (m/z) 
Observed 
mass (m/z) 
b7 ALCNCNR + mal C3-C5 884.35 884.30 
b 8 ALCNCNRI + mal C3-C5 997.43 997.26 
b 9 ALCNCNRII + mal C3-C5 1110.52 1110.52 
b 10 ALCNCNRIII + mal C3-C5 1223.60 1223.41 
b 12 ALCNCNRIIIPH + mal C3-C5 1457.71 1457.50 
b13 ALCNCNRIIIPHQ + mal C3-C5 1585.77 1585.47 
y11 KKGCKKWCQHP + mal C3-C5 1339.69 1339.46 
y12 KKGCKKWCQHPI + mal C3-C5 1452.77 1452.45 
 
The results suggest that it is neighbouring cysteines that have again been bridged; more 
specifically the C3 and C5 residues. The b9 and b10 fragments were again observed, a 
location at which one would not expect tertiapin Q to fragment at had it be bridged with 
the correct, native connectivity. This propensity to fragment at these sites is also 
observed with the native, reduced peptide suggesting the compact structure has again 
been lost. Interestingly, no fragments corresponding to any other regioisomer were 
b9 
b10 
y11 
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observed, implying the C3-C5 connectivity, i.e. the regioisomer 56, to be the major or 
sole product formed. It appears that maleimide 53 is selective for a pair of cysteine 
residues and suggests C3 and C5 are the most reactive; however, this is not a desired 
native pair. We would expect that inhibitory activity would have again been lost due to 
the associated structural perturbation. 
 
 
 
 
 
Figure 2.45: The C3-C5 connectivity (regioisomer 56) and the sites of fragmentation observed. 
 
Finally, we wished to confirm that both disulfides were reduced during this protocol, 
again facilitating such incorrect bridging. To test this, 1.5 equivalents of maleimide 53 
was added to tertiapin Q followed by subsequent addition of 0.5 equivalents of TCEP 
every hour, as before. After two hours, 10 equivalents of maleimide 6 were added; 
adding such a reagent in excess should serve to cap any free thiols of tertiapin Q. In this 
way, it should be possible to determine by LC-MS whether the second, unmodified 
disulfide is in its oxidised or reduced state – a reduced disulfide should lead to a mass 
change of +190.02 m/z upon addition of maleimide, and formation of product 60 
(Scheme 2.17). Results are shown in Table 2.13. 
 
 
Scheme 2.17: The in situ modification of tertiapin Q using maleimide 53 (1.5 equiv.) and 
incremental addition of 0.5 equivalents of TCEP every hour - free thiols capped with maleimide 
6 at these 1 h time points. 
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Table 2.13: The results of the in situ modification with maleimide 53 and TCEP with free thiol 
capping with maleimide 6. 
 
Total 
Reaction 
Time (h) 
Total 
equivalents 
of TCEP 
Native 
TPNQ (40) 
(%) 
Singly Bridged  
+ 2 x 
maleimide (60) 
(%) 
Singly 
Bridged (56) 
(%) 
2 1.0 23 58 19 
 
A large proportion of product 60, the singly bridged product capped by maleimide, 
confirms the presence of two free thiols. This proves that the second disulfide is often 
also reduced, facilitating the bridging of an incorrect cysteine-cysteine pair by the 
maleimide.  
 
In this case, the attenuated reactivity of maleimide 53, although facilitating a slower 
modification reaction and the formation of a singly modified product, cannot overcome 
the continual issue of complete reduction of the disulfide bonds of tertiapin Q by TCEP. 
As with the thiophenolmaleimide 22, selectivity for native cysteine pairs is not possible. 
 
2.2.9 Summary of Tertiapin Q Modification 
Tertiapin Q presented itself as an ideal candidate for probing the utility of the 3,4-
disubstituted maleimide reagents. Until the start of this project, analysis of such 
reagents had been limited to systems with a single disulfide bond, where modification 
was straightforward and efficient. In the case of tertiapin Q, its two disulfide bonds 
allowed us to probe a more challenging system, to test the scope of the methodology 
and whether controlled reduction and/or bridging was possible.  
 
Analysis of the reactivity of the disulfides to the reducing agents TCEP, DTT and 
benzeneselenol revealed them both to be solvent accessible and reactive; this was quite 
expected from the small size and limited tertiary structure of the peptide resulting in the 
lack of a hydrophobic core in which to bury and protect essential residues and bonds.  
 
Initial work using an organic solvent-free, step-wise protocol to modify both the 
disulfide bonds of tertiapin Q resulted in, what appeared to be, a fast and efficient 
reaction to form the doubly modified product 48. However, subsequent analysis of 
biological activity by patch clamp analysis demonstrated the product formed had 
negligible inhibitory activity towards the GIRK 1/4 channel. It was postulated that this 
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was due to disulfide scrambling as a result of the extensive time the peptide is left to 
reduce and unfold during the protocol. 
 
Focus quickly turned to development of an in situ protocol in attempt to overcome this 
predicted problem. Initial attempts using the water-soluble maleimide 45 were 
unsuccessful however, due to, what we postulate to be, retention of the thiosalicylic acid 
moiety. Unable to employ organic solvent-free conditions effectively led us back to 
dithiophenolmaleimide 22 and, to try and make the reaction as rapid as possible in order 
to circumvent disulfide scrambling, benzeneselenol to aid reduction catalysis. Again 
rapid formation of the doubly modified peptide 48 was observed. Patch clamp 
experiments revealed that unfortunately biological activity of the tertiapin Q had again 
been abolished by the modification. It was predicted that this must again be due to 
disulfide scrambling, but we wished to prove this to be the case. In order to do so, we 
embarked on tandem MS analysis. Pleasingly, efficient fragmentation and careful 
comparison of the acquired mass spectra with the predicted regioisomers formed 
allowed us to determine the exact location of the maleimide bridges. Incorrect cysteine-
cysteine pairing by the maleimide had occurred, more specifically the C3-C5/C15-C18 
regioisomer 51, which would explain the loss of biological activity. Such an isomer 
would undoubtedly have a significantly different tertiary structure to the native peptide.  
 
In attempts to overcome this issue, we tried to obtain selectivity by attenuating the 
reduction reaction. We were limited by the compatibility of the reducing agents we had 
available to us meaning that TCEP was the only suitable option. To try and aid slow and 
selective disulfide reduction we added TCEP in small aliquots to the peptide in excess 
maleimide 22. We hoped that, as soon as one disulfide was reduced there would be a 
maleimide reagent in close proximity to immediately re-bridge the cysteines. Once 
again, despite being able to slow the reaction, selectivity was still not obtained. Double 
modification resulted and, when analysed by tandem MS, the resultant product was the 
commonly observed C3-C5/C15-C18 regioisomer 51. 
 
We also tried to achieve selective modification of just one disulfide bond. We 
investigated maleimide reagents with attenuated reactivity as a means to selectively 
modify solely the most reactive disulfide. Despite successfully obtaining high yields of 
the desired singly bridged product, tandem MS experiments revealed that incorrect 
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cysteine-cysteine pairing had again occurred. The fragments observed in the mass 
spectra suggested C3-C5 cysteines were modified exclusively, forming regioisomer 56. 
Once again the structural changes that this would confer would undoubtedly affect the 
inhibitory activity of tertiapin Q. 
 
In conclusion, despite various attempts to obtain a maleimide modified derivative of 
tertiapin Q, the proximity of the disulfide bonds meant that this remained a challenge 
throughout. It appeared that reduction of one disulfide led to the almost immediate 
reduction of the second meaning that selectivity was not possible; tertiapin Q had a 
propensity to exist in the completely reduced state. We hypothesise that this is either 
due to a slight conformational change upon reduction of the first disulfide leading to 
increased reactivity of the second, or due to rapid thiol-disulfide exchange causing 
disulfide scrambling prior to maleimide bridging. This was an issue that our maleimide 
modification reagents could not overcome and modification of the correct cysteine pairs 
was not possible in any case. It also became apparent that modification of the C3-C5 
pair was most favourable, being found in every protocol tested. This could be reasoned 
by the proximity of these two cysteines within the peptide chain, residing in a 
favourable distance for a maleimide to react. 
 
This demonstrates a limitation to the applicability of the 3,4-disubstituted maleimides in 
the modification of small, multiply disulfide bonded systems. Although each system is 
variable in nature, the structure of the peptide or protein, and the location of the 
disulfide bonds and their local environment need to be carefully considered before 
applying such a modification strategy. 
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2.3 Modification of Octreotide 
 
 
2.3.1 Native Octreotide Analysis  
2.3.1.1 Dose-Response Analysis  
As described in the introduction, octreotide is a known agonist of the somatostatin 
receptor. With its longer half-life and improved potency it presents itself as a more 
attractive clinical candidate than the natural peptide somatostatin and, as a result, there 
continues to be interest in using octreotide for therapeutic and diagnostic 
applications.107 Unlike the more promiscuous somatostatin, octreotide displays almost 
exclusive selectivity for the somatostatin receptor subtype 2, with additional low 
selectivity for subtype 5. In order to assess the agonistic activity of octreotide in its 
native state, activation of the somatostatin receptor was analysed.107  It is reported that 
somatostatin and its analogues cause hyperpolarisation of neuroendocrine and neuronal 
cell membranes as a result of activation of GIRK channels; in fact, it is the 
hyperpolarisation of the cell membrane of pituitary cells in this fashion which is 
responsible for the characteristic inhibition of growth hormone release associated with 
somatostatin.164 Studies have shown that the somatostatin receptor 2 couples most 
efficiently to the GIRK channel family over any of the other receptor subtypes. Co-
expression of somatostatin receptor 2 with GIRK1 followed by administration of 
somatostatin leads to strong activation of inwards potassium currents through the GIRK 
channel. This activation of GIRK channels via the somatostatin receptor is mediated by 
G-protein.164 
 
With this information in hand, we designed our octreotide activity analysis accordingly. 
A HEK293 cell line stably expressing the GIRK1/2a channel subtype was transiently 
transfected with the somatostatin receptor 2. The GIRK1/2a subtype was chosen as it is 
reported to predominate in neuroendocrine cells, providing the most physiologically 
relevant system for these experiments.146 Successful transfection of the somatostatin 
receptor was observed by epifluorescence from eGFP which was also transfected into 
the cells as a visible indicator. With this engineered cell line, whole-cell patch clamp 
experiments were conducted. Typical current recordings for the GIRK1/2a channel, 
both at rest and after administration of native octreotide, are shown in Figure 2.46. 
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Figure 2.46: Current recordings of A) the resting GIRK1/2a channel and B) GIRK1/2a channel 
activation by octreotide (100 nM). Current was recorded over 20 mV voltage steps, over a range 
of -120 to +40 mV from a holding potential of -50 mV. 
 
These representative recordings show the larger inwards currents and smaller outwards 
currents of the GIRK1/2a channel at rest (Figure 2.46 A). Immediate current activation 
is observed following capacitive transient spikes. Upon administration of octreotide, 
rapid activation of the GIRK1/2a channel is seen; both the inwards and outwards 
currents are enlarged, the inwards current significantly more so which is characteristic 
of inwardly rectifying channels (Figure 2.46 B).  
 
Native octreotide was prepared over a range of concentrations (from 0.01 nM to 100 
nM), and these were subsequently perfused over the cells in a sequential manner with 
increasing concentration. Octreotide was washed out between each concentration step 
by perfusion with extracellular solution in order to regain the resting current levels. The 
recordings we acquired using AxonTM pCLAMPTM 10.2 software and analysed using 
AxonTM ClampfitTM 10.2 software. The mean of the maxiumum inwards currents 
through the GIRK1/2a channels in response to increasing concentrations of octreotide 
was plotted (Figure 2.47). 
A 
B 
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Figure 2.47: Mean absolute current increase (pA/pF) with increasing concentration of native 
octreotide (plotted as log [octreotide (µM)]). The sigmoidal fit line (red) was produced using a 
fit with function y = Bottom+(Top-Bottom)/(1+10^(X-LogIC50)). R2 = 0.9905. X at Y50 = -3.18. 
The error bars shown are calculated as the standard error of the mean. Raw data in Appendix 
Table 12. 
 
 
The data points plotted were fitted using a standard dose-response curve and this created 
the sigmoidal fit line characteristic of a dose-response analysis. At the lowest 
concentrations tested (0.1 nM) we observe negligible current suggesting minimal 
activation of the somatostatin receptor. As octreotide concentration is increased we 
observe significant current activation; octreotide is binding to and activating the 
somatostatin receptor, which in turn activates the GIRK channel, allowing increased 
inwards flux of potassium. At the highest tested concentrations of octreotide (100 nM) 
the current increase begins to plateau as maximal activation is reached. This 
concentration dependence on activity is characteristic of agonists and antagonists. The 
high R2 score of the fit line demonstrates a very reliable fit of the data. From the curve 
we can determine a numerical value for the half-maximal effective concentration (EC50) 
in order to quantify the agonist activity. From this study, an EC50 of 0.66 nM was 
obtained which demonstrates the high potency of the peptide in activation of the 
somatostatin receptor subtype 2. This value correlates well with the literature which 
reports the EC50 of octreotide as greater than 0.1 nM, often around 0.5 nM, for 
somatostatin receptor 2.165 
 
During the patch clamp analysis, it was observed that, shortly after maximal current 
activation had been achieved after administration of octreotide, the current levels began 
to diminish despite continuing perfusion with the agonist. This is a typical feature 
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commonly observed in GPCR-mediated signalling and is a result of desensitisation of 
the receptor with prolonged agonist exposure. There are a variety of mechanisms by 
which this desensitisation can occur such as receptor phosphorylation, palmitoylation 
and internalisation; the mechanism is dependent upon receptor type and the cell type 
expressing it.166,167 
 
2.3.1.2 Wash-Out Analysis 
It is also reported in the literature that, for somatostatin receptor subtypes 2-5, baseline 
current levels can be recovered upon wash-out of somatostatin.164 This was observed 
during this study, with baseline level current regained rapidly with all concentrations of 
octreotide tested by continuous perfusion with extracellular solution. An example of this 
is shown below in Figure 2.48. Resting current levels are first recorded (green) before 
administration of 1 µM octreotide where the associated activation of inwards potassium 
currents is observed (blue). Upon maximum activation, subsequent agonist wash-out 
brings the current levels back to the resting state (orange). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.48: K+ current (pA/pF) activation over a range of membrane potentials (mV) with 1 
µM octreotide and baseline K+ current recovery after washing with extracellular solution. 
 
The conclusions obtained from studying the activity of native octreotide on this system 
serves as a sound control for comparison with the octreotide derivatives synthesised, 
analysed and discussed later. 
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2.3.2 Maleimide Modified Octreotide 
2.3.2.1 Maleimide Modification of Octreotide 
With the vision of creating novel derivatives of octreotide by maleimide modification 
we wanted to ensure that insertion of the maleimide bridge into the disulfide bond of the 
peptide did not have a detrimental effect on its action as an agonist. Previous work on 
tertiapin Q demonstrated just how sensitive these small peptides are to perturbations to 
their tertiary structure. In this case, the presence of a single disulfide bond rules out the 
possibility of disulfide scrambling, the main issue faced when working with multiply 
disulfide bonded systems. In addition, previous work in the group on somatostatin, 
which is structurally similar to octreotide, demonstrated that the modification of its 
disulfide was facile and did not lead to loss of biological activity. 
 
Conditions were developed to rapidly bridge the disulfide bond of octreotide 34. Due to 
the simplicity accompanied with just having a single disulfide bond, a step-wise 
protocol could be employed. By reduction of the disulfide bond with 1.2 equivalents of 
the reducing agent TCEP before addition of 1.2 equivalents of the 
dithiophenolmaleimide 22, full conversion to the bridged peptide 61 was obtained 
within 10 minutes (Scheme 2.18) 
 
Scheme 2.18: The step-wise maleimide modification of octreotide 34 by reduction with TCEP 
(1.2 equiv.) for 1 h followed by addition of maleimide 22 (1.2 equiv.). 
 
Conversion to the bridged peptide 61 was determined by observation of the appropriate 
mass change by LC-MS. An example of such spectra is shown below in Figure 2.49. 
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Figure 2.49: ESI mass spectrum of A) peak at m/z 1021.7 corresponding to reduced octreotide 
(expected mass = m/z 1021. 3) and B) peak at m/z 1114.8 corresponding to modified octreotide 
61 (expected mass = m/z 1115.2).  
 
2.3.2.2 Purification & Characterisation of Modified Octreotide 
With the desired product in hand, it was purified by RP-HPLC using an analytical C-18 
column, in order to remove the unwanted buffer salts and unreacted starting materials. 
The RP-HPLC trace obtained is shown below in Figure 2.50, with analysis at 280 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.50: HPLC chromatogram (absorbance at 280 nm) of the octreotide modification 
reaction mixture (peak A retention time: 19.6 min, peak B retention time: 20 min). 
 
 
Peaks A and B were isolated, concentrated and characterised by MALDI mass 
spectrometry. The spectra obtained are shown below in Figure 2.51. 
A 
B 
A B 
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Figure 2.51: MALDI mass spectra of peaks A and B from the LC chromatogram in Figure 2.50. 
Peak at m/z 1116.0 corresponds to the modified peptide 61 (Expected mass = m/z 1115.2). The 
sodiated product (+23 m/z) and potassiated (+35 m/z) products are also visible.  
 
From the spectra obtained it is apparent that both peaks observed by RP-HPLC, despite 
their slightly differing retention times, appear to have the mass corresponding to the 
bridged octreotide 61. No unreacted starting material, expected at m/z 1019, is detected 
confirming the reaction had reached full conversion to the desired product. 
Interestingly, the main difference between these two products appears to be their 
isotopic distribution profile, with that of the peak A being uncharacteristic of what has 
been previously observed for octreotide. This suggests that perhaps there is an impurity 
within this sample causing the observed effect. The major product, peak B, was 
successfully isolated from such impurities and an overall yield of 68% after purification 
was obtained. This product only was used for further analysis. 
 
It was also noted during RP-HPLC purification that upon co-injection with native 
octreotide, the peptides co-eluted (Figure 2.52). 
A 
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Figure 2.52: RP-HPLC chromatogram (absorbance at 280 nm) of the octreotide modification 
reaction mixture doped with native octreotide (peak A retention time: 19.6 min, peak B 
retention time: 20 min). 
 
Modified octreotide 61 and native peptide 35 have identical retention times; in 
comparison to Figure 2.50 the only difference observed is an increase in peak B 
integration. Despite numerous attempts at tuning the solvent gradient to achieve the 
desired separation, surprisingly the two different species could not be separated. It was 
reasoned that perhaps incorporation of the small maleimide bridge within the peptide 
structure did not alter its conformation or hydrophobicity significantly enough to 
differentiate the two products on the column.  
 
2.3.2.3 Biological Activity of Modified Octreotide 
With the pure maleimide modified peptide in hand, analysis of biological activity was 
conducted. In analogous fashion to with native octreotide, whole-cell patch clamp 
experiments were carried out on the HEK293 cell line stably expressing the GIRK1/2a 
channel and transiently transfected with both somatostatin receptor subtype 2 and eGFP. 
Modified peptide 61 was administered over a range of concentrations (from 1 nM to 10 
µM) and the agonist was washed out with extracellular solution between each 
concentration tested. The current recordings were analysed as previously described and 
results obtained are shown in Figure 2.53 below in the form of a dose-response curve. 
 
 
 
 
 
 
B 
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Figure 2.53: Mean absolute current increase (pA/pF) with increasing concentration of modified 
octreotide 61 (plotted as log [modified octreotide (µM)]). The sigmoidal fit line (red) was 
produced using a fit with function y = Bottom+(Top-Bottom)/(1+10^(X-LogIC50)). R2 = 0.9734. 
X at Y50 = -0.929. The error bars shown are calculated as the standard error of the mean. Raw 
data in Appendix Table 13. 
 
Similarly to with native octreotide, the fit of the data produces a sigmoidal dose-
response relationship, with an R2 value of 0.9937 confirming a reliable fit. It became 
apparent while conducting the patch clamp experiments that the level of current elicited 
by modified octreotide 61 was significantly lower than with the native peptide and, as a 
result, higher concentrations were also tested. From the fit line, an EC50 value of 118 
nM was determined. Overlaying the dose-response curve of modified octreotide with 
that of the native peptide allows for ease of comparison of the two agonists (Figure 
2.54). 
 
 
 
 
 
 
 
 
 
 
Figure 2.54: Overlay of the mean absolute current increase (pA/pF) with increasing 
concentration of modified octreotide 61 (solid line) and native octreotide (dashed line) (plotted 
as log [octreotide (µM)]). 
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In comparison to native octreotide with an EC50 value of 0.66 nM, there has clearly 
been an attenuation of agonist affinity as a result of disulfide bond modification. The 
way in which, despite being tested at higher concentrations, the modified peptide 61 
does not elicit a maximum current increase comparable to the native peptide suggests a 
decrease is agonist efficacy also. In this way, the modified peptide 61 shows 
pharmacological action of a partial agonist.145 
 
This decrease in agonist affinity and efficacy can be well reasoned by the proximity of 
the disulfide bonded cysteines to the pharmacophore of the peptide (Figure 2.55) – the 
cysteines directly neighbour the four residues (Phe-Trp-Lys-Thr) that make up the 
receptor binding site of octreotide. It is well known that sequence alterations to this 
fundamental region of the peptide are not tolerated, suggesting geometrical changes like 
those resulting from maleimide bridging could also be detrimental.106 
 
 
 
 
Figure 2.55: The structure of octreotide A) the atomic structure with the pharmacophore shown 
in red B) the solution NMR structure (PDB entry code 1SOC).78   
 
It is not unreasonable to assume that insertion of a two-carbon bridge into the disulfide 
bond could distort the structure in such a way as to hinder the binding of the peptide to 
its receptor target.  The average length of a disulfide bond is 2.05 Å and the ideal C-S-
S-C dihedral angle is around 90°168; such geometric constraints mean the disulfide bond 
has a significant influence on the conformation of the local amino acid environment. A 
maleimide bridge is expected to hold the two cysteine sulphur atoms at a slightly larger 
distance of 2.5 Å169. This, albeit small, difference could in turn alter the geometry of 
A) B) 
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neighbouring bonds. It appears that this is not tolerated in octreotide and a negative 
effect on receptor binding results. 
 
Despite this, maleimide bridging does not abolish biological activity, and EC50 is still 
within the nanomolar range. This suggests that the modified octreotide 61 retains the 
ability to bind to the somatostatin receptor and elicit its agonist effects to a certain 
degree. Research progressed on to designing an octreotide-based bioconjugate using this 
chemistry for novel therapeutic or diagnostic applications. It was hypothesised that 
incorporation of an alkyne on the nitrogen of the maleimide ring would activate it in 
such a way that a compatible, functional biomolecule of choice could subsequently be 
attached. 
 
2.3.3 Alkyne Functionalised Octreotide 
2.3.3.1 Maleimide Modification of Octreotide 
N-alkyne functionalised maleimide 63 was readily synthesised in two steps from 
dibromomaleimide, as depicted in Scheme 2.19170. The first step involved converting 
the maleimide nitrogen into the corresponding carbamate 62 in order to activate it; this 
was done using N-methylmorpholine and methyl chloroformate. Subsequent addition of 
a stoichiometric amount propargylamine and stirring with excess silica efficiently 
installed the desired alkyne moiety, with an overall yield of maleimide 63 of 74%. 
 
 
 
 
 
Scheme 2.19: The synthesis of N-alkyne dithiophenolmaleimide 63. 
 
With this reagent in hand, the same step-wise protocol employed previously was 
followed in order to insert the functionalised maleimide 63 into the disulfide bond of 
octreotide (Scheme 2.20). 
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Scheme 2.20: Step wise modification of octreotide 34 by reduction with TCEP (1.2 equiv.) and 
addition of maleimide 64 (1.2 equiv.). 
 
Conversion to the modified peptide 64 was determined by observation of the 
appropriate mass change by LC-MS, an example of such spectra is shown below in 
Figure 2.56. 
 
 
Figure 2.56: ESI mass spectrum of A) peak at m/z 1021.7 corresponding to reduced octreotide 
(expected mass = m/z 1021. 3) and B) peak at m/z 1152.8 corresponding to alkyne modified 
octreotide 64 (expected mass = m/z 1151.55).  
 
Complete conversion to the modified peptide 64 was observed within 10 minutes and 
was reproducible. 
 
 
 
A 
B A 
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2.3.3.2 Purification & Characterisation of Functionalised Octreotide 
As before, isolation of the desired product was carried out by RP-HPLC purification. 
The RP-HPLC trace obtained is shown below in Figure 2.57, with analysis at 280 nm. 
 
Figure 2.57: RP-HPLC chromatograms of A) octreotide modification reaction mixture and B) 
octreotide modification reaction mixture doped with native octreotide (peak X retention time: 
21.7 min, peak Y retention time: 20.8 min). 
 
 
From the RP-HPLC trace A, modified octreotide 64 (peak X) has a retention time of 
21.7 minutes. This peak was collected, concentrated under vacuum and re-dissolved in 
deionised water before analysis by MALDI to assess the purity of the product. The 
MALDI spectrum obtained is shown below in Figure 2.58. The recovered yield of 
modified peptide after RP-HPLC purification was calculated to be 77%. By co-injection 
of the reaction mixture with native octreotide (RP-HPLC trace B, peak Y) we can 
observe the associated retention time shift as a result of maleimide modification. This 
confirms that there was no unmodified octreotide in our reaction mixture. The shift in 
retention time is relatively small, giving hope that the structure of the peptide had not 
been drastically altered.  
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Figure 2.58: MALDI mass spectrum of peak X from the LC chromatogram in Figure 2.57A. 
Peak at m/z 1152.53 corresponds to the modified peptide 64 (Expected mass = m/z 1151.55). 
The sodiated product (m/z +23) is also visible (m/z 1175.09).  
 
Satisfied with the purity of the desired product, the biological activity was next 
evaluated. 
 
2.3.3.3 Biological Activity of Functionalised Octreotide 
Whole-cell patch clamp experiments were again carried out on the HEK293 cell line 
stably expressing the GIRK1/2a channel and transiently transfected with both 
somatostatin receptor subtype 2 and eGFP. Modified peptide 64 was administered over 
a range of concentrations (from 1 nM to 10 µM), again with agonist wash out between 
each tested concentration. The resulting dose-response curve from the recorded currents 
is shown below in Figure 2.59. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.59: Mean absolute current increase (pA/pF) with increasing concentration of modified 
octreotide 64 (plotted as log [modified octreotide (µM)]). The sigmoidal fit line (red) was 
produced using a fit with function y = Bottom+(Top-Bottom)/(1+10^(X-LogIC50)). R2 = 0.9975. 
X at Y50 = -0.981. The error bars shown are calculated as the standard error of the mean. Raw 
data in Appendix Table 14. 
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Similarly to modified octreotide 61, the fit of the data for alkyne functionalised 
octreotide 64 produces a sigmoidal dose-response relationship with an R2 value of 
0.9975. From the fit line, an EC50 value of 105 nM was determined. Once again, overlay 
of the dose-response curve of the modified peptide 64 with that of the native peptide 
facilitates ease of comparison of the two agonists (Figure 2.60). 
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Figure 2.60: Overlay of the mean absolute current increase (pA/pF) with increasing 
concentration of modified octreotide 64 (solid line) and native octreotide (dashed line) (plotted 
as log [octreotide (µM)]). 
 
As expected, in comparison to native octreotide with an EC50 value of 0.66 nM, a 
decrease in agonistic affinity, i.e. an increase in EC50, is observed. The loss of biological 
activity is of similar magnitude to that of maleimide modified octreotide 61, whose 
EC50 was calculated to be 118 nM. This adds further conclusive evidence to suggest that 
incorporation of a two-carbon bridge within the disulfide bond of octreotide perturbs the 
tertiary structure and hinders, but does not abolish, binding to the somatostatin receptor. 
Interestingly, the decrease in agonist efficacy observed previously with modified 
octreotide 61 is not seen in this case; maximal current increase is observed by 
administration of the modified octreotide 64, albeit at a higher dose than in the native 
case. This suggests the modified peptide displays full agonist characteristics.145  
 
This variance between the observed efficacy of the two modified derivatives could be as 
result of the nature of the chemical modification, perhaps the differing chemical 
conformation of each serves to alter agonist efficacy considerably in the case of a small 
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peptide such as octreotide. To confirm this hypothesis, higher concentrations of 
modified peptide 61 would be tested, to fully confirm the partial agonistic activity. 
 
Despite the attenuated affinity of the alkyne functionalised octreotide 64, and with the 
knowledge that nanomolar activity is still viable for certain applications, efforts towards 
a novel octreotide-based bioconjugate continued. Alkyne functionalised octreotide 64 
was subsequently investigated as a precursor for attachment to a desired biomolecule by 
means of click chemistry. 
 
2.3.3.4 Click Reactions of Functionalised Octreotide  
Click chemistry is a powerful synthetic strategy for covalently combining two 
molecules. One of the most utilised reactions of this kind is the Huisgen 1,3-dipolar 
cycloaddition between an alkyne and an azide to yield 1,2,3-triazoles. A copper catalyst 
is often utilised to selectively produce the 1,4-disubstituted triazole 65, which can 
proceed under aqueous conditions, as shown in Scheme 2.21 below. This reaction is 
renowned for being highly reliable and selective and has proven to be an incredibly 
versatile bond forming process, as proven by its extensive coverage in the literature.171 
 
 
 
 
Scheme 2.21: The copper(I) catalysed cycloaddition between an alkyne and an azide. 
 
A key application for this reaction has been found in bioconjugation, whereby 
biomolecules such as proteins, peptides or nucleic acids can be attached to a second 
entity of choice, for example fluorophores, therapeutic drugs or affinity tags.172-174 This 
type of click cycloaddition proves efficient here due to the ease at which the alkyne and 
azide moieties can be incorporated into organic compounds, the selectivity of the 
reaction partners and the bioorthogonal nature of the reaction.171 
 
We envisaged utilising our alkyne-labelled octreotide as a precursor onto which a 
second functional molecule could be attached. By utilising functionalised azides, an 
array of different bioconjugates could be created. To first determine whether the alkyne 
labelled octreotide was functional in a click cycloaddition reaction, a test reaction was 
run using the small PEG-azide 66 as shown in Scheme 2.22. The conditions employed 
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were based on those described by Hong et al..175 Sodium ascorbate is the chosen 
reducing agent to produce Cu(I) from the CuSO4 salt in situ, employed largely because 
of its good water-solubility. To prevent further reduction or re-oxidation of the Cu(I), a 
stabilising ligand is often added. Tris-(hydroxypropyltriazolylmethyl)amine (THPTA) 
was chosen in this case, due to its reported efficiency and, again, water-solubility. These 
reagents allow the reaction to be carried out in fully aqueous, biologically compatible 
conditions.173 
 
Scheme 2.22: The copper(I) catalysed click cycloaddition between alkyne functionalised 
octreotide 64 and PEG-azide 66 at varying equivalents (10, 20 or 50). 
 
The reaction was carried out using varying number of equivalents of the PEG-azide, 
being in excess in all cases. All other possible variables remained constant throughout. 
The results are summarised in Table 2.14. 
 
Table 2.14: The effect of increasing equivalents of PEG-azide 66 on formation of the desired 
product 67 (by apparent conversion by LC-MS). 
 
Number of equivalents 
of PEG-azide 66 
Yield of desired product  
67 (apparent 
conversion by LC-MS) 
5 0% 
10 48% 
20 95% 
 
The reaction proceeded well, with 20 equivalents of azide leading to the greatest 
formation of modified product 66. The LC-MS spectrum of the product is shown below 
in Figure 2.61. Increasing the number of equivalents further lead to a more complex 
mixture of unidentifiable products. 
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Figure 2.61: ESI mass spectrum of the reaction mixture with 20 equivalents of PEG-azide 66 
with the peak at m/z 685.9 and m/z 457.47 corresponding to the doubly and triply charged ions 
of the expected click product 67 respectively (expected mass = m/z 685.7 and m/z 457.2). 
 
With good evidence to suggest that, despite the alkyne moiety being attached to a 
peptide, the click cycloaddition is efficient, work progressed onto incorporation of a 
functional azide. The first example chosen was azide functionalised derivative of the 
therapeutic drug doxorubicin. Doxorubicin is a chemotherapeutic given for the 
treatment of a number of different cancers and exerts its pharmacological effect by 
means of DNA intercalation. Although the drug has proven effective in the treatment of 
many cancer patients, it is well known that it often causes numerous unwanted side 
effects such as alopecia, nausea, vomiting and neutropenia, to name just a few, and 
these limit its clinical usefulness. Attempts to improve tumour cell selectivity include 
encapsulation of the drug into liposomes176, formation of doxorubicin hydrogels177 and 
conjugation of the drug to a targeting moiety.178,179 
 
We envisaged direct conjugation of doxorubicin to octreotide as a means to deliver the 
drug to tumours expressing the somatostatin receptor. As discussed in the introduction, 
many tumours tissues such as breast, kidney, thyroid and neuroendocrine have been 
found to overexpress this receptor, making it a popular means by which to differentiate 
and target tumour cells from healthy ones. In turn this can help minimise undesirable 
side effects. We attempted to attach doxorubicin as shown in Scheme 2.23 below. The 
azide functionalised drug 68 was synthesised and kindly donated by Dr João Nunes.180  
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Scheme 2.23: The copper(I) catalysed click cycloaddition between alkyne functionalised 
octreotide 64 and doxorubicin-azide 68 in varying equivalents. 
 
Despite using identical reagent ratios as previously described, the reaction between the 
alkyne-labelled octreotide 64 and doxorubicin-azide 68 did not proceed efficiently. A 
complex mixture of products was obtained, perhaps as a result of the degradation of 
doxorubicin by the copper iodide. There was evidence of product formation as shown in 
Figure 2.62, but the yield was low and difficult to quantify. Despite attempts at 
purification by RP-HPLC, the desired product 69 could not be isolated. Attempts to 
improve the efficacy of the reaction included increasing azide to 40 equivalents and 
extended reaction time of 24 hours, but with no improvement.  
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Figure 2.62: ESI mass spectrum of the reaction mixture with 20 equivalents of doxorubicin-
azide 68 after 1 h. Peak at m/z 1957.00 and m/z 978.30 corresponding to the singly and doubly 
charged ions of the expected click product 69 respectively (expected mass = m/z 1955.49 and 
m/z 977.6). 
 
After experiencing difficulties with this route to a functionalised octreotide 
bioconjugate, we sought an alternative strategy. It was envisaged that, conducting the 
click cycloaddition between the azide and the maleimide-alkyne to create a 
functionalised maleimide prior to insertion into the peptide disulfide could overcome 
the issue; the disulfide bridging reaction was consistently efficient and quantitative. 
With a concomitant shift in our focus from a drug-based conjugate to new methodology 
development for multimodal imaging, efforts in this alternative strategy were pursued 
and are discussed below. 
 
 
2.3.4 Octreotide as a Monomolecular Multimodal Imaging Agent (MOMIA) 
 
As described in the introduction, in cancer diagnosis, employing multiple imaging 
agents in conjunction helps to improve the accuracy of the staging and localisation of 
tumours. There are a variety of imaging techniques currently used in the clinic, each 
using different imaging moieties.181 A relatively new concept is the combining of two or 
more of these moieties into a single molecule in order to minimise the number of doses 
administered to the patient and the pharmacokinetic variance associated with giving 
each diagnostic agent separately.124 We envisaged making such a molecule, by 
employing octreotide as a somatostatin receptor targeting moiety, as before, and then 
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attachment of two different imaging modalities using a maleimide functionalised with 
both. A schematic of such a construct is shown below in Figure 2.63. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.63: The proposed octreotide-based multimodal imaging agent. 
 
 
2.3.4.1 Maleimide Synthesis 
 
There were a number of synthetic considerations to be taken into account when 
designing the molecule of choice: 
 
- The fluorophore needs to modifiable without detriment to its fluorescence 
lifetime or quantum yield. Rhodamine B 70 is commercially available at 
relatively low cost, has good photostability, quantum yield and water-solubility 
and has a carboxylic acid group which lends itself to functionalization.182 It was 
decided that this would be a suitable fluorophore to enable visualisation.  
 
 
 
 
 
  
Figure 2.64: Rhodamine B (70). 
 
- In order for the molecule to be ‘clickable’, alkyne or azide functionality needed 
to be incorporated. An azide was chosen, connected to the fluorophore by a 6-
carbon linker; this is important as the bulky rhodamine molecule may hinder the 
click cycloaddition if it is too close to the reactive site.  
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- It was decided that this linker should be adjoined to rhodamine by means of an 
amide connectivity; amide bonds being less prone to hydrolysis than the 
corresponding ester linkage. To install this, a piperidine moiety was utilised, this 
way a tertiary amide is produced in connection with the rhodamine molecule 
(Figure 2.65). This should inhibit any intramolecular cyclisation which is 
reported to occur with secondary amide connectivity – this is found to cause loss 
of fluorescence.183 
 
 
 
 
 
 
 
 Figure 2.65: Azide functionalised rhodamine B 
 
- It was proposed that a radiolabel would be a beneficial second imaging 
modality. This would enable imaging by SPECT or PET. A novel route to 
incorporate 125I into the triazole product of a click cycloaddition in a one-pot, 
three component, copper(II)-mediated reaction has been pioneered by the Arstad 
group at UCL and described by Yan et al.184 (Scheme 2.24); it was envisaged 
that this could be employed in conjunction with our rhodamine-azide and N-
alkyne maleimide. 
 
 
 
 
 
 
 Scheme 2.24: Synthesis of 5-[125,127I]Iodo-1,2,3-triazoles.184 
 
- Lastly, the nature of the N-alkyne maleimide was considered. The 
dibromomaleimide derivative 63 was considered but, in order to eliminate the 
chance of any halogen exchange reactions occurring between the iodine in the 
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click reaction and the bromine eliminated during the disulfide bridging reaction, 
the dithiophenol derivative 71 was synthesised and utilised instead.170  
 
The synthetic strategy devised is shown below (Scheme 2.26). The carboxylic acid of 
rhodamine B was first converted to the more reactive acid chloride 72 using excess 
oxalyl chloride. This reaction is fast and efficient and was quantitative, meaning further 
purification was not necessary. This acid chloride was taken on immediately to avoid 
degradation. It was reacted with the N-Boc amino piperidine, with CsCO3 as a base, to 
produce the product 73 with the desired tertiary amide linkage in 67% yield.46 
Deprotection of this with TFA lead to quantitative formation of the desired rhodamine 
moiety as the TFA salt 74.  
 
Meanwhile, 6-bromohexanoic acid was converted to the azide 75 by reaction with 
sodium azide and heating at 50 °C (Scheme 2.25).185 Despite attempts with longer 
reaction times and solvent mixtures, the yield of this reaction remained at around 40% 
which is lower than expected but still acceptable.  
 
 
 
 
Scheme 2.25: The synthetic route to 6-azidohexanoic acid. 
 
Acid 75 was coupled to the rhodamine-TFA salt by means of a classic N,N,N′,N′-
Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) coupling 
with catalytic 1-hydroxybenzotriazole (HOBt) and N,N-diisopropylethylamine (DIPEA) 
as a base. Yields of the desired azide 76 were good, between 65-77% over 3 attempts.  
 
Finally, this azide-functionalised rhodamine B 76 was taken on to the final step, the 
click reaction with N-alkyne dithiophenolmaleimide 71. As previously mentioned, this 
reaction has been pioneered by the Arstad group at UCL, with whom we worked in 
collaboration for this section of the project. The group have carried out thorough 
optimisation of the protocol to obtain high yields of the iodinated triazoles from a range 
of alkynes and azides. The mechanism of the reaction remains largely elusive; various 
speculations are discussed in their published paper.184 For structural characterisation and 
future imaging studies and activity testing the nonradioactive 127I containing compound 
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77 was synthesised. This uses Cu(I) iodide, TEA and N-chlorosuccinimide (NCS) with 
the alkyne and azide in a one-pot protocol, as shown in Scheme 2.24. In this case, a 
37% yield of the desired product 77 was obtained as a dark purple solid and was kept 
for further experiments. The synthetic strategy is shown below in Scheme 2.26. 
 
 
Scheme 2.26: The synthetic route to the desired MOMIA-maleimide reagent (77). 
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When synthesising the radioactive derivative 78, which was carried out by our 
collaborators, the order of addition of the reagents has been found to be important; the 
highest yields were obtained when the alkyne, copper(II) chloride and the TEA were 
combined prior to the addition [125I]NaI and the azide.184 This protocol was followed 
using the azide-functionalised rhodamine B 76 and the alkyne functionalised maleimide 
71 (Scheme 2.27). 
Scheme 2.27: Synthesis of the radiolabelled maleimide 78. 
 
2.3.4.2 Characterisation of Radioactive [125I] Multimodal Maleimide 
 
In order to characterise and quantify the radiolabelled maleimide 78, radio-HPLC was 
employed.184 To determine the exact retention time expected for the desired product, the 
nonradioactive compound 77 was run as a reference. The LC-chromatogram obtained is 
shown below in Figure 2.66. 
 
 
Figure 2.66: The LC chromatogram of maleimide 77 (retention time: 23.4 min). 
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A sharp peak was observed for compound 77 and a retention time of 23.36 minutes was 
recorded. Subsequently, the reaction in Scheme 2.27 was carried out, and the reaction 
mixture analysed by radio-HPLC using exactly the same conditions as previously 
employed. The LC-chromatogram (A) and the radio-chromatogram (B) are shown in 
Figure 2.67. 
 
Figure 2.67: A) The LC chromatogram of the ‘click’ cycloaddition reaction mixture (retention 
time of non-iodinated product: 21.6 min, retention time of iodinated product: 23.8 min), B) The 
radio-chromatogram of the ‘click’ cycloaddition reaction mixture (retention time of iodinated 
product: 23.7 min). 
 
From the comparison of the LC-chromatogram A with that of the reference compound 
in Figure 2.66, we can assign the peak of retention time 23.76 minutes as the 
radiolabelled maleimide 78. The large peak at 21.59 minutes is most likely the non-
iodinated triazole which is the competing reaction in such a protocol. Comparing LC-
chromatogram A with the radio-chromatogram B provides complimentary evidence. 
The peaks in chromatogram B show products that have incorporated 125I; the major peak 
in this case being that with a retention time of 23.72 minutes, which correlates well with 
the retention time of the assigned product 78 in chromatogram A. In addition, there is 
no peak in the radio-chromatogram at or around 21.59 minutes, again suggesting that 
this is the non-iodinated derivative.  
 A 
 B 
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To fully confirm that the product at 23.76 minutes is the desired radiolabelled 
maleimide 78, this peak was collected and co-injected with the non-radiolabelled 
reference compound 77. If the compounds are atomically identical, besides the isotopic 
nature of the iodine, then co-elution should be observed. The LC- and radio-
chromatograms are shown in Figure 2.68.  
 
Figure 2.68: A) The LC chromatogram of maleimide 77 and maleimide 78 co-injection 
(retention time: 23.6 min), B) The radio-chromatogram of maleimide 77 and maleimide 78 co-
injection (retention time: 23.7 min). 
 
Besides a small impurity at 22.38 minutes, we observed very good co-elution of both 
the non-radiolabelled maleimide 77 and the labelled derivative 78 at 23.57 minutes 
confirming formation of the desired product.  
 
Confident that formation of the desired product was successful, it was then quantified. 
The analytical radiochemical yield (RCY), which is determined from the area under the 
peak in the radio-chromatogram B (Figure 2.67), was determined to be 58%. The 
isolated RCY is determined by the amount of product-associated radioactivity isolated 
from a known amount of radioactivity added into the reaction.184 In this case, 1.263 
MBq of radioactivity was added into the reaction in the form of [125I]NaI and 0.58 MBq 
of product-associated radioactivity was isolated following the reaction. This equated to 
an isolated RCY of 49%. Considering the bulky nature of the azide participating in the 
 A 
 B 
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reaction and the competing formation of the non-iodinated triazole, a yield of around 
50% of the desired product is pleasing.  
 
2.3.4.3 Maleimide Modification of Octreotide  
In order to examine the bridging efficacy of the doubly functionalised maleimide, the 
nonradioactive derivative was used to reduce unnecessary exposure to radioactivity; this 
and the radioactive compound should act identically. As with all other octreotide 
bridging experiments, octreotide 34 was first reduced using 1.2 equivalents of TCEP 
before addition of 1.2 equivalents of maleimide 77 in a step wise protocol (Scheme 
2.28). 
 
Scheme 2.28: Step wise bridging of octreotide 34 by reduction with TCEP (1.2 equiv.) followed 
by addision of maleimide 77 (1.2 equiv.). 
 
Full conversion to the bridged peptide 79 was observed within 15 minutes. This 
suggests that, despite the bulky substituents attached to the maleimide, insertion into the 
disulfide bond is still efficient. The mass spectra of the reaction are shown below in 
Figure 2.69. 
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Figure 2.69: ESI mass spectrum of A) peak at m/z 1021.7 corresponding to reduced octreotide 
(expected mass = m/z 1021. 3) and B) peak at m/z 1943.31 corresponding to modified octreotide 
79 (expected mass = m/z 1942.51).  
 
In order to remove the organic solvents, buffer salts and any excess reducing agent and 
maleimide, the modified octreotide was purified by dialysis. The product was then dried 
by centrifugation in vacuo before being redissolved in deionised water. This product 
was then analysed for its purity by LC-MS analysis (Figure 2.70).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.70: LC chromatogram of A) crude reaction before dialysis B) after dialysis. (Modified 
peptide 79 retention time: 1.75-1.76 min, maleimide 77 retention time: 2.83 min). 
 
A very clean UV-vis spectrum of the desired product was obtained after dialysis. Purity 
was confirmed from the mass spectrum (not shown) confirming no contaminating small 
molecules remained. This product was used for further experimentation. 
A) 
B) 
A B 
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2.3.4.4 Imaging Studies Using Octreotide-MOMIA 
With the functionalised octreotide derivative 79 in hand, analysis of its utility as a 
MOMIA began. It is imperative that, despite conjugation, octreotide retained its 
specificity for the somatostatin receptor and that the rhodamine and radioisotopic iodine 
retained their activity to enable visualisation.  
 
In order to determine whether the functionalised peptide still bound to the receptor and 
whether the fluorescence of the attached rhodamine moiety could be visualised 
effectively, confocal microscopy experiments were carried out. Three cell models were 
employed in these experiments: 
- Cell line with endogenous expression of the somatostatin receptor: human 
pancreatic BON-1 cells derived from a neuroendocrine tumour, which are 
reported to display somatostatin receptor subtype 2 expression.186,187 
- Cell line with heterologous expression of the somatostatin receptor: HEK293 
cells transiently transfected with somatostatin receptor subtype 2, which should 
display high levels of receptor expression. These were co-transfected with eGFP 
to determine precisely which cells express the receptor. 
- Negative control cell line: HEK293 cells with no somatostatin receptor 
expression. 
 
These cell lines were cultured onto glass bottomed petri dishes and the ‘engineered’ cell 
line transfected with the somatostatin receptor subtype 2. Each cell line was incubated 
with 1 µM of the octreotide-MOMIA 79 for 20 minutes at room temperature before 
removal and washing with buffer to remove excess unbound octreotide-MOMIA. The 
cells were then visualised by confocal microscopy at two excitation wavelengths; 488 
nm was used to visualise fluorescence from eGFP as a marker of successful cell 
transfection and 543 nm was used to visualise rhodamine fluorescence. Some images 
from these experiments are shown below in Figures 2.71 and 2.72. 
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Figure 2.71: Confocal images of HEK293 cells transfected with the somatostatin receptor 
subtype 2 and eGFP after incubation with 1 µM octreotide-MOMIA 79 for 20 min. A) & C) 
Visualisation at 488 nm shows positively expressing cells fluorescing green. B) & D) 
Visualisation at 543 nm shows rhodamine fluorescing red. A) and B) Visualisation before 
removal of octreotide-MOMIA and buffer wash. C) and D) Visualisation after removal of 
octreotide-MOMIA and buffer wash. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.72: Confocal images of non-transfected HEK293 cells after incubation with 1 µM 
octreotide-MOMIA 79 for 20 min. A) Visualisation at 488 nm. B) Visualisation at 543 nm. 
 
C D 
A B 
A B 
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Fluorescence imaging at a wavelength of 488 nm allowed effective visualisation of cells 
expressing eGFP and therefore expressing the somatostatin receptor subtype 2. 
Subsequent visualisation of the same field of cells at 543 nm allowed for visualisation 
of the red fluorescence of the rhodamine bearing octreotide-MOMIA 79. From Figure 
2.71, localisation of fluorescence in images A and B suggests octreotide-MOMIA 79 
can effectively target somatostatin receptor positive cells. To determine whether this 
cell binding is specific and due to interaction with the somatostatin receptor, identical 
experiments were carried out on the same cell line but without transfection with the 
receptor. No fluorescence was observed at 543 nm (Figure 2.72 B), suggesting no 
binding of the octreotide-MOMIA 79 to the cells.   
 
Identical experiments were also carried out the BON-1 cells which were originally 
derived from a young male presenting a lymph node metastatic pancreatic tumour 
(Figure 2.73). This neuroendocrine cell line is commonly used as the cells display the 
morphology and cell-surface markers characteristic of such tumours.186 As discussed in 
the introduction, up-regulation of somatostatin receptor expression is well known in 
neuroendocrine tumours and so we chose them as a suitable model for our experiments. 
Using a cell line such as BON-1 that naturally expresses the receptor allows a more 
physiologically relevant analysis of the utility of octreotide-MOMIA 79 as levels of 
expression are more representative of what they would be in tumour tissue in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.73: A) Confocal image of BON-1 cells at 543 nm after incubation with octreotide-
MOMIA 79 for 20 min B) a zoomed image of a group of cells from Figure 2.73 A. 
 
 
From Figure 2.73, cell membrane localisation of the octreotide-MOMIA 79 can be seen. 
These experiments give more promising evidence to suggest that the peptide has 
A B 
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retained the ability to bind to its target. Unlike the previous images of the transfected 
HEK293 cells where fluorescence seemed to be quite uniform around the cell 
membrane, localisation in this case appears to be more punctuated around the 
membrane. This could be as a result of receptor internalisation upon binding of 
octreotide-MOMIA 79, as known, and previously discussed, for the somatostatin 
receptor upon binding of its agonists. The punctuation on the periphery of the cells 
could be the formation of vesicles; a common route by which receptor internalisation 
and trafficking occurs.188 Such endocytosis could be further investigated by experiments 
with longer incubation times.  
 
Altogether, these confocal imaging studies suggest that the MOMIA 79 still has the 
ability to selectively bind to its receptor target, meaning the tumour-cell targeting aspect 
of the bioconjugate is still functional. In addition, good fluorescence was observed 
during visualisation, showing that the rhodamine had maintained its fluorescent nature 
during synthesis of MOMIA 79.  Although the compound tested in this case was the 
non-radiolabelled derivative, comparable results would be expected from the 
radiolabelled maleimide 78 when incorporated into octreotide. This bioconjugate could 
then also be employed in SPECT imaging.  
 
2.3.5 Summary of Octreotide Modification 
Octreotide presented itself as in ideal candidate for maleimide modification at its 
disulfide bond. Considerable coverage in the literature of creating functionalised 
bioconjugates from this peptide highlighted the utility of octreotide in this field. 
Presence of a single disulfide made the modification procedure considerably more 
straightforward than with tertiapin Q as issues with disulfide scrambling were 
circumvented.  
 
To accurately determine the effect of the insertion of a maleimide bridge into the 
disulfide bond of such a small peptide, a non-functionalised maleimide was first 
utilised. The modification was rapid and efficient and the desired product was purified 
and characterised before being tested for any alteration to biological activity. The ability 
of the modified peptide 61 to activate the somatostatin receptor was monitored using 
whole-cell patch clamp experiments. The modified peptide was still able to activate the 
receptor, with an EC50 of 118 nM. Compared to native octreotide 35 with an EC50 of 
0.66 nM, the agonistic activity of our modified derivative had been attenuated. A 
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decrease in agonist efficacy was also observed, suggesting partial agonist 
characteristics. This was reasoned to be as a result of the proximity of the cysteine 
residues to the pharmacophore of the peptide which is a region where perturbations to 
structure and conformation are not well tolerated. 
 
As agonistic activity was still in the nanomolar range, work progressed on to 
synthesising functionalised octreotide bioconjugates. Our first target was an alkyne-
linked derivative, with the aim of using this as a precursor onto which a variety of 
azide-functionalised biomolecules could be attached. The alkyne-functionalised 
octreotide 64 was again synthesised with relative ease. When examined for its agonistic 
activity, the expected attenuation was again observed; an EC50 of 105 nM was obtained. 
The agonistic efficacy of this modified derivative was not compromised in this case 
however, and maximal current increase was observed at higher concentrations. Work 
progressed onto optimising the conditions for an efficient ‘click’ cycloaddition reaction 
between alkyne-functionalised octreotide and an azide. Preliminary experiments with a 
small azide were promising, but this did not translate well when a larger, functional 
azide was employed. Doxorubicin-azide did not react well under any conditions 
attempted. 
 
After concluding that this may not be the most efficient route to a functionalised 
octreotide bioconjugate, our focus altered towards creating the desired functionalised 
maleimide prior to incorporation into the disulfide bond. Concurrent with this was the 
discovery of the field of targeted, multimodal imaging agents within the literature. We 
postulated that, using the N-alkyne maleimide, we could create such a molecule. In 
collaboration with the Arstad group at UCL, and utilising their one-pot, three-
component approach to forming iodinated triazoles via a ‘click’ cycloaddition, we 
pursued this. A maleimide functionalised with both the fluorophore rhodamine and the 
radiolabel 125I was synthesised using this strategy, and subsequently incorporated into 
the disulfide bond of octreotide. In this way we hoped to have created a new candidate 
for the next generation of MOMIA – octreotide as the targeting moiety for localising 
somatostatin receptor positive tumours, rhodamine to enable subsequent fluorescent 
imaging and 125I to facilitate SPECT imaging.  
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Confocal microscopy imaging was employed to visualise the possible binding of the 
octreotide-MOMIA 79 to the somatostatin receptor. Efficient fluorescence intensity 
from the rhodamine moiety allowed visualisation of the bioconjugate binding to cells. 
Pleasingly, the octreotide-MOMIA showed specific binding to cells endogenously 
expressing the somatostatin receptor (BON-1 cell line) and those transfected with the 
receptor. Fluorescence appeared to accumulate in to what we predict to be vesicles, 
suggesting internalisation of the octreotide-MOMIA could be occurring upon receptor 
binding. Further experiments are required to confirm this hypothesis. 
 
In conclusion, maleimide modification of the disulfide bond of octreotide is relatively 
straightforward. However, incorporation of a two-carbon bridge between the cysteine 
residues is not completely tolerated and, as a result, agonistic activity towards its 
receptor target is attenuated. Despite this, biological activity remained within the 
nanomolar range. An octreotide bioconjugate linked to a fluorophore and a radiolabel 
has been synthesised and promising imaging studies suggest this could be a new novel 
candidate for a MOMIA to aid the diagnosis and localisation of somatostatin receptor 
positive tumours. Such diagnostic agents serve to minimise the number of compounds 
administered to patients during diagnosis and, as a result, helps reduce pharmacokinetic 
variance and associated side-effects. Current methods to incorporate multiple 
visualisation agents into one molecule efficiently are currently limited; our 
methodology provides a novel and straightforward strategy to address this issue. 
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Chapter 3 
Concluding Remarks & Future Directions 
 
 
Cysteine residues present themselves as a convenient target for site-selective 
modification, owing largely to their low natural abundance and significant 
nucleophilicity. The concept of targeting disulfide bonds as a site of modification is 
relatively new, and has been recently advanced by the advent of the ‘modification by re-
bridging’ strategy. Exploiting naturally occurring disulfide bonds with this methodology 
allows the incorporation of a desired functional moiety whilst maintaining the structural 
integrity conferred by the original bond. It also means that no prior manipulation of the 
peptide or protein, such as incorporation of a non-natural amino acid residue, needs to 
be carried out prior to the modification. This methodology continues to be developed 
and fine-tuned, which the work in this project aimed to further.  
 
The 3,4-disubstituted maleimides pioneered and developed by our group have proved 
efficient in the modification of disulfide bonds. They act fast, with incorporation into a 
reduced disulfide occurring in minutes. Recent work has allowed their utility in an in 
situ methodology, serving to re-bridge the two cysteine residues as soon as they are 
exposed by reduction. Work in this project has helped further the development of both 
the reagents and the protocols employed. The way in which the maleimides can be 
tailored towards the desired application with significant ease was demonstrated; the 
reactivity of the reagent can be varied by altering the chemistry of the leaving groups, 
depending on whether a faster or slower acting reagent is sought. The properties of the 
compounds can also be adjusted by design, for example improving water-solubility to 
remove the need for organic solvents in the protocols means that aqueous conditions can 
be employed – highly desirable when working with biological systems. Finally, by 
careful design and employing the right chemistry, the nitrogen of the maleimide ring 
provides a convenient site for attachment to a functional moiety of choice. The library 
of functionalised maleimides available continues to expand; a novel bi-modal example 
synthesised within this project has enabled the scope of this to be furthered. Pleasingly, 
development of such bi-modal reagents is set to continue. 
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Despite the efficiency and scope of these reagents, they are not without limitations 
which became apparent over the course of this project. Disulfide bonds are fundamental, 
most predominantly in cases where the geometry of the local environment is integral to 
the biological activity and target specificity of the peptide or protein. In small peptides 
limited structural constraint is conferred by the non-covalent interactions between 
amino acid side chains, for which disulfide bonds must compensate. It is this which 
makes the modification of these bonds very challenging.  
 
Although the maleimides studied are indisputably fast reacting and selective for 
cysteine thiolates over other nucleophilic sites within the peptide, their incorporation 
into the disulfide bond is not without detriment. From the work on octreotide it is clear 
that the incorporation of an unnatural two-carbon bridge is not completely tolerated in 
small peptides; there is an associated attenuation of biological activity. It appears that 
the, albeit relatively small, increase in distance between the cysteines is enough of a 
geometric alteration to hinder binding to the target. This is compounded by the 
proximity of the disulfide to the pharmacophore of the peptide, a limitation which will 
be common amongst many small peptides.  
 
In addition, small peptides with multiple disulfide bonds in proximity also bring 
challenges. Limited tertiary structure means that such peptides effectively lack a 
significant hydrophobic core - the site at which larger proteins bury residues and bonds 
that are integral to their structure and function. As a result, the disulfides of small 
peptides are often all solvent accessible and have similar reactivity towards both 
reducing agents and modification reagents. In this way, selectively targeting one 
disulfide bond as a site of modification is very difficult, as observed in the work on 
tertiapin Q. 
 
These issues present themselves as the limitations to the maleimide modification 
strategy. In such cases alternative routes to bioconjugates may be superior; N- or C- 
terminal attachment of a functional moiety for example. In this way, the pharmacophore 
of the peptide can hopefully remain unperturbed.  
 
Despite the discussed challenges and limitations encountered, the value and efficacy of 
the analytical techniques employed throughout this project should be highlighted. 
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Although a relatively complex technique, the patch clamp analysis proved to be an 
informative and accurate method for monitoring the biological activity of the studied 
peptides upon binding to their targets. Such high-resolution current recordings allowed 
for precise determination of IC50 or EC50 values and the utility of such a technique for 
the detailed study of physiological systems was quickly realised. In addition, the tandem 
MS analysis presented itself as another invaluable technique; it facilitated the 
unequivocal location of the maleimide modification within a peptide chain. Detailed and 
informative data was obtained in minutes using very small amounts of product and, in 
some cases, without the need for prior purification. The scope of such an analytical 
method is undoubtedly huge. 
 
With regards to the future directions for this study, the aforementioned limitations to 
maleimide modification are predicted to be overcome with careful consideration of the 
target. Larger peptides or proteins with significantly greater structural integrity are more 
likely to tolerate the incorporation of a maleimide bridge without detriment to their 
biological activity. In this way, the multimodal maleimide incorporating a radiolabel 
and fluorophore would perhaps be of increased value if employed on a larger protein. 
The protein would of course need high affinity for a desirable receptor, one that is 
overexpressed on tumour cells, but we postulate that this affinity is less likely to be 
attenuated after incorporation of our multimodal maleimide. As a result, a superior 
MOMIA could effectively be created. Such a hypothesis is supported by recent 
publications from our group where antibody fragments have been efficiently modified 
using the maleimide bridging strategy, with full maintenance of their target binding 
affinity.59,189 In these cases incorporation of the maleimide proves not to have 
detrimental effect on the structure of the protein.  
 
Further to this, the multimodality of this reagent is not limited to diagnostics. One can 
envisage incorporation of a drug, instead of a fluorophore, alongside the radiolabel to 
create a reagent that confers both diagnostic and therapeutic functionality. Such 
constructs are often termed ‘theranostics’.190 In order to do this, the drug of choice will 
require activation as an azide to be able to participate in the ‘click’ cycloaddition 
reaction.  
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When considering tertiapin Q, and other small peptides with multiple disulfides in close 
proximity, the outlook is not so clear. There are other strategies that could be considered 
to attempt to circumvent the issue of disulfide scrambling; the employment of additives 
which could help stabilise the tertiary structure of the peptide is one example. If the 
issue cannot be overcome in this fashion, it would seem that the most facile way to 
selectively target one disulfide would be during solid-phase synthesis of the peptide. In 
this way cysteines can be selectively protected as desired, facilitating with confidence 
the modification of only the desired residues. 
 
Overall, it is clear that every peptide or protein target should be considered individually 
when attempting modification to produce bioconjugates. The chemistry and structure of 
peptides and proteins is extensively variable and, as a result, no one strategy for 
modification will be universal. Extensive consideration and careful design of reagents 
and protocols is required with each case. Combined, however, the continually 
increasing variety of modification technologies is proving hugely successful in the 
pursuit and development of novel bioconjugates for diagnostic and therapeutic 
applications. 
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Chapter 4 
Experimental Procedures 
 
4.1 General Information 
Synthetic reactions were all carried out at room temperature and under an inert 
atmosphere unless otherwise stated. All commercially available reagents were used as 
received without further purification. 
1H and 13C NMR spectra were recorded on either a Brüker Avance-500 machine or a 
Brüker Avance-600 machine (as stated), ran at a frequency of 500 MHz and 600 MHz 
respectively for 1H spectra and 125 MHz and 150 MHz respectively for 13C spectra. 
Deuterated solvents used were obtained from Sigma Aldrich. Peaks are assigned as 
singlet (s), doublet (d), triplet (t) or multiplet (m) and are sharp peaks unless denoted as 
broad (br). Chemical shifts are recorded in parts per million (ppm) denoted by δ. Proton 
coupling constants (J values) are reported in Hertz (Hz). Where necessary, assignments 
were confirmed with the aid of DEPT spectra. 
Mass spectra were recorded on a VG70-SE mass spectrometer running in EI or CI 
mode. 
Matrix-assisted laser desorption/ionisation (MALDI) mass spectra were recorded on an 
Axima-CFR (Shimadzu) instrument. 
Infra-red (IR) spectra were recorded on a PerkinElmer Spectrum 100 FT-IR 
spectrometer operating in ATR mode. 
Melting points were measured using a Gallenkamp apparatus and are uncorrected. 
LC-MS measurements were taken on an Acquity Ultra Performance LC instrument. LC 
data was recorded at a wavelength of 280 nm and MS data obtained in ES+ and ES- 
mode with a detection range between m/z 90 – 2000. LC solvent solutions: A - H2O 
(0.1% TFA); B – MeCN (0.1% TFA); running conditions: Gradient 5-95% B in 5 min; 
injection volume: 10 µl. Masses are assigned as a mass to charge ratio (m/z). For 
tertiapin Q analysis, LC-MS spectra are de-convoluted. This was done using the 
maximum entropy algorithm MaxEnt-1. The output mass ranges were set to 2000-4000 
m/z, with a resolution of 2 Da/channel. The damage model used uniform Gaussian, with 
a peak width at half height of 0.75 Da. The minimum intensity ratios were set at 33% 
for either side of the peak. 
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For peptide purification by RP-HPLC, a Shimadzu LC-10AT instrument fitted with a 
C18 column, 150 x 4.60 mm (Phenomenex) was used. Solvent solutions: A - H2O (0.1% 
TFA); B – MeCN (0.1% TFA). Flow rate: 1 mL/min. 
Somatostatin (83% peptide content), equine heart cytochrome c (95% peptide content) 
and equine heart myoglobin (90% peptide content) used were  all obtained from Sigma 
Aldrich. Octreotide was obtained from LKT Laboratories. Tertiapin Q (73% peptide 
content) was obtained from Abcam. Lyophilised somatostatin (1 mg) was resolubilised 
in buffer (2 mL, 50 mM NaHPO4
-, pH 6.2, 40% MeCN, 2.5 % DMF) and stored at 4 °C 
until use. Lyophilised tertiapin Q (1mg) was resolubilised in buffer (2 mL, 50 mM, 
NaHPO4
-, pH 6.2), flash frozen with liquid nitrogen and stored as 150 µL aliquots at -
20°C until use. 
Peptide concentrations were determined using a nanodrop ND-1000 spectrophotometer. 
‘Peptide buffer’ employed in experiments consisted of pH 6.2 phosphate buffer (50 
mM) with 40 % MeCN and 2.5 % DMF. 
 
4.2 Syntheses 
4.2.1 Synthesis of dithiophenolmaleimide24 
3,4-Bis-phenylsulfanyl-pyrrolidine-2,5-dione (22) 
 
 
 
 
 
To a solution of 3,4-dibromomaleimide (80.9 mg, 0.318 mmol) and sodium hydrogen 
carbonate (129 mg, 1.54 mmol) in methanol (6 mL) was added thiophenol (66.6 µL, 
0.648 mmol) in methanol (1 mL) drop-wise and the reaction mixture stirred for 15 min. 
The solvent was removed in vacuo to afford a yellow solid which was purified by flash 
chromatography on silica gel (petroleum ether : ethyl acetate, gradient elution from 9 : 1 
to 7:3) to afford the product (22) as a yellow solid (84.7 mg, 84 % yield). 
 
m.p. 101-103 °C (literature value: 123-126 °C); IR υmax(solid): 3231 (m), 3060 (w), 
1774 (m), 1701 (s) cm-1; 1H NMR (600 MHz, MeOD): δ = 7.29-7.24 (m, 6H, Ar-H), 
7.16-7.14 (m, 4H, Ar-H); 13C NMR (150 MHz, MeOD): δ = 165.5 (C=O), 135.5 (C), 
132.4 (CH), 130.6 (C), 130.1 (CH), 129.2 (CH); MS (EI+) m/z: 313 (36%, M+), 133 
(100%); Mass calculated for [C16H11O2NS2]: 313.0226; Found: 313.0230. 
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4.2.2 Synthesis of di-ortho-thiocresolmaleimide 
3,4-Bis-o-tolylsulfanyl-pyrrole-2,5-dione (41) 
 
 
 
 
 
 
To a solution of 3,4-dibromomaleimide (99.3 mg, 0.390 mmol) and sodium hydrogen 
carbonate (130 mg, 1.55 mmol) in methanol (10 mL) was added a solution of thiocresol 
(92.4 µL, 0.784 mmol) in methanol (2 mL) drop-wise and the reaction mixture stirred 
for 2 h. The solvent was removed in vacuo to afford a yellow solid which was purified 
by flash chromatography on silica gel (petroleum ether : ethyl acetate, gradient elution 
from 9 : 1 to 7 : 3) affording the product (41) as a yellow solid (99.9 mg, 75 % yield). 
 
m.p. 137-138 °C; IR υmax(solid): 3172 (m), 3059 (m), 1771 (m), 1694 (s) cm-1; 1H NMR 
(600 MHz, MeOD): δ = 7.21 (td, 2H, J = 7.2, 1.4 Hz, Ar-H), 7.16 (t, 4H, J = 7.3 Hz, Ar-
H),  7.12-7.08 (m, 2H, Ar-H), 2.19 (s, 6H, CH3); 
13C NMR (150 MHz, MeOD): δ = 
169.3 (C=O), 141.1 (C), 137.5 (CH), 133.7 (C), 131.6 (CH), 130.3 (CH), 129.8 (C), 
127.6 (CH), 20.8 (CH3); MS (EI+) m/z: 341 (100%, M
+), 91 (58%); Mass calculated for 
[C18H15O2NS2]: 341.0539; Found: 341.0529.  
 
4.2.3 Synthesis of di-ortho-chlorothiophenolmaleimide 
3,4-Bis-(2-chloro-phenylsulfanyl)-pyrrole-2,5-dione (42) 
 
 
 
 
 
To a solution of 3,4-dibromomaleimide (498 mg, 1.96 mmol) and sodium hydrogen 
carbonate (655 mg, 7.84 mmol) in methanol (25 mL) was added ortho-chlorothiophenol 
(445 µL, 3.92 mmol) in methanol (5 mL) drop-wise and reaction mixture stirred for 20 
min. The solvent was removed in vacuo to afford an orange solid which was purified by 
flash chromatography on silica gel (petroleum ether : ethyl acetate, gradient elution 
from 9 : 1 to 7 : 3) affording the product (42) an orange solid (685 mg, 91 % yield). 
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m.p. 135-137 °C; IR υmax(solid): 3189 (w), 3063 (w), 2451 (w), 2340 (w), 2324 (w), 
1776 (m), 1703 (s) cm-1; 1H NMR (500 MHz, MeOD): δ = 7.36 (d, 2H, J = 8.1 Hz, Ar-
H), 7.30-7.28 (m, 4H,  Ar-H),  7.21 (td, 2H, J = 7.6, 1.4 Hz, Ar-H); 13C NMR (125 
MHz, MeOD): δ = 168.6 (C=O), 137.5 (C), 136.8 (C), 134.5 (CH), 131.0 (2xCH), 129.9 
(C), 128.6 (CH); MS (EI+) m/z: 381 (63%, M+), 383 (42%), 385 (7%), 350 (5%), 348 
(55%), 346 (100%), 144 (45%); Mass calculated for [C16H9O2NS2
35Cl2]: 380.9446; 
Found: 380.9437. 
 
4.2.4 Synthesis of di-ortho-methylthiosalicylatemaleimide 
3,4-Bis-(2-methyl ester-phenylsulfanyl)-pyrrole-2,5-dione (43) 
 
 
 
 
 
 
 
 
To a solution of 3,4-dibromomaleimide (210 mg, 0.823 mmol) and sodium hydrogen 
carbonate (264 mg, 3.14 mmol) in methanol (40 mL) was added ortho-
methylthiosalicylate (216 µL, 1.57 mmol) in methanol (2 mL) drop-wise and reaction 
mixture stirred for 30 min. The solvent was removed in vacuo to afford an orange solid 
which was purified by flash chromatography on silica gel (petroleum ether : ethyl 
acetate, gradient elution from 9 : 1 to 7 : 3) to afford the product (43) as a deep orange 
solid (168.3 mg, 48 % yield).  
 
m.p. 146-149 °C; IR υmax(solid): 3190 (w), 2947 (w), 2344 (w), 1769 (m), 1686 (s) cm-
1; 1H NMR (500 MHz, DMSO): δ = 11.40 (s, 1H, N-H), 7.69 (dd, J = 7.9, 1.4 Hz, 2H, 
Ar-H), 7.40 (td, J = 7.7, 1.6 Hz, 2H, Ar-H), 7.26 (td, J = 7.6, 1.5 Hz, 2H, Ar-H), 7.21 
(dd, J = 8.0, 1.5 Hz, 2H, Ar-H), 3.78 (s, 6H, OCH3); 
13C NMR (125 MHz, DMSO): δ = 
170.1 (C=O), 167.3 (C=O), 137.2 (C), 133.1 (C), 133.0 (C), 132.4 (CH), 132.3 (CH), 
130.1 (CH), 128.1 (CH), 52.7 (CH3); MS (EI+) m/z: 428 (100%, M
+); Mass calculated 
for [C20H14NO6S2]: 428.0263; Found: 428.0246. 
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4.2.5 Synthesis of di-N-Boc-L-cysteine methyl ester maleimide  
2-tert-Butoxycarbonylamino-3-[4-(2-tert-butoxycarbonylamino-2-methoxy carbonyl -
ethylsulfanyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-ylsulfanyl]-propionic acid methyl 
ester (44) 
 
 
 
 
 
 
 
 
 
To a solution of maleimide 22 (31.4 mg, 0.100 mmol) in DMF (1.25 mL), was added 
buffer (21.3 mL, 50 mM NaHPO4
-, pH 6.2, 1.25 mL DMF) slowly, with stirring. N-
Boc-Cys-OMe (50.9 mg, 0.216 mmol) in DMF (1.25 mL) was added drop-wise to the 
maleimide solution (final concentration of DMF, 15%) and the mixture stirred for 30 
min. A yellow precipitate formed which was dissolved in ethyl acetate (25 mL) and the 
organic phase washed with distilled water (2 x 25 mL), saturated aqueous LiCl (3 x 25 
mL) and brine (2 x 25 mL). The solvent was removed in vacuo and the crude product 
purified by flash chromatography on silica gel (petroleum ether : ethyl acetate, gradient 
elution from 9 : 1 to 6 : 4) to afford the product (44) as a yellow solid (47.8 mg, 85 % 
yield).  
 
IR υmax(in MeOH): 3367 (w), 2972 (w), 1730 (s), 1513 (m) cm-1; 1H NMR (600 MHz, 
CDCl3): δ = 7.82 (s, 1H, CONH), 5.84 (d, 2H,  J = 7.5 Hz, NHCO2tBu),  4.70-4.67  (m, 
2H, NHCHCH2), 3.82-3.79 (m, 2H, SCHH), 3.77 (s, 6H, CO2CH3), 3.70 (m, 2H, 
SCHH), 1.42 (s, 18H, CO2C(CH3)3) ; 
13C NMR (150 MHz, CDCl3): δ = 170.8 (C=O), 
165.7 (C=O), 155.1 (C=O), 137.2 (C), 80.4 (C), 53.9 (CH), 53.0 (CH3) 33.8 (CH2), 28.4 
(3xCH3); MS (EI+) m/z: 564 (27%, M
+), 408 (100%), 364 (12%); Mass calculated for 
[C22H34O10N3S2]: 564.1686; Found: 564.1664. 
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4.2.6 Synthesis of di-ortho-thiosalicylicacidmaleimide 
(3,4-Bis-(2-mercapto-benzoic acid)-pyrrole-2,5-dione) (45) 
 
 
 
 
 
 
 
 
To a solution of 3,4-dibromomaleimide (201 mg, 0.787 mmol) and sodium hydrogen 
carbonate (532 mg, 6.34 mmol) in methanol (20 mL) was added ortho-thiosalycylic 
acid (247 mg, 1.60 mmol) in methanol (4 mL) drop-wise and the reaction mixture 
stirred for 45 min. The solvent was removed in vacuo to afford a yellow solid crude 
product. The crude product was re-dissolved in water (40 mL), acidified with aqueous 
HCl (2M, 80 mL) and extracted with ethyl acetate (4 x 100 mL). The organic layers 
were combined, dried (MgSO4) and the solvent removed in vacuo to afford maleimide 
(45) as a yellow solid (301 mg, 95 %). 
 
m.p. 257-258 °C; IR υmax(solid): 3042 (w), 1772 (s), 1681 (m) cm-1; 1H NMR (500 
MHz, MeOD): δ = 7.80 (d, J = 8.0 Hz, 2H, Ar-H), 7.36 (t, J = 7.0 Hz, 2H, Ar-H), 7.22 
(t, J = 7.5 Hz, 2H, Ar-H) 7.09 (d, J = 8.0 Hz, 2H, Ar-H); 13C NMR (125 MHz, MeOD): 
δ = 170.1 (C=O), 168.8 (C=O), 137.8 (C), 133.0 (C), 132.9 (C), 132.7 (CH), 132.5 
(CH), 130.7 (CH), 128.1 (CH); MS (EI+) m/z: 401 (55%, M+), 136 (100%); Mass 
calculated for [C18H11NO6S2]: 401.0022; Found: 401.0025. 
 
4.2.7 Synthesis of N-methyl diphenoxymaleimide  
3,4-diphenoxy-1H-pyrrole-2,5-dione (53) 
 
 
 
 
 
 
 
A solution of phenol (100 mg, 1.07 mmol) in dry dioxane (2 mL) was added drop-wise 
to a solution of potassium tert-butoxide (143 mg, 1.27 mmol) and 18-crown-6 (333 mg, 
1.26 mmol) in dry dioxane (3.5 mL). The mixture was stirred for 20 min before being 
added drop-wise to a solution of N-methyl-3,4-dibromomaleimide (137 mg, 0.510 
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mmol) in dry dioxane (2 mL) over 20 min. The reaction mixture was stirred at room 
temperature for 48 h. The solvent was removed in vacuo and the crude product re-
dissolved in ethyl acetate (20 mL), washed with aqueous NaOH (1M, 3 x 3 mL) and 
brine (3 x 5 mL) before being dried (MgSO4) and the solvent removed in vacuo. The 
product was purified by flash chromatography on silica gel (petroleum ether : ethyl 
acetate, gradient elution from 9 : 1 to 8 : 2) to afford the product (53) as a white solid 
(50.2 mg, 33 % yield). 
 
m.p. 110-111 °C; IR υmax(solid): 3058 (w), 2923 (w), 1712 (m), 1681 (m), 1588 (m) cm-
1; 1H NMR (500 MHz, CDCl3): δ = 7.19-7.16 (m, 4H, Ar-H), 7.04 (t, J = 6.7 Hz, 2H, 
Ar-H), 6.85-6.83 (m, 4H, Ar-H) 3.08 (s, 3H, NCH3); 
13C NMR (125 MHz, CDCl3): δ = 
165.5 (C=O), 154.9 (C), 133.3 (C), 129.5 (CH), 124.6 (CH), 117.3 (CH), 23.7 (CH3) ; 
MS (EI+) m/z: 295 (100%, M+); Mass calculated for [C17H13NO4]: 296.09228 ; Found: 
296.091210. 
 
4.2.8 Synthesis of N-methoxycarbonyl-3,4-dibromomaleimide170 
Methyl 3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrole-1-carboxylate (62) 
 
 
 
 
To a solution of 3,4-dibromomaleimide (511 mg, 2.00 mmol) and N-methylmorpholine 
(220 µL, 2.00 mmol) in THF (20 mL) was added methylchloroformate (160 µL, 2.00 
mmol) and the mixture was stirred for 20 min. DCM (30 mL) was added and the 
organic phase was washed with water (3 x 20 mL) and dried (MgSO4) before the 
solvent was removed in vacuo to afford the product (62) as a purple solid (557 mg, 90 
% yield). 
 
m.p. 111-112 °C; IR υmax(solid): 3240 (w), 3005 (w), 1807 (m), 1723 (s), 1599 (m) cm-
1; 1H NMR (500 MHz, CDCl3): δ = 4.00 (s, 3H, COOCH3); 13C NMR (125 MHz, 
CDCl3): δ = 159.3 (C=O), 147.0 (C=O), 131.5 (C), 54.9 (CH3); MS (EI+) m/z: 311 
(100%, M+), 310 (40%); Mass calculated for [C6H3NO4Br2]: 310.8429; Found: 
310.8425. 
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4.2.9 Synthesis of N-propargyl dibromomaleimide170 
3,4-dibromo-1-(prop-2-yn-1-yl)-1H-pyrrole-2,5-dione (63) 
 
 
 
 
Propargylamine (26.0 µL, 0.400 mmol) was added to a stirred solution of N-
methoxycarbonyl-3,4-dibromomaleimide (62) (101 mg, 0.321 mmol) in DCM (4 mL) 
and the mixture stirred for 30 min. EtOAc (4 mL) was added and the organic phase 
washed with saturated ammonium chloride solution (3 x 10 mL) and water (3 x 10 mL) 
before being dried (MgSO4) and the solvent removed in vacuo. The crude product was 
purified by flash chromatography on silica gel (DCM) to afford the product (63) as a 
pale yellow solid (77 mg, 82 %). 
 
m.p. 115-118 °C; IR υmax(solid): 3264 (w), 2905 (w), 1718 (s), 1589 (m) cm-1; 1H NMR 
(500 MHz, CDCl3): δ = 4.38 (d, J = 2.5 Hz, 2H, NCH2,), 2.26 (t, J = 2.5 Hz, 1H, CCH); 
13C NMR (125 MHz, CDCl3): δ = 162.7 (C=O), 129.9 (C), 76.1 (C), 72.6 (CH), 28.6 
(CH2); MS (EI+) m/z: 295 (50%), 293 (100%, M
+), 291 (60%), 246 (13%); Mass 
calculated for [C7H4NO2Br2]: 291.8603; Found: 291.8605. 
 
4.2.10 Synthesis of N-methoxycarbonyl-3,4-dithiophenolmaleimide170 
Methyl 2,5-dioxo-3,4-bis(phenylthio0-2,5-dihydro-1H-pyrrole-1-carboxylate (80) 
 
 
 
 
To a solution of 3,4-dithiophenolmaleimide (22) (49.8 mg, 0.160 mmol) and N-
methylmorpholine (18.0 µL, 0.160 mmol) in EtOAc (6 mL) was added 
methylchloroformate (14.0 µL, 0.170 mmol) and the mixture stirred for 30 min. The 
organic phase was washed with water (3 x 10 mL), dried (MgSO4) and the solvent 
removed in vacuo to afford the product (80) as an orange solid (57.7 mg, 97 % yield).  
 
m.p. 105-107 °C; IR υmax(solid): 3103 (w), 2913 (w), 1803 (m), 1761 (m), 1713 (m), 
1438 (m) cm-1; 1H NMR (500 MHz, CDCl3): δ = 7.34-7.26 (m, 10H, Ar-H), 3.91 (s, 3H, 
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COOCH3); 
13C NMR (125 MHz, CDCl3): δ = 161.8 (C=O), 137.3 (C=O), 132.7 (2xC), 
129.3 (CH), 129.1 (CH) 128.2 (CH), 54.4 (CH3); MS (EI+) m/z: 372 (100%, M
+), 369 
(35%), 367 (30%); Mass calculated for [C18H13NO4S2]: 372.0481; Found: 372.0478. 
 
4.2.11 Synthesis of N-alkyne dithiophenol maleimide170 
3,4-bis(phenylthio)-1-(prop-2-yn-1-yl)-1H-pyrrole-2,5-dione (71) 
 
 
 
 
Propargylamine (6.20 µL, 0.0960 mmol) was added to a stirred solution of maleimide 
(80) (33.9 mg, 0.0960 mmol) in DCM (6 mL) for 2 h before silica was added and the 
reaction mixture left to stir overnight. The silica was removed by filtering under 
vacuum andthe filtrate concentrated in vacuo. The resulting product was purified by 
flash chromatography on silica gel (petroleum ether : ethyl acetate, gradient elution 
from 9 : 1 to 8 : 2) to afford the product (71) as a yellow solid (25.7 mg, 76 % yield). 
 
m.p. 123-124 °C; IR υmax(solid): 3269 (m), 3000 (w), 1771 (m), 1704 (s) cm-1; 1H NMR 
(500 MHz, CDCl3): δ = 7.32-7.21 (m, 10H, Ar-H), 4.26 (d, 2H, J = 2.4 Hz, NCH2), 2.20 
(t, 1H, J = 2.2 Hz, CCH); 13C NMR (125 MHz, CDCl3): δ = 165.5 (C=O), 136.0 (C), 
132.2 (CH), 129.1 (CH), 128.8 (C), 128.6 (CH), 76.8 (C), 71.8 (CH), 27.8 (CH2); MS 
(EI+) m/z: 351 (100%, M+); Mass calculated for [C19H13NO2S2]: 351.03877; Found: 
351.03830. 
 
4.2.12 Synthesis of Boc-protected aminopiperidine-rhodamine B46 
N-(9-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-carbonyl)phenyl)-6-
(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium chloride (73) 
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Rhodamine B (427 mg, 0.891 mmol) was dissolved in DCM (30 mL), oxalyl chloride 
(2.5 mL) was added and the reaction mixture stirred for 2 h. The solvent and excess 
oxalyl chloride was removed in vacuo. The purple residue was re-dissolved in DCM (15 
mL) before being slowly added to a solution of Cs2CO3 (1.50 g. 4.56 mmol) and 4-(N-
Boc-amino)-piperidine (913 mg, 4.56 mmol) in DCM (15 mL). The mixture was stirred 
for 18 h before the solvent was removed in vacuo to yield the crude product as a purple 
solid. This was purified by flash chromatography on silica gel (DCM : MeOH, gradient 
elution from 98 : 2 to 90 : 10) to afford the product (73) as a dark purple solid (331 mg, 
59%). 
 
m.p. 205-207 °C; IR υmax(oil): 2977 (w), 2910 (w), 1702 (m), 1584 (m) cm-1; 1H NMR 
(500 MHz, MeOD): δ = 7.76-7.73 (m, 2H, CH-10 & 11), 7.65 (dd, 1H, J = 6.0, 3.0 Hz, 
CH-9), 7.49 (dd, 1H, J = 6.0, 2.5 Hz, CH-12), 7.27 (d, 2H, J = 9.5 Hz, 2xCH-15), 7.09-
7.04 (m, 2H, 2xCH-16), 6.97 (d, 2H, J = 2.5 Hz, 2xCH-18), 4.05 (m, 1H, CH-6 eq.), 
3.71 (m, 1H, CH-4), 3.69 (q, 8H,  J = 7.5 Hz, 4xCH2-20), 3.45-3.42 (m, 1H, CH-6’ eq.), 
3.03 (bs, 1H, CH-6’ ax.), 2.68 (m, 1H, CH-6 ax.) 1.77-1.72 (m, 2H, CH-5 eq. & 5’ eq.), 
1.40 (s, 9H, 3xCH3-1), 1.31 (t, 12H, J = 7.5 Hz, 4xCH3-21), 1.16 (m, 2H, CH-5 ax. & 
5’ ax.); 13C NMR (125 MHz, MeOD): δ = 169.3 (C=O), 159.3 (C), 157.6 (C=O), 157.2 
(C), 157.0 (C), 137.1 (C), 133.3 (CH), 132.0 (C), 131.7 (CH), 131.3 (CH), 131.0 (CH), 
128.6 (CH), 115.4 (CH), 114.8 (C), 97.3 (CH), 80.1 (C), 49.9 (CH), 47.7 (CH2), 46.9 
(CH2), 41.8 (CH2), 33.5 (CH2), 32.3 (CH2), 28.7 (CH3), 12.9 (CH3); MS (EI+) m/z: 625 
(100%, M+), 372 (30%); Mass calculated for [C38H49N4O4]: 625.3754; Found: 
625.3761. 
 
4.2.13 Synthesis of aminopiperidine-rhodamine B46 
1-(2-(6-(diethylamino)-3-(diethyliminio)-3H-xanthen-9-yl)benzoyl)piperidin-4-
aminium 2,2,2-trifluoroacetate chloride (74) 
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TFA (15 mL) was added to a stirred solution of Boc-protected rhodamine (73) (257 mg, 
0.410 mmol) in DCM (15 mL) and the solution stirred for 4 h. The solvent was then 
removed azeotropically using toluene (3 x 15 mL) followed by chloroform (4 x 10 mL) 
to yield the product (74) as a purple solid (402 mg, quantitative yield). 
 
m.p. 231-234 °C; 1H NMR (500 MHz, MeOD): δ = 7.78-7.76 (m, 2H, CH-7 & 8), 7.66-
7.64 (m, 1H, CH-6), 7.50-7.48 (m, 1H, CH-9), 7.26 (d, 2H, J = 9.5 Hz, 2xCH-12), 7.07-
7.05 (m, 2H, 2xCH-13), 6.97-6.95 (m, 2H, 2xCH-15), 4.31 (m, 1H, CH-3 eq.), 3.84  (m, 
1H, CH-3’ eq.), 3.71-3.70 (m, 1H, CH-1), 3.69-3.67 (m, 8H, 4xCH2-17), 2.97-2.92 (m, 
1H, CH-3 ax.), 2.57-2.55 (m, 1H, CH-3’ ax.), 1.95 (m, 2H, J = 11.5 Hz, CH-2 eq. & 2’ 
eq.), 1.42-1.39 (m, 2H, CH-2 ax. & 2’ ax.), 1.31 (t, 12H, J = 7.5, 4xCH3-18); 13C NMR 
(125 MHz, MeOD): δ = 169.6 (C=O), 159.3 (C), 157.3 (C=O), 157.2 (C), 156.8 (C), 
136.7 (C), 133.4 (CH), 132.0 (C), 131.9 (CH), 131.4 (CH), 131.3 (CH), 128.4 (CH), 
117.0 (C), 115.4 (CH), 115.3 (CH), 115.1 (C), 97.4 (CH), 46.9 (CH2), 31.4 (CH2), 30.5 
(CH2), 12.8 (CH3); MS (EI+) m/z: 525 (100%, M
+), 338 (10%); Mass calculated for 
[C38H41N4O2]: 525.3230; Found: 525.3238. 
 
4.2.14 Synthesis of azidohexanoic acid185 
6-Azidohexanoic acid (75) 
 
 
 
A mixture of 6-bromohexanoic acid (402 mg, 2.06 mmol) and sodium azide (668 mg, 
10.3 mmol) in DMF (1.5 mL) was stirred at 50°C for 3 h. The mixture was cooled to 
room temperature and DCM (30 mL) added. The organic phase was washed with water 
(2 x 30 mL), saturated aqueous LiCl (5 x 30 mL) and brine (2 x 30 mL), dried (MgSO4) 
and the solvent removed in vacuo. The crude product was purified by flash 
chromatography on silica gel (petroleum ether : ethyl acetate, gradient elution from 8 : 2 
to 6 : 4) to afford the product (75) as a colourless liquid (124 mg, 39 %). 
 
IR υmax(oil): 3200 (m), 2925 (m), 2095 (m), 1702 (s)cm-1; 1H NMR (500 MHz, CDCl3): 
δ = 3.28 (t, 2H, J = 7.0 Hz, HOOCCH2), 2.37 (t, 2H, J = 7.5 Hz, CH2), 1.70-1.59 (m, 
4H, 2xCH2), 1.46-1.40 (m, 2H, CH2); 
13C NMR (125 MHz, CDCl3): δ = 180.0 (C=O), 
51.3 (CH2), 33.9 (CH2), 28.6 (CH2), 26.2 (CH2), 24.4 (CH2); MS (EI+) as sodium 
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adduct m/z: 180 (100%, M+Na+); Mass calculated for [C6H11N3O2Na]: 180.0749; 
Found: 180.0733. 
 
4.2.15 Synthesis of rhodamine B-azide 
N-(9-(2-(4-(6-azidohexanamido)piperidine-1-carbonyl)phenyl)-6-(diethylamino)-3H-
xanthen-3-ylidene)-N-ethylethanaminium chloride (76) 
 
 
 
 
 
 
 
 
To a solution of 6-azidohexanoic acid (75) (29.5 mg, 0.189 mmol), HBTU (71.7 mg, 
0.189 mmol), and HOBt (25.5 mg, 0.189 mmol) in DMF (2 mL) was added DIPEA 
(99.0 µL, 0.576 mmol) in DMF (2 mL). The reaction mixture was stirred for 20 min 
before a solution of rhodamine B-amine (74) (99.3 mg, 0.189 mmol) in DMF (2 mL) 
was added drop-wise and the mixture stirred for 3 h. The solvent was then removed in 
vacuo and the crude product re-dissolved in DCM (10 mL) before being washed with 
saturated aqueous LiCl (3 x 10 mL), 15 % aqueous K2CO3 (2 x 10 mL), 15 % aqueous 
citric acid (2 x 10 mL) and water (2 x 10 mL). The resulting product was dried (MgSO4) 
and the remaining solvent removed in vacuo before being purified by flash 
chromatography on silica gel (DCM : MeOH, gradient elution from 100 : 0 to 96 : 4) to 
yield the product (76) as a purple solid (96.9 mg, 77 % yield). 
 
m.p. 199-202 °C; IR υmax(solid): 2963 (w), 2928 (w), 2875 (w), 2090 (s) 1582 (m) cm-1; 
1H NMR (500 MHz, MeOD): δ = 7.75 (m, 2H, J = 7.0, 2.5 Hz, CH-13&14), 7.65-7.63 
(m, 1H, CH-12), 7.50-7.48 (m, 1H, CH-15), 7.26 (d, 2H, J = 9.5 Hz, 2xCH-18), 7.07-
7.03 (m, 2H, 2xCH-19), 6.95 (d, 2H, J = 2.5 Hz, 2xCH-21), 4.10 (m, 1H, J = 15.7 Hz, 
CH-9 eq.), 3.77-3.75 (m, 2H, CH-7 & 9’ eq.), 3.68 (q, 8H, J = 7.5 Hz, 4xCH2-23), 3.27 
(t, 2H, J = 7.0 Hz, CH2-1), 3.06-3.03 (m, 1H, CH-9’ ax.), 2.69-2.65 (m, 1H, CH-9 ax.), 
2.15-2.14 (m, 2H, CH2-5), 1.80-1.70 (m, 2H, CH-8 eq. & 8’ eq.), 1.67-1.55 (m, 4H, 
CH2-2 & 4), 1.41-1.39 (m, 2H, CH2-3), 1.38-1.36 (m, 1H, CH-8 ax.), 1.31 (t, 12H, J = 
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6.5 Hz, 4xCH3-24), 1.29-1.20 (m, 1H, CH-8’ ax.); 13C NMR (125 MHz, MeOD): δ = 
175.3 (C=O), 169.4 (C=O), 159.3 (C), 157.2 (C), 157.0 (C), 137.0 (C), 133.3 (CH), 
132.0 (C), 131.7 (CH), 131.3 (CH), 131.1 (CH), 128.5 (CH),  115.4 (CH), 114.8 (C), 
97.3 (CH), 52.3 (CH2), 47.7 (CH), 46.9 (CH2), 41.8 (CH2), 36.8 (CH2), 33.0 (CH2), 31.9 
(CH2), 29.6 (CH2), 27.3 (CH2), 26.5 (CH2), 25.6 (CH2), 12.9 (CH3); MS (EI+) m/z: 664 
(100%, M+); Mass calculated for [C39H50N7O3]: 664.3975; Found: 664.3950. 
 
4.2.16 Synthesis of rhodamine B-[127I]-dithiophenol maleimide 
N-(6-(diethylamino)-9-(2-(4-(6-(4-((2,5-dioxo-3,4-bis(phenylthio)-2,5-dihydro-1H-
pyrrol -1-yl)methyl)-5-iodo-1H-1,2,3-triazol-1-yl)hexanamido)piperidine-1-carbonyl) 
phenyl)-3H-xanthen-3-ylidene)-N-ethylethanaminium (77) 
 
 
 
 
 
 
 
 
 
To a solution of copper (I) iodide (8.00 mg, 0.0420 mmol) in dry acetonitrile (5 mL) 
was added N-alkyne dithiophenolmaleimide (71) (13.4 mg, 0.0380 mmol), rhodamine-
azide (76) (27.9 mg, 0.0420 mmol), triethylamine (5.3 µL, 0.0380 mmol) and N-
chlorosuccinimide (6.10 mg, 0.0460 mmol) and the reaction mixture stirred overnight. 
The copper was removed by gravity filtration and the filtrate concentrated in vacuo. The 
crude product was purified by flash chromatography on silica gel (DCM : MeOH, 
gradient elution from 100 : 0 to 95 : 5) to afford the product (77) as a purple solid (15.9 
mg, 37 % yield). 
 
m.p. 223-224 °C; IR υmax(solid): 2969 (m), 2904 (m), 1709 (m), 1583 (m) cm-1; 1H 
NMR (600 MHz, MeOD): δ = 7.75 (td, 1H, J = 7.6 Hz, 1.6, CH-22), 7.74 (td, 1H, J = 
7.6, 1.6 Hz, CH-23), 7.66-7.64 (m, 1H, CH-21), 7.50-7.48 (m, 1H, CH-24), 7.28 (d, 2H, 
J = 9.6 Hz, 2xCH-27), 7.28-7.26 (m, 2H, 2xCH-1), 7.23-7.21 (m, 4H, 4xCH-2), 7.15-
7.13 (m, 4H, 4xCH-3), 7.06 (m, 2H, 2xCH-28),  6.94 (d, 1H, J = 2.0 Hz, CH-30), 6.93 
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(d, 1H, J = 2.0 Hz, CH-30), 4.73 (d, 1H, J = 15.7 Hz, CH-7), 4.69 (d, 1H, J = 15.7 Hz, 
CH-7), 4.40 (t, 2H, J = 6.8 Hz, CH2-10), 4.10 (m, 1H, J = 13.2 Hz, CH-18 eq.), 3.75-
3.73 (m, 1H, CH-16), 3.72-3.70 (m, 1H, CH-18’ eq.), 3.65 (bq, 8H, J = 7.0 Hz, 4xCH2-
32), 3.08-3.02 (m, 1H, CH-18’ ax.), 2.68-2.64 (m, 1H, CH-18 ax.), 2.11 (td, 2H, J = 7.1, 
2.0 Hz, CH2-14), 1.89-1.85 (m, 2H, CH2-11), 1.75 (d, 1H, J = 12.5 Hz, CH-17’ eq.), 
1.73 (d, 1H, J = 12.5 Hz, CH-17 eq.), 1.62-1.58 (m, 2H, CH2-13), 1.30 (t, 12H, J = 7.0 
Hz, 4xCH3-33), 1.28-1.26 (m, 1H, CH-17’ ax.), 1.26-1.24 (m, 2H, CH2-12), 1.25-1.20 
(m, 1H, CH-17 ax.); 13C NMR (125 MHz, MeOD): δ = 175.3 (C), 169.5 (C), 167.7 (C), 
159.3 (C), 157.2 (C), 157.0 (C), 147.2 (C), 137.1 (C), 137.0 (C), 133.3 (CH), 132.4 
(CH), 131.9 (C), 131.8 (CH), 131.4 (CH), 131.1 (CH), 130.4 (C), 130.2 (CH), 129.3 
(CH), 128.6 (CH),  115.4 (CH), 114.8 (C), 97.3 (CH), 81.1 (C), 51.6 (CH2), 47.8 (CH2), 
47.6 (CH), 46.9 (CH2), 41.9 (CH2), 36.6 (CH2), 35.5 (CH2), 33.1 (CH2), 31.8 (CH2), 
30.4 (CH2), 26.6 (CH2), 26.2 (CH2), 12.9 (CH3); MS (EI+) m/z: 1141 (100%, M
+), 285 
(20%); Mass calculated for [C58H62IN8O5S2]: 1141.33; Found: 1141.3103. 
 
4.2.17 Synthesis of rhodamine B-[125I]-dithiophenol maleimide (78)184 
 
 
 
 
 
 
 
 
Radio-HPLC analysis was performed with an Agilent 1200 HPLC system equipped 
with a GABI Star NaI(Tl) scintillation detector and a Knauer Smartline fixed 
wavelength 254 nm UV-detector. A ZORBAX column (300SB-C18, 9.4 x 250 mm) 
was used. Reductant free [125I]NaI was purchased from Perkin Elmer with a 
concentration of 370 mCi/mL (13.69 GBq/mL) and specific activity of 629 GBq/mg in 
10-5 M NaOH (pH 8-11) aqueous solution.  
 
To copper(II) chloride (13.4 mg, 0.100 mmol) was added anhydrous acetonitrile (4 mL) 
followed by anhydrous triethylamine (20.9 µL, 0.150 mmol), and the mixture was 
mixed by vortex. 
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To the alkyne 71 (0.35 mg, 1.0 µmol) was added the above solution of the 
CuCl2/triethylamine complex in acetonitrile (40 µL) and the mixture vortexed. After 5 
min, Na125I in water (6.00 µL, 1.438 MBq) was added to the mixture. Azide 76 (6.64 
mg, 10.0 µmol) was dissolved in MeCN (200 µL) before 20 µL (1.00 µmol) was added 
to the reaction mixture. The tube was capped and the reaction was heated at 60 °C for 
90 min. The reaction was quenched with acetonitrile and water (1:1, 400 µL) and the 
resulting solution was purified by HPLC (Buffer A: water + 0.1 % TFA, Buffer B: 
methanol + 0.1 % TFA, gradient elution from 60-90 % Buffer B over 30 min, flow rate 
3 mL/min). The labelled compound 78 was identified by co-injection and co-elution 
with the non-radioactive reference compound 77. The isolated RCY of 78 was 47%. 
 
4.3 TCEP Cross Reactivity Studies 
To a solution of 22 (35.0 mg, 0.112 mmol) in DMF (6.25 mL) was added TCEP (31.8 
mg, 0.111 mmol) fully dissolved in peptide buffer (43.75 mL) (final concentration of 
DMF, 15 %). The reaction was stirred for 15 min before being extracted with ethyl 
acetate (50 mL). The organic phase was washed with saturated aqueous LiCl (3 x 50 
mL), saturated aqueous NaCl (3 x 50 mL) and water (2 x 50 mL). The organic phase 
was then dried (MgSO4) and the solvent removed in vacuo to regain maleimide 22 (31.9 
mg, 94 %). 
 
A control reaction was run, with TCEP absent, to determine the amount of product lost 
by experimental procedures. For this, peptide buffer (43.75 mL) was added to 1 (35.8 
mg, 0.114 mmol) in DMF (6.25 mL). The solution was left stirring for 15 min before 
extracted, washed and dried as before to regain maleimide 22 (34.9 mg, 97.4%). 
 
This procedure was repeated using maleimides 41, 42 and 43 and using the same molar 
equivalents ratio. 
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4.4 Maleimide Bridging of Somatostatin 
N.B. These general bridging procedures were repeated with some changes in the 
number of equivalents used, as described in the Results and Discussion. 
 
4.4.1 General Step Wise Protocol with TCEP 
Somatostatin (344 µL, 199.7 µM) was diluted to a concentration of 152.6 µM with 
peptide buffer (106 µL). TCEP (3.91 mg) was prepared at a concentration of 15.26 mM 
using peptide buffer (894 µL). 1.7 equivalents of the TCEP solution (7.5 µL, 0.114 
mmol) was then added to the diluted somatostatin (450 µL, 0.0687 mmol) and left to 
reduce for 1 h. Stock solutions of 3,4-dibromomaleimide and maleimides 22 and 41-43 
were prepared at a concentration of 15.26 mM using DMF (50%) and peptide buffer 
(50%).  An aliquot of reduced somatostatin (30 µL, 0.00458 mmol) was taken and 5 
equivalents of 3,4-dibromomaleimide (1.5 µL, 0.0229 mmol) was added and left to 
react for 10 min. This mixture was removed and analysed by LC-MS to test for full 
reduction of somatostatin. Full conversion to maleimide-bridged somatostatin was 
observed (LC retention time: 1.30 min, m/z 866.9 (m/2)), confirming complete reduction 
of all disulfides.  
 
From the remaining reduced somatostatin stock, 4 aliquots (90 µL, 0.0137 mmol) were 
taken and to each 1.1 equivalents of a different maleimide (22 and 41-43) (0.99 µL, 
0.0151 mmol) was added and left to react for 10 min. From these, aliquots (30 µL) were 
removed at 1, 10 and 60 min and analysed by LC-MS. The percentage of bridged (LC 
retention time: 1.30 min, m/z 866.90 (m/2)) and reduced, non-bridged (LC retention 
time: 1.23 min, m/z 820.34 (m/2)) somatostatin was recorded in each case. 
 
4.4.2 General In-situ Protocol  
4.4.2.1 Using TCEP 
Somatostatin (474 µL, 199.7 µM) was diluted to a concentration of 152.6 µM with 
peptide buffer (146 µL). TCEP (3.68 mg) was prepared at a concentration of 15.26 mM 
using peptide buffer (841 µL). Stock solutions of maleimides 22 and 41-43 were 
prepared at a concentration of 15.26 mM using DMF (50%) and peptide buffer (50%).  
The diluted somatostatin (620 µL, 0.0946 mmol) was split into 4 aliquots (150 µL, 
0.0229 mmol) and to each 5 equivalents of one of the maleimides 22 and 41-43 stock 
solution (7.5 µL, 0.114 mmol) was added and left to react for 10 min. 3 equivalents of 
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the TCEP solution (4.5 µL, 0.0687 mmol) was then added to each and aliquots (30 µL) 
removed at 1, 5, 10, 20 and 30 min and analysed by LC-MS. The percentage of bridged 
(LC retention time: 1.30 min, m/z 866.90 (m/2)) and reduced, non-bridged (LC retention 
time: 1.23 min, m/z 820.34 (m/2)) somatostatin was recorded. 
 
4.4.2.2 Using Benzeneselenol 
Somatostatin (322 µL, 293.6 µM) was diluted to a concentration of 152.6 µM using 
peptide buffer (298 µL) and 4 aliquots (150 µL, 0.0229 mmol) were taken. Stock 
solutions of maleimides 22 and 41-43 were prepared at a concentration of 15.26 mM 
using DMF (50%) and peptide buffer (50%).  To each somatostatin aliquot, 10 
equivalents of the maleimide 22 and 41-44 stock solution (15 µL, 0.229 mmol) were 
added. Benzeneselenol (1.62 µL) was prepared at a concentration of 15.26 mM using 
DMF (50 µL) and peptide buffer (950 µL). 5 equivalents (7.5 µL, 0.114 mmol) of this 
were added to the somatostatin solutioniv. Aliquots (30 µL) of the reaction mixture were 
removed at 1, 5, 10, 20 and 30 min and analysed by LC-MS. The percentage of bridged 
(LC retention time: 1.30 min, m/z 866.90 (m/2)) and reduced, non-bridged (LC retention 
time: 1.23 min, m/z 820.34 (m/2)) somatostatin was recorded. 
 
4. 5 Double Maleimide Bridging of Tertiapin Q 
N.B. These general bridging procedures were repeated with some changes in the 
maleimide reagent employed and the number of equivalents of both this and reducing 
agent used, as described in the Results and Discussion. 
 
4.5.1 General Step Wise Protocol with TCEP 
Tertiapin Q (299 µL, 127 µM) was diluted to a concentration of 100 µM using pH 6.2 
phosphate buffer (81 µL). TCEP (2.50 mg) was prepared at a concentration of 10 mM 
using peptide buffer (872 µL) before 3 equivalents (11.4 µL, 0.114 mmol) of this was 
added to the tertiapin Q solution (380 µL, 0.038 mmol). The peptide was left to reduce 
for 1 h and reduction was confirmed as previously described using a 30 µL aliquot. A 
solution of maleimide 45 (2.06 mg) was prepared at a concentration of 10 mM using 
DMF (77.0 µL) and peptide buffer (436 µL).  3 equivalents (10.5 µL, 0.105 mmol) of 
the maleimide solution were added to the remaining reduced tertiapin Q (350 µL, 0.035 
mmol) and, after 10 min, an aliquot (30 µL) of this reaction mixture was removed and 
                                                 
iv Note: Due to the formation of the unwanted diselenide product upon exposure to air, fresh solutions of 
the benzeneselenol stock were made for each reaction. 
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analysed by LC-MS to ensure full conversion from reduced, non-bridged peptide (LC 
retention time: 0.89 min, m/z 2457.0) to the bridged product (LC retention time: 0.99 
min, m/z 2642.0).  
 
4.5.2 General In Situ Protocol 
4.5.2.1 Using TCEP: 
Tertiapin Q (307 µL, 130.4 µM) was diluted to a concentration of 100 µM by addition 
of pH 6.2 phosphate buffer (93.0 µL). Maleimide 45 (2.60 mg) was prepared at a 
concentration of 10 mM using DMF (65.0 µL) and peptide buffer (583 µL). An aliquot 
(150 µL, 0.0150 mmol) of the diluted tertiapin Q was removed and 2.1 equivalents 
(3.20 µL, 0.0320 mmol) of the maleimide were added to the peptide. TCEP (2.53 mg) 
was prepared at a concentration of 10 mM using pH 6.2 phosphate buffer (882 µL) 
before 2.1 equivalents (3.20 µL, 0.0320 mmol) were added to the reaction mixture. 
Aliquots (30 µL) were taken at 1, 5, 10, 30 and 60 min analysed by LC-MS. The 
percentage of bridged (LC retention time: 0.99 min, m/z 2642.0) and reduced, non-
bridged (LC retention time: 0.89 min, m/z 2457.0) peptide was recorded. 
 
4.5.2.2 Using Benzeneselenol: 
Tertiapin Q (184 µL, 130.4 µM) was diluted to a concentration of 100 µM by addition 
of DMF (5.0 µL) and MeCN (61.0 µL). Maleimide 22 (2.24 mg) was prepared at a 
concentration of 10 mM using DMF (143 µL) and peptide buffer (572 µL). An aliquot 
(120 µL, 0.0120 mmol) of the diluted tertiapin Q was taken and 20 equivalents (24.0 
µL, 0.240 mmol) of the maleimide were added to the peptide. Benzeneselenol (1.1 µL) 
was prepared at a concentration of 10 mM using DMF (99 µL) before 5 equivalents (6.0 
µL, 0.0600 mmol) were added to the reaction mixture. Aliquots (30 µL) were taken at 1, 
15, 30 and 60 min and analysed by LC-MS. The percentage of bridged (LC retention 
time: 0.99 min, m/z 2642.0) and reduced, non-bridged (LC retention time: 0.89 min, m/z 
2457.0) peptide was recorded. 
 
4. 6 Single Maleimide Bridging of Tertiapin Q  
N.B. These general bridging procedures were repeated with some changes in the 
number of equivalents used, as described in the Results and Discussion. 
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4.6.1 General Step Wise Protocol Using TCEP 
Tertiapin Q (193 µL, 144.9 µM) was diluted to a concentration of 100 µM by addition 
of pH 6.2 phosphate buffer (87.0 µL). Maleimide 53 (1.00 mg) was prepared at a 
concentration of 10 mM using DMF (339 µL) and 1.5 equivalents (4.20 µL, 0.0420 
mmol) were added to the peptide. TCEP (2.27 mg) was prepared at a concentration of 
10 mM using pH 6.2 phosphate buffer (792 µL) before 1.5 equivalents (4.20 µL, 0.0420 
mmol) were added to the reaction mixture. An aliquot (30 µL) was removed at 60 min 
and analysed by LC-MS. A further 0.5 equivalent (1.3 µL, 0.0130 mmol) of TCEP was 
added to the peptide and after 60 min an aliquot (30 µL) was taken and analysed by LC-
MS. A final 0.5 equivalent (1.1 µL, 0.0110 mmol) of TCEP was added to the peptide 
and after 60 min, an aliquot (30 µL) was taken and analysed by LC-MS. The percentage 
of bridged (LC retention time: 1.20 min, m/z 2567.0) and reduced, non-bridged (LC 
retention time: 0.89 min, m/z 2457.0) peptide was recorded. 
 
4.6.2 With Capping of Free Thiols 
Tertiapin Q (98.0 µL, 154.8 µM) was diluted to a concentration of 100 µM by addition 
of pH 6.2 phosphate buffer (52.0 µL). Maleimide 45 (0.63 mg) was prepared at a 
concentration of 10 mM using DMF (213 µL) and 1.5 equivalents (2.25 µL, 0.0225 
mmol) were added to the peptide. TCEP (2.35 mg) was prepared at a concentration of 
10 mM using pH 6.2 phosphate buffer (820 µL) before 1.5 equivalents (2.25 µL, 0.0225 
mmol) were added to the reaction mixture. This was left to react for 1 h. Meanwhile, 
maleimide (0.79 mg) was prepared at a concentration of 10 mM using pH 6.2 phosphate 
buffer (814 µL). An aliquot (30 µL) of the tertiapin Q reaction mixture was taken, and 
to this 10 equivalents (3 µL, 0.0300 mmol) of maleimide was added and mixed. This 
was left to react for 10 min before analysis by LC-MS. The percentage of bridged (LC 
retention time: 1.20 min, m/z 2567.0), reduced, non-bridged (LC retention time: 0.89 
min, m/z 2457.0) and thiol-capped (LC retention time: 1.24 min, m/z 2757.0) peptide 
was recorded. 
 
4.7 Maleimide Bridging of Octreotide 
N.B. ‘Peptide buffer’ employed in these experiments consisted of pH 6.2 phosphate 
buffer (50 mM) with 40 % MeCN and 2.5 % DMF. 
This general bridging procedure was repeated variation in the maleimide reagent 
employed. 
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4.7.1 General Step Wise Protocol using TCEP 
Octreotide (140 µL, 643 µM) was diluted to a concentration of 300 µM using peptide 
buffer (160 µL). TCEP (5.93 mg) was prepared at a concentration of 30 mM using 
peptide buffer (690 µL) before 1.5 equivalents (4.50 µL, 0.135 mmol) of this was added 
to the octreotide solution and mixed. The peptide was left to reduce for 1 h before an 
aliquot (30 µL) was removed and analysed by LC-MS to ensure complete disulfide 
reduction. A solution of maleimide 63 (2.71 mg) was prepared at a concentration of 30 
mM using DMF (144 µL). 1.5 equivalents (4.05 µL, 0.122 mmol) of the maleimide 
solution were added to the reduced octreotide and mixed. After 10 min, an aliquot (30 
µL) of this reaction mixture was removed and analysed by LC-MS to ensure full 
conversion to the bridged product (LC retention time: 1.10 min, m/z 1152.8).  
 
4.8 Step Wise Click Modification of Octreotide 
General Information 
The 11, azido-3,6,9-trioxaundecan-1-amine, sodium ascorbate, CuSO4, amino guanidine 
and tris-(hydroxypropyltriazolylmethyl)-amine (THPTA) used were all obtained from 
Sigma Aldrich. The doxorubicin-azide was kindly provided by Dr. João Nunes 
(UCL)180. 
 
4.8.1 Using a Small PEG-azide 
Step 1: The above procedure (4.7.1) was repeated. 
 
Step 2: CuSO4 (2.5 µL, 0.2 mM) was added to THPTA (5 µL, 1 mM) and mixed until a 
blue coloration appeared. Meanwhile, 11, azido-3,6,9-trioxaundecan-1-amine (6 µL) 
was prepared at a concentration of 30 mM in DMF (1 mL) before 5 equivalents (5 µL) 
were added to the alkyne-maleimide bridged octreotide from Step 1 (100 µL) and 
mixed. To this was added 1 µL of the CuSO4:THPTA solution before mixing. Next, 
amino guanidine (10 µL, 5 mM) and sodium ascorbate (10 µL, 5 mM) were added 
before the solution was mixed thoroughly and left to react for 1 h at room temperature. 
The reaction was analysed by LC-MS to ensure full conversion to the bridged product 
(LC retention time: 1.00 min, m/z 685.7 (m/2)).  
 
This protocol was repeated using 10, 20 and 50 equivalents of 11, azido-3,6,9-
trioxaundecan-1-amine. It was also repeated with reaction time of 24 h. 
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4.8.2 Using Doxorubicin-azide 
Step 1: Octreotide (47 µL, 643 µM) was diluted to a concentration of 200 µM using 
peptide buffer (103 µL). TCEP (2.0 mg) was prepared at a concentration of 20 mM 
using peptide buffer (349 µL) before 1.5 equivalents (1.50 µL, 0.0300 mmol) of this 
was added to the octreotide solution and mixed. The peptide was left to reduce for 1 h. 
A solution of maleimide 63 (1.65 mg) was prepared at a concentration of 20 mM using 
DMF (282 µL). 1.5 equivalents (1.5 µL, 0.0300 mmol) of the maleimide solution were 
added to the reduced octreotide and mixed. After 10 min, an aliquot (30 µL) of this 
reaction mixture was removed and analysed by LC-MS to ensure full conversion to the 
bridged product. (LC retention time: 1.10 min, m/z 1152.8). 
 
Step 2: CuSO4 (2.5 µL, 0.2 mM) was added to THPTA (5 µL, 1 mM) and mixed until a 
blue coloration appeared. Meanwhile, 20 equivalents (33 µL, 12 mM) of doxorubicin-
azide in DMF were added to the alkyne-maleimide bridged octreotide from Step 1 (100 
µL) and mixed. To this was added 1 µL of the CuSO4:THPTA solution before mixing. 
Next, amino guanidine (10 µL, 5 mM) and sodium ascorbate (10 µL, 5 mM) were added 
before the solution was mixed thoroughly and left to react for 90 mins at room 
temperature. The reaction was analysed by LC-MS to ensure full conversion to the 
bridged product (LC retention time: 1.35 min, m/z 1957.01).  
 
4.9 Purification of Peptide Products 
i) Dialysis 
The remaining reaction mixture was added to a Slide-A-Lyzer Mini Dialysis Unit (2000 
MWCO, ThermoScientific) and dialysed into distilled water for 24 h at 4 ˚C with 
stirring.  
 
ii) RP-HPLC 
A Shimadzu LC-10AT instrument fitted with a C18 column, 150 x 4.60 mm 
(Phenomenex) was used for all purification procedures. The mobile phases were water, 
0.1%  TFA (solvent A) and acetonitrile, 0.1 % TFA (solvent B). Flow rate of 1 mL/min. 
Species eluting from the column was monitored by measuring the absorbance at 280 
nm. A fraction collector was used to collect the desired peaks (1 mL fractions) and 
identical fractions were pooled before being lyophilised using a Scanvac vacuumed 
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centrifuge (Labmode). The residual peptide was reconstituted in distilled water (RP-
HPLC-grade, Fisher Chemicals).  
 
Tertiapin Q product purification method: 
Time (min) 
Solvent B 
(%) 
1.0 0 
15.0 30 
19.0 90 
22.0 90 
24.50 0 
30.0 0 
 
Octreotide product purification method: 
Time (min) 
Solvent B 
(%) 
1.0 0 
15.0 60 
19.0 60 
22.0 90 
24.50 0 
30.0 0 
 
4.10 Cell Culture 
4.10.1 Cell Line and Cell Culture Reagents 
The cells used in this study were: 
- Human Embryonic Kidney (HEK293) cell line stably expressing GIRK channel 
subtype 1/4 and the gene encoding zeocin resistance (referred to as GIRK1/4 
cells). 
- HEK293 cell line stably expressing GIRK channel subtype 1/2a and the gene 
encoding G418 resistance (referred to as GIRK1/2a cells). 
- Human pancreatic neuroendocrine tumour cell line BON-1. 
 
The HEK293 cell line is an immortalised human cell line derived from primary 
embryonic kidney cells and was already stored in the frozen cell line stock library at the 
William Harvey Research Institute, Queen Mary University of London. The BON-1 cell 
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line is an immortalised human cell line derived from a metastatic carcinoid tumour of 
the pancreas and was kindly donated by Professor Meyer (UCL).  
 
For the GIRK1/4 cell line: The medium used was Minimum Essential Medium (MEM) 
containing Earle’s salts obtained from PAA Laboratories. This was supplemented with 
10% Foetal Bovine Serum (FBS) and the antibiotic zeocin (364 µg/mL) (Invitrogen).  
For the GIRK1/2a cell line: The medium used was MEM containing Earle’s salts 
supplemented with 10% FBS and the antibiotic G-418 (800 µg/mL) (Melford).  
For the BON-1 cell line: The medium used was 1:1 MEM:Ham’s F-12 K Nutrient 
Mixture (F-12K) supplemented with 10% FBS and 1% penicillin/streptomycin (Life 
Technologies). 
The Phosphate Buffered Saline (PBS) and 0.25% trypsin solutions used were obtained 
from Gibco Life Technologies. The culture medium, PBS and trypsin were all warmed 
to 37 ˚C prior to use. 
 
4.10.2 Cell Culture Procedure 
The cell culture procedure was identical for all cell lines used. 
 
4.10.2.1 Revival of Frozen Stocks, Subculture and General Maintenance  
A 1 mL aliquot of cells stored in dimethyl sulfoxide (DMSO) at -80 ˚C was taken and 
defrosted in a water bath at 37 ˚C. The cells were pipetted into a 10 mL Falcon tube and 
~6 mL of supplemented MEM media added. This was centrifuged for 2 min at 1000 
rpm. The media was removed and 2 mL of fresh media added to resuspend the cell 
pellet. This was pipetted into a T75 flask (Nunclon) containing 8 mL of fresh media. 
The flask was incubated at 37 ˚C in a humidified atmosphere with 95% air and 5% CO2. 
 
Once the cells were 90% confluent they were passaged. The medium was removed and 
the remaining cells washed with PBS. Cells were detached from the flask base by 
adding 3 mL of trypsin and incubating at room temperature for 2-3 min. 7 mL of fresh 
medium was added to inhibit the trypsin and the mixture centrifuged at 1000 rpm for 3 
min. The medium was removed and the cell pellet resuspended in 2 mL of fresh 
medium. A dilution of the resuspended pellet was made (typically to a ratio of 1:20) 
with fresh media in a new T75 flask. This was incubated at 37 ˚C. Passaging was 
carried out weekly. 
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4.10.2.2 Culture of Cells for Patch Clamp Experiments 
When cells were required for patch clamp experiments they were passaged directly onto 
glass coverslips (10 mm diameter, borosilicate glass, VWR International). Once the cell 
pellet was resuspended in 2 mL of fresh medium (see above), ~0.2 mL of the 
resuspension was added to 12 mL of fresh media. This was then added in 1 mL aliquots 
to the wells of a 12 well plate (Nunclon) containing a single glass coverslip. The plate 
was incubated at 37 ˚C for 2 days before use.  
 
4.10.3 Bacterial Transformation 
4.10.3.1 General Information 
The competent cells used for the transformation were TOP10 E. coli cells (Life 
Technologies). The DNA used was encoding the somatostatin receptor subtype 2 and 
eGFP. The DNA fragment encoding the somatostatin receptor was cloned into the 
plasmid vector pcDNA3.1+ (Life Technologies), also encoding ampicillin resistance. 
The eGFP was encoded in the pEGFP-N1 plasmid (Life Technologies), also encoding 
kanamycin resistance. 
The antibiotics kanamycin and carbenicillin were purchased from Sigma Aldrich. The 
carbenicillin stock solution was made at 100 mg/mL in molecular grade water (Sigma 
Aldrich). The kanamycin stock solution was made at 25 mg/mL in molecular grade 
water. 
 
4.10.3.2 Preparation of Liquid Broth (LB) Medium 
20 LB medium tablets (Sigma Aldrich) were dissolved in 1 L of distilled water. This 
was autoclaved for sterilisation and allowed to cool to room temperature before use. 
 
LB for somatostatin receptor transformation: 
To 54 mL of liquid broth medium was added 54 µL of carbenicillin stock solution 
(stock solution at 100 mg/mL in distilled water) to make a final carbenicillin 
concentration of 100 µg/mL. 
 
LB for eGFP transformation: 
To 54 mL of liquid broth medium was added 54 µL of kanamycin stock solution (stock 
solution at 25 mg/mL in distilled water) to give a final kanamycin concentration of 25 
µg/mL. 
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4.10.3.3 Preparation of LB-Agar Plates 
To 100 mL of liquid broth medium was added 1.5 g of agar (Life Technologies). This 
was heated in the microwave on full power for 90 seconds. The agar was allowed to 
cool to 50 °C before the relevant antibiotics were added (100 µg/mL carbenicillin or 25 
µg/mL kanamycin). Once the antibiotics were added, the LB-agar was mixed by 
inversion before being poured into sterile 100 x 20 mm tissue culture dishes (Sarstedt) 
and left to set at room temperature. The plates were stored at 4 °C until future use. 
 
4.10.3.4 Transformation of Plasmid DNA 
On ice, 30 µL of TOP10 E. coli cells were mixed with 1 µL of plasmid DNA. This was 
then incubated for 30 mins on ice. The bacteria were heat shocked for 90 seconds at 42 
°C in a water bath before being returned to the ice. 1 mL of liquid broth medium 
(antibiotic free) was added and the bacteria then left for 30 mins at 37 °C. Lastly, 150 
µL of bacteria was plated onto agar plates with the correct selective antibiotic. The 
plates were left overnight in an incubator at 37 °C. 
 
4.10.3.5 Purification of Plasmid DNA 
An individual colony from a plate was picked using a sterile pipette tip. This tip was 
added to 4 mL of liquid broth medium containing the correct selective antibiotic and 
shaken overnight at 37 °C. 
 
The desired plasmids were then extracted and purified using the QIAGEN Plasmid 
Purification kit which contained all reagents required and mentioned below. The 
reagents were prepared as described in the enclosed handbook. The procedure for a 
midi-preparation from a bacterial suspension was described and followed from the 
enclosed handbook.  
 
In brief: 
The bacterial cells were harvested by centrifugation at 6000 x g for 15 min at 4 °C and 
the bacterial pellet was re-suspended in 4 mL of re-suspension buffer P1. 4 mL of lysis 
buffer P2 was added and mixed thoroughly by inversion several times before being 
incubated at room temperature for 5 mins to allow the bacteria to lyse and release the 
plasmid DNA. Next, 4 mL of chilled (4 °C) neutralisation buffer P3 was added and 
mixed immediately by inversion several times. This was then incubated on ice for 15 
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mins before being centrifuged at 20, 000 x g for 30 mins at 4 °C. The supernatant 
containing the plasmid DNA was removed promptly. 
 
A QIAGEN-tip 100 column was equilibrated with 4 mL of equilibration buffer QBT. 
The collected supernatant was applied to the column and allowed to enter the resin by 
gravity flow. The column was washed with 2 x 10 mL of wash buffer QC and the 
plasmid DNA was then finally eluted with 5 mL of elution buffer QF. The plasmid 
DNA was precipitated by the addition of 3.5 mL of room temperature isopropanol; this 
was mixed and centrifuged immediately at 15, 000 x g for 30 mins at 4 °C. The 
supernatant was decanted and the DNA pellet washed with 2 mL of room temperature 
ethanol (70%) before being centrifuged at 15, 000 x g for 10 mins. The supernatant was 
again decanted and the pellet left to air-dry for 10 minutes. The pellet was re-suspended 
in 100 µL of molecular grade water and stored at -20 °C until further use. 
 
The concentration of plasmid DNA stock solutions were determined by absorbance at 
260 nm using a nanophotometer (Geneflow). The concentration of somatostatin receptor 
subtype 2 DNA stock solution was determined to be 766 ng/µL. The concentration of 
eGFP DNA stock solution was determined to be 974 ng/ µL. 
 
4.10.4 Transfection of Cells 
In a 1.5 mL Eppendorf was mixed 50 ng eGFP plasmid DNA (from stock solution), 800 
ng SSTR2 plasmid DNA (from stock solution) and 97 µL of MEM media (containing 
no antibiotics or serum) per transfection well. This was mixed thoroughly by vortex. To 
this was added 5 µL of Fugene HD (Promega) per transfection well and mixed by gentle 
inversion. The mixture was incubated for 15 mins at room temperature.  
 
Meanwhile, cells cultured onto 12 or 6 well plates for patch clamp experiments (as 
previously described in Section 4.5.2.2) were prepared for transfection. The antibiotic-
conatining media was carefully removed, the coverslips washed with 2 mL of antibiotic- 
free media and replaced with 2 mL of antibiotic-free media per transfection well. 100 
µL of the transfection mixture prepared above was added to each transfection well. 
Following incubation at 37 °C for 4 h, the media was removed, the cells were washed 
with 2 mL of antibiotic-free media and lastly the media replaced with 2 mL of G418 
media. The cells were incubated at 37 °C until experiments commenced. 
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4.11 Electrophysiology 
4.11.1 Patch Clamp Equipment Setup 
A Faraday cage was used to reduce the effects of electrostatic noise and this was 
mounted on an air table to minimise vibrations. Prior to use, a glass-bottomed recording 
chamber, which is mounted above a microscope, is perfused with extracellular solution 
using a gravity-driven perfusion system. A vacuum pump system was used to remove 
the extracellular solution and to allow a continuous perfusion flow; a solution depth of 
around 5 mm was maintained throughout experiments. The microscope was fitted with a 
UV light source to allow visualisation of transfected cells. A glass coverslip with cells 
adhered was placed in the recording chamber. The recording chamber was grounded by 
an Ag/AgCl reference electrode (Axon instruments).  
  
Patch pipettes were pulled from borosilicate glass (1.17 mm internal diameter, Harvard 
Apparatus) and a pipette puller (PP-830, Narishige). Pipettes were pulled to have a 
resistance of close to 2 MΩ when filled with intracellular solution. The pipette was 
filled with intracellular solution and attached onto the headstage. A slight positive 
pressure is applied to prevent the pipette tip being blocked with debris. The course 
controls on the manipulator (Sutter Instruments) is used to roughly position the pipette 
above the cell and the fine control is then used to touch the cell membrane. In order to 
achieve the gigaohm seal on the membrane, gentle suction is often required; to achieve 
this, the pipette holder is attached to tubing allowing suction and positive pressure to be 
applied by the experimenter. After a gigaohm seal is formed (cell-attached 
configuration, see Figure 1.19), increased suction leads to membrane rupture (whole-
cell configuration, see Figure 1.20). At this point, after the membrane capacitance has 
been corrected, the whole-cell voltage clamp protocol can begin. From a holding 
potential of -50 mV, 20 mV steps were applied from -120 mV to +40 mV. The 
micropipette electrode was connected to a unitary voltage gain headstage amplifier (HS-
2, Axon Instruments) containing a 10 M resistor. Signals were further amplified by an 
Axopatch 200B amplifier (Axon Instruments), converted from analogue to digital 
signals by a Digidata 1440 converter, and captured and analysed using pClamp software 
(version 10.0, Axon Instruments). Voltage commands were generated using pClamp10 
software.  
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4.11.2 Solutions Used for Whole Cell Patch Clamp Experiments 
Extracellular (Bath) Solution: 
KCl (20 mM), NaCl (120 mM), CaCl2 (2 mM), MgCl2 and HEPES (10 mM) were 
dissolved in high quality 18 Ω distilled water in a 1 L volumetric flask. The pH of the 
solution was adjusted to pH7.4 using NaOH (5 M) as required. The solution was stored 
at 4 ˚C and warmed to room temperature before use. 
 
Intracellular (Pipette) Solution: 
KCl (130 mM), NaCl (10 mM), MgCl2 (1 mM), MgATP (2 mM), EGTA (2 mM), GTP 
(0.3 mM) and HEPES (10 mM) were dissolved in high quality 18 Ω distilled water in a 
100 mL volumetric flask. The pH of the solution was adjusted to pH7.4 using KOH (5 
M) as required. The solution was pipetted into 1 mL aliquots and stored at -20 ˚C. An 
aliquot was defrosted and sterile filtered before use ad incubated on ice throughout the 
experiments to reduce breakdown of ATP. 
  
Tertiapin Q Solutions: 
The concentration of the native and bridged tertiapin Q products was determined by UV 
absorption at 280 nm and the extinction coefficient of the peptide (5,750 L mol-1 cm-1). 
With this a serial dilution to 100 nM, 50 nM, 30 nM, 10 nM, 5 nM and 1 nM was made 
in the extracellular solution prepared previously. 10 mL batches of each concentration 
were made on the day of the experiment. 
 
Octreotide Solutions: 
The concentration of native and bridged tertiapin Q products was determined by UV 
absorption at 280 nm and the extinction coefficient of the peptide (5, 630 L mol-1 cm-1). 
With this a serial dilution to 10 µM, 1 µM, 100 nM, 10 nM, 1 nM, 0.1 nM and 0.01 nM 
was made in the extracellular solution prepared previously. 10 mL batches of each 
concentration were made on the day of the experiment.  
 
4.11.3 Dose-Response Analysis of Tertiapin Q 
Whole-cell patch clamp was carried out on HEK293 cells stably expressing the 
GIRK1/4 channel prepared as described in Section 2.8.2. Once a satisfactory seal to the 
cell membrane was formed (>1 GΩ), and a whole-cell had been achieved, transient 
spikes caused by cell capacitance were negated using the amplifier-circuitry. The cells 
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were voltage-clamped at -50 mV and the current measuring protocol (voltage steps from 
-120 to 50 mV in 10 mV increments) was run every minute until maximum inwards K+ 
current was observed. At this point, the perfusion solution was switched to that of 1nM 
tertiapin Q. Again, the protocol was run every minute until K+ current reduction by 
GIRK inhibition stabilised. At this point, the perfusion solution was switched to that of 
5 nM tertiapin Q and again the protocol was run until the current reduction stabilised. 
This was repeated with tertiapin Q concentrations of 10, 30, 50 and 100 nM. 
 
This procedure was repeated with bridged tertiapin Q concentrations of 10, 30, 50 and 
100 nM. 
 
4.11.4 Wash-Out Study of Tertiapin Q 
After the above procedure was completed, the perfusion was switched back to 
extracellular solution and the voltage-clamp protocol run every 5 min to test for reversal 
of the drug effect. 
 
4.11.5 Dose-Response Analysis of Octreotide 
Whole-cell patch clamp was carried out on HEK293 cells stably expressing the 
GIRK1/2a channel and transiently transfected with both the somatostatin receptor 
subtype 2 and eGFP to enable identification of transfected cells (as described in Section 
4.5.4). Once a fluorescent cell on the coverslip had been located, current recordings 
were conducted, as described in Section 2.9.4. In this case, agonist activity of octreotide 
was monitored by activation of the somatostatin receptor leading to increased K+ current 
through GIRK channels. This was monitored by sequential perfusion with 0.01, 0.1, 1, 
10 and 100 nM octreotide. 
 
This procedure was repeated with bridged octreotide concentrations of 1, 10, 100, 103 
and 104 nM.   
 
4.11.6 Wash-Out Study of Octreotide 
After the above procedure was completed, the perfusion was switched back to 
extracellular solution and the voltage-clamp protocol run every 2 min to test for 
regeneration of resting K+ currents. 
 
 195 
4.12 Confocal Microscopy Imaging 
4.12.1 General Information 
For these experiments, HEK293 cells stably expressing the GIRK1/2a channel and 
BON-1 cells were used. 
 
Tyrode’s solution: 
NaCl (135 mM), KCl (5.4 mM), CaCl2 (2 mM), MgCl2 (1 mM), HEPES (5 mM) and 
glucose (10 mM) were dissolved in distilled water in a 500 mL volumetric flask. The 
pH of the solution was adjusted to pH 7.4 using NaOH (5 M) as required. The solution 
was stored at 4 ˚C and warmed to room temperature before use. 
 
4.12.2 Cell Preparation 
When ~80% confluent, cells were passaged, as described previously in Section 4.10.2.2, 
onto glass bottomed petri dishes (40 mm). One dish of HEK293 cells was transfected, 
as described in Section 4.10.4, with SSTR 2 and eGFP and these cells were imaged 48 h 
after transfection. Prior to imaging, the cells were washed with Tyrode’s solution (2 x 1 
mL) and 2 mL of Tyrode’s solution added.  
 
To each petri dish, maleimide 77 in distilled water (1 µM, 33 µL) was added and left 
either at room temperature or 37 °C for 20 minutes before confocal imaging. After 
preliminary imaging, the solution containing maleimide 77 was removed and the cells 
washed with Tyrode’s solution (3 x 1 mL) before 2 mL of Tyrode’s solution was added 
and the cells imaged again. 
 
4.12.3 Microscopy Imaging 
Live cells were imaged using a Zeiss LSM510 (Mark 4) confocal microscope and a 
Plan-Apochromat 63× oil lens objective (1.4 numerical aperture). eGFP was visualized 
using a multi-line Argon laser (wavelength 488 nm) and ﬁltered using a BP505-530 
(band pass) emission ﬁlter. Rhodamine B was visualised using a helium/neon laser 
(wavelength 543 nm) and ﬁltered using a BP560-615 emission ﬁlter. To avoid ‘cross-
talk’ between eGFP and rhodamine B signals, images were acquired sequentially. 
Images were taken at 1024×1024 frame size, a bit depth of 16 bit, and were averaged 
twice. 
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4.13 Mass Spectrometry Analysis 
These IM-MS/MS experiments were performed in a hybrid quadrupole-ion mobility-
orthogonal acceleration time-of-ﬂight (oa-TOF) mass spectrometer (Synapt HDMS, 
Waters, Manchester, UK). 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: A schematic of the IM-MS/MS instrument.v 
 
4.13.1 Ion-Mobility-Mass Spectrometry/Mass Spectrometry (IM-MS/MS) 
The instrument was fitted with a nanoﬂow electrospray ion source and operated at a 
source temperature of 40 °C. The cone was optimized between 30 V and 70 V for 
electrospray ionisation mass spectrometry/mass spectrometry (ESI-MS/MS) 
experiments and the collision energy was increased from 20 eV to 80 eV during the 
each acquisition. Samples were introduced into the instrument by direct infusion ESI 
and ions were subsequently mass selected, prior to MS/MS experiments, by use of an 
installed quadrupole. All MS/MS experiments were performed after ion mobility 
separation in the Tri-wave transfer cell. The pressure in the Tri-wave IM cell was 0.58 
mbar with nitrogen employed as the mobility gas. The T-wave height and velocity were 
set at 7 V and 300 m/s respectively. The time-of-flight (TOF) mass analyzer recorded 
200 pushes, each one representing a single mass spectrum. Mass spectra were acquired 
at an acquisition rate of two spectra per second with a scan time of 1 s. Data acquisition 
and subsequent processing were carried out using Mass Lynx (v4.1) software (Waters 
Corp., Milford, MA). 
 
                                                 
v Arnaud, C. H. Chemical & Engineering News Archive 2008, 86, 11. 
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4.13.2 Calibration for Ion-Mobility Analysis 
Equine myoglobin and cytochrome c data were used to create a calibration curve for ion 
mobility experiments. Absolute cross sections for myoglobin and cytochrome c were 
previously obtained from drift-time ion mobility mass spectrometry (DTIMS) 
experiments. Normalised cross sections (corrected for charge state) were plotted against 
corrected drift times (corrected to exclude time spent outside the ion mobility cell) to 
produce a calibration curve. This curve could then be used to determine unknown cross 
sections from known drift times. 
 
To compare the experimental cross sections of native and modified tertiapin with 
theoretical values, cross sections were calculated using the open source software 
programme MOBCAL, a program to calculate mobilities from published X-ray 
structure files held at the RCSB Protein Data Bank. In these experiments, cross sections 
were calculated using both the projection approximation (PA) and exact hard-sphere 
scattering (EHSS) model methods on the RCSB Protein Data Bank file 1TER. 
 
4.13.3 Capillary Liquid Chromatography/Mass Spectrometry (capLC/MS, -MS2) 
Chromatographic separation was performed using an Accela capillary LC system 
(Thermo Scientific, UK). The LC system is consisted of an Accela solvent rack, Accela 
600 pressure dual gradient pumping system with an on-line solvent degasser and an 
Accela autosampler.  
 
The LC system was fitted with a Hypersil Gold, C18 column, 100 x 2.1 mm, 1.9 µL 
(Thermo Scientific, UK) and coupled to a Finnigan LTQ mass spectrometer (Thermo 
Scientific, UK). The mobile phases were water, 0.1% formic acid (solvent A) and 
methanol, 0.1 % formic acid (solvent B). A linear gradient was utilised for the LC-MS, -
MS2 analyses as shown in Table 4.1, with a total run time of 10 minutes. An injection 
loop of 25 µL was used, and between sample injections the needle and injection loop 
were washed with methanol - water (1:1) to eliminate sample carry-over. 
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Table 4.1: LC method conditions 
 
 
 
 
 
 
 
 
 
10 µL of the sample was diluted with 90 µL water, 0.1% formic acid. The sample was 
centrifuged at 13,000 x g for 3 minutes. 20 µL was injected onto the reversed phase 
column via the injection loop. Eluent from the C18 column was continuously directed to 
the capillary electrospray source of the Finnigan LTQ mass spectrometer via a fused 
silica emitter. The LTQ mass spectrometer was operated in the positive ion ES mode 
with four scan events over the 10 min gradient LC run. The scan events were MS and 
MS2. MS2 was programmed on [M+H]+, [M+2H]2+/2, [M+3H]3+/3 and [M+4H]4+/4.  
For acquisition of the MS2 spectra, the collision energy was 35%. The mass 
spectrometer was operated under the following settings:-spray voltage 4.5 kV, capillary 
temperature 280 °C, sheath gas flow rate 40, auxiliary gas flow rate 10. MS, MS2 scans 
consisted of three averaged “microscans” each with a maximum injection time of 200 
ms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (min) Solvent A (%) Solvent B (%) Flow rate 
(µL/min) 
0 99 1 200 
8.0 5 95 200 
9.0 5 95 200 
9.1 99 1 200 
10 99 1 200 
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Appendix 
 
 
Table 1: Data for the dose-response curve of native tertiapin Q (0-100 nM). 
 
Concentration 
(nM) 
Log 
Concentration 
Average 
Current 
Inhibition 
No. of 
experiments 
Standard 
Error of the 
Mean 
Normalised 
Average 
Current 
Inhibition 
(%) 
0 -6.00 0 - - 0 
1 -3.00 18.032 4 4.051 22.69 
5 -2.30 43.494 7 4.726 54.72 
10 -2.00 54.820 6 5.249 68.97 
30 -1.52 72.162 5 5.064 90.79 
50 -1.30 77.562 4 4.314 97.58 
100 -1.00 79.485 5 5.483 100.00 
 
 
 
Table 2: Expected fragment ions produced from MS/MS of reduced tertiapin Q. 
 
Fragment Exact mass Fragment Exact mass 
b1 72.04 y1 145.12 
b2 185.13 y2 273.22 
b3 288.14 y3 330.24 
b4 402.18 y4 433.25 
b5 505.19 y5 561.34 
b6 619.23 y6 689.44 
b7 777.35 y7 875.52 
b8 890.43 y8 978.53 
b9 1003.52 y9 1106.59 
b10 1116.6 y10 1243.65 
b11 1213.65 y11 1340.7 
b12 1350.71 y12 1453.78 
b13 1478.77 y13 1566.87 
b14 1581.78 y14 1679.97 
b15 1767.86 y15 1838.07 
b16 1895.96 y16 1952.11 
b17 2024.05 y17 2055.12 
b18 2127.06 y18 2169.16 
b19 2184.08 y19 2272.17 
b20 2312.18 y20 2385.26 
b21 2456.29 y21 2456.29 
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Table 3-5: Expected fragment ions produced from MS/MS of doubly modified tertiapin Q. 
 
Table 3: C3-C14/C5-C18 disulfide connectivity 
 
Fragment Exact mass  Fragment Exact mass  
b1 72.04 no mal y1 145.12 no mal 
b2 185.13 no mal y2 273.22 no mal 
b3 n/a mal y3 330.24 no mal 
b4 n/a mal y4 n/a mal 
b5 n/a mal y5 n/a mal 
b6 n/a mal y6 n/a mal 
b7 n/a mal y7 n/a mal 
b8 n/a mal y8 n/a mal 
b9 n/a mal y9 n/a mal 
b10 n/a mal y10 n/a mal 
b11 n/a mal y11 n/a mal 
b12 n/a mal y12 n/a mal 
b13 n/a mal y13 n/a mal 
b14 n/a mal y14 n/a mal 
b15 n/a mal y15 n/a mal 
b16 n/a mal y16 n/a mal 
b17 n/a mal y17 n/a mal 
b18 2311.01 mal y18 n/a mal 
b19 2368.04 mal y19 2458.14 mal 
b20 2496.13 mal y20 2571.23 mal 
b21 2642.26 mal y21 2642.26 mal 
 
Table 4: C3-C5/C14-C18 disulfide connectivity 
 
Fragment Exact mass  Fragment Exact mass  
b1 72.04 no mal y1 145.12 no mal 
b2 185.13 no mal y2 273.22 no mal 
b3 n/a mal y3 330.24 no mal 
b4 n/a mal y4 n/a mal 
b5 598.17 mal y5 n/a mal 
b6 712.23 mal y6 n/a mal 
b7 868.34 mal y7 n/a mal 
b8 981.42 mal y8 1071.51 mal 
b9 1094.50 mal y9 1199.57 mal 
b10 1207.60 mal y10 1337.34 mal 
b11 1304.67 mal y11 1434.71 mal 
b12 1441.71 mal y12 1547.78 mal 
b13 1569.77 mal y13 1660.86 mal 
b14 n/a mal y14 1773.95 mal 
b15 n/a mal y15 1930.05 mal 
b16 n/a mal y16 2044.09 mal 
b17 n/a mal y17 n/a mal 
b18 2311.01 mal y18 n/a mal 
b19 2368.04 mal y19 2458.14 mal 
b20 2496.13 mal y20 2571.23 mal 
b21 2642.26 mal y21 2642.26 mal 
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Table 5: C3-C18/C5-C14 disulfide connectivity 
 
Fragment Exact mass  Fragment Exact mass  
b1 72.04 no mal y1 145.12 no mal 
b2 185.13 no mal y2 273.22 no mal 
b3 n/a mal y3 330.24 no mal 
b4 n/a mal y4 n/a mal 
b5 n/a mal y5 n/a mal 
b6 n/a mal y6 n/a mal 
b7 n/a mal y7 n/a mal 
b8 n/a mal y8 n/a mal 
b9 n/a mal y9 n/a mal 
b10 n/a mal y10 n/a mal 
b11 n/a mal y11 n/a mal 
b12 n/a mal y12 n/a mal 
b13 n/a mal y13 n/a mal 
b14 n/a mal y14 n/a mal 
b15 n/a mal y15 n/a mal 
b16 n/a mal n/a n/a mal 
b17 n/a mal y17 n/a mal 
b18 2311.01 mal y18 n/a mal 
b19 2368.04 mal y19 2458.14 mal 
b20 2496.13 mal y20 2571.23 mal 
b21 2642.26 mal y21 2642.26 mal 
 
 
Figure 1: Calibration curve of corrected collision cross section against drift time created using 
myoglobin and cytochrome c. 
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Table 6-11: Expected fragment ions produced from MS/MS of singly modified tertiapin Q. 
 
Table 6: C3-C5 disulfide connectivity 
 
Fragment Exact mass  Fragment Exact mass  
b1 72.04 no mal y1 144.11 no mal 
b2 185.13 no mal y2 272.21 no mal 
b3 n/a mal y3 329.23 no mal 
b4 n/a mal y4 432.24 no mal 
b5 612.19 mal y5 560.33 no mal 
b6 726.23 mal y6 688.43 no mal 
b7 884.35 mal y7 874.51 no mal 
b8 997.43 mal y8 977.52 no mal 
b9 1110.52 mal y9 1105.58 no mal 
b10 1223.6 mal y10 1242.64 no mal 
b11 1320.66 mal y11 1339.69 no mal 
b12 1457.71 mal y12 1452.77 no mal 
b13 1585.77 mal y13 1565.86 no mal 
b14 1688.78 mal y14 1678.96 no mal 
b15 1874.86 mal y15 1837.06 no mal 
b16 2002.96 mal y16 1951.1 no mal 
b17 2131.05 mal y17 n/a mal 
b18 2234.06 mal y18 n/a mal 
b19 2291.08 mal y19 2378.16 mal 
b20 2419.18 mal y20 2491.25 mal 
b21 2563.29 mal y21 2563.29 mal 
 
Table 7: C14-C18 disulfide connectivity 
 
Fragment Exact mass  Fragment Exact mass  
b1 72.04 no mal y1 144.11 no mal 
b2 185.13 no mal y2 272.21 no mal 
b3 288.14 no mal y3 329.23 no mal 
b4 402.18 no mal y4 n/a mal 
b5 505.19 no mal y5 n/a mal 
b6 619.23 no mal y6 n/a mal 
b7 777.35 no mal y7 n/a mal 
b8 890.43 no mal y8 1084.52 mal 
b9 1003.52 no mal y9 1212.58 mal 
b10 1116.6 no mal y10 1349.64 mal 
b11 1213.65 no mal y11 1446.69 mal 
b12 1350.71 no mal y12 1559.77 mal 
b13 1478.77 no mal y13 1672.86 mal 
b14 n/a mal y14 1785.94 mal 
b15 n/a mal y15 1944.06 mal 
b16 n/a mal y16 2058.1 mal 
b17 n/a mal y17 2161.11 mal 
b18 2234.06 mal y18 2275.15 mal 
b19 2291.08 mal y19 2378.16 mal 
b20 2419.18 mal y20 2491.25 mal 
b21 2563.29 mal y21 2563.29 mal 
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Table 8: C3-C14 disulfide connectivity 
 
Fragment Exact mass  Fragment Exact mass  
b1 72.04 no mal y1 144.11 no mal 
b2 185.13 no mal y2 272.21 no mal 
b3 n/a mal y3 329.23 no mal 
b4 n/a mal y4 432.24 no mal 
b5 n/a mal y5 560.33 no mal 
b6 n/a mal y6 688.43 no mal 
b7 n/a mal y7 874.51 no mal 
b8 n/a mal y8 n/a mal 
b9 n/a mal y9 n/a mal 
b10 n/a mal y10 n/a mal 
b11 n/a mal y11 n/a mal 
b12 n/a mal y12 n/a mal 
b13 n/a mal y13 n/a mal 
b14 1688.78 mal y14 n/a mal 
b15 1874.86 mal y15 n/a mal 
b16 2002.96 mal y16 n/a mal 
b17 2131.05 mal y17 n/a mal 
b18 2234.06 mal y18 n/a mal 
b19 2291.08 mal y19 2378.16 mal 
b20 2419.18 mal y20 2491.25 mal 
b21 2563.29 mal y21 2563.29 mal 
 
Table 9: C5-C18 disulfide connectivity 
 
Fragment Exact Mass  Fragment Exact Mass  
b1 72.04 no mal y1 144.11 no mal 
b2 185.13 no mal y2 272.21 no mal 
b3 288.14 no mal y3 329.23 no mal 
b4 402.18 no mal y4 n/a mal 
b5 n/a mal y5 n/a mal 
b6 n/a mal y6 n/a mal 
b7 n/a mal y7 n/a mal 
b8 n/a mal y8 n/a mal 
b9 n/a mal y9 n/a mal 
b10 n/a mal y10 n/a mal 
b11 n/a mal y11 n/a mal 
b12 n/a mal y12 n/a mal 
b13 n/a mal y13 n/a mal 
b14 n/a mal y14 n/a mal 
b15 n/a mal y15 n/a mal 
b16 n/a mal y16 n/a mal 
b17 n/a mal y17 2161.11 mal 
b18 2234.06 mal y18 2275.15 mal 
b19 2291.08 mal y19 2378.16 mal 
b20 2419.18 mal y20 2491.25 mal 
b21 2563.29 mal y21 2563.29 mal 
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Table 10: C3-C18 disulfide connectivity 
 
Fragment Exact mass  Fragment Exact mass  
b1 72.04 no mal y1 144.11 no mal 
b2 185.13 no mal y2 272.21 no mal 
b3 n/a mal y3 329.23 no mal 
b4 n/a mal y4 n/a mal 
b5 n/a mal y5 n/a mal 
b6 n/a mal y6 n/a mal 
b7 n/a mal y7 n/a mal 
b8 n/a mal y8 n/a mal 
b9 n/a mal y9 n/a mal 
b10 n/a mal y10 n/a mal 
b11 n/a mal y11 n/a mal 
b12 n/a mal y12 n/a mal 
b13 n/a mal y13 n/a mal 
b14 n/a mal y14 n/a mal 
b15 n/a mal y15 n/a mal 
b16 n/a mal y16 n/a mal 
b17 n/a mal y17 n/a mal 
b18 2234.06 mal y18 n/a mal 
b19 2291.08 mal y19 2378.16 mal 
b20 2419.18 mal y20 2491.25 mal 
b21 2563.29 mal y21 2563.29 mal 
 
Table 11: C5-C14 disulfide connectivity 
 
Fragment Exact mass  Fragment Exact mass  
b1 72.04 no mal y1 144.11 no mal 
b2 185.13 no mal y2 272.21 no mal 
b3 288.14 no mal y3 329.23 no mal 
b4 402.18 no mal y4 432.24 no mal 
b5 n/a mal y5 560.33 no mal 
b6 n/a mal y6 688.43 no mal 
b7 n/a mal y7 874.51 no mal 
b8 n/a mal y8 n/a mal 
b9 n/a mal y9 n/a mal 
b10 n/a mal y10 n/a mal 
b11 n/a mal y11 n/a mal 
b12 n/a mal y12 n/a mal 
b13 n/a mal y13 n/a mal 
b14 1688.78 mal y14 n/a mal 
b15 1874.86 mal y15 n/a mal 
b16 2002.96 mal y16 n/a mal 
b17 2131.05 mal y17 2161.11 mal 
b18 2234.06 mal y18 2275.15 mal 
b19 2291.08 mal y19 2378.16 mal 
b20 2419.18 mal y20 2419.18 mal 
b21 2563.29 mal y21 2563.29 mal 
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Table 12: Data for the dose-response curve of native octreotide (0-100 nM). 
 
Concentration 
(nM) 
Log 
Concentration 
Absolute Current 
Activation (pA/pF) 
No. of 
experiments 
Standard Error 
of the Mean 
(pA/pF) 
0 -6.00 -12.237 7 1.372 
0.01 -5.00 -15.730 4 1.129 
0.10 -4.00 -24.606 7 1.203 
1.00 -3.00 -41.777 5 4.063 
10.0 -2.00 -59.441 4 5.164 
100 -1.00 -62.824 4 4.429 
 
Table 13: Data for the dose-response curve of modified octreotide (0-10 µM). 
 
Concentration 
(nM) 
Log 
Concentration 
Absolute Current 
Activation (pA/pF) 
No. of 
experiments 
Standard Error 
of the Mean 
(pA/pF) 
0 -6.00 -11.292 7 1.174 
1.00 -3.00 -11.642 7 1.123 
10.00 -2.00 -18.417 6 1.151 
100.00 -1.00 -26.093 4 2.971 
1 x103 0 -36.800 4 4.245 
1 x104 1.00 -43.680 4 6.494 
 
 
Table 14: Data for the dose-response curve of alkyne modified octreotide (0-10 µM). 
 
Concentration 
(nM) 
Log 
Concentration 
Absolute Current 
Activation (pA/pF) 
No. of 
experiments 
Standard Error 
of the Mean 
(pA/pF) 
0 -6.00 -17.303 7 3.030 
1.00 -3.00 -18.079 5 4.436 
10.00 -2.00 -24.193 6 3.506 
100.00 -1.00 -40.784 8 3.582 
1 x103 0 -62.323 6 5.454 
1 x104 1.00 -65.167 5 5.934 
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